

## Central Lancashire Online Knowledge (CLOK)

|          |  |
|----------|--|
| Title    | Remote care through telehealth for people with inflammatory bowel disease (Review)   |
| Type     | Article  |
| URL      | <a href="https://clock.uclan.ac.uk/id/eprint/46179/">https://clock.uclan.ac.uk/id/eprint/46179/</a>  |
| DOI      | <a href="https://doi.org/10.1002/14651858.CD014821.pub2">https://doi.org/10.1002/14651858.CD014821.pub2</a>  |
| Date     | 2023   |
| Citation | Gordon, Morris, Sinopoulou, Vasiliki, Lakunina, Svetlana, Hellon, Teuta, Bracewell, Kelly and Akobeng, Anthony K (2023) Remote care through telehealth for people with inflammatory bowel disease (Review). Cochrane Database of Systematic Reviews. |
| Creators | Gordon, Morris, Sinopoulou, Vasiliki, Lakunina, Svetlana, Hellon, Teuta, Bracewell, Kelly and Akobeng, Anthony K   |

It is advisable to refer to the publisher's version if you intend to cite from the work.  
<https://doi.org/10.1002/14651858.CD014821.pub2>

For information about Research at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLOK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <http://clock.uclan.ac.uk/policies/>



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## Remote care through telehealth for people with inflammatory bowel disease (Review)

Gordon M, Sinopoulou V, Lakunina S, Gjuladin-Hellon T, Bracewell K, Akobeng AK

Gordon M, Sinopoulou V, Lakunina S, Gjuladin-Hellon T, Bracewell K, Akobeng AK.  
Remote care through telehealth for people with inflammatory bowel disease.  
*Cochrane Database of Systematic Reviews* 2023, Issue 5. Art. No.: CD014821.  
DOI: [10.1002/14651858.CD014821.pub2](https://doi.org/10.1002/14651858.CD014821.pub2).

[www.cochranelibrary.com](http://www.cochranelibrary.com)

Remote care through telehealth for people with inflammatory bowel disease (Review)

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

WILEY

## TABLE OF CONTENTS

|   |    |
|---|----|
| ABSTRACT .....  | 1  |
| PLAIN LANGUAGE SUMMARY .....  | 2  |
| SUMMARY OF FINDINGS .....   | 5  |
| BACKGROUND .....  | 11 |
| OBJECTIVES .....  | 11 |
| METHODS .....   | 11 |
| RESULTS .....   | 14 |
| Figure 1. ....  | 15 |
| Figure 2. ....  | 19 |
| Figure 3. ....  | 20 |
| DISCUSSION .....  | 26 |
| AUTHORS' CONCLUSIONS .....  | 27 |
| ACKNOWLEDGEMENTS .....  | 28 |
| REFERENCES .....  | 29 |
| CHARACTERISTICS OF STUDIES .....  | 37 |
| DATA AND ANALYSES .....   | 83 |
| Analysis 1.1. Comparison 1: Web-based disease monitoring versus usual care, Outcome 1: Disease activity (adults) .....  | 86 |
| Analysis 1.2. Comparison 1: Web-based disease monitoring versus usual care, Outcome 2: Disease activity (adults; fixed-effect sensitivity analysis) .....   | 87 |
| Analysis 1.3. Comparison 1: Web-based disease monitoring versus usual care, Outcome 3: Flare-ups/relapse (dichotomous; adults) .....  | 88 |
| Analysis 1.4. Comparison 1: Web-based disease monitoring versus usual care, Outcome 4: Flare-ups/relapse (dichotomous; adults; fixed-effect sensitivity analysis) .....   | 89 |
| Analysis 1.5. Comparison 1: Web-based disease monitoring versus usual care, Outcome 5: Flare-ups (continuous; adults) .....   | 90 |
| Analysis 1.6. Comparison 1: Web-based disease monitoring versus usual care, Outcome 6: Flare-ups/relapse (dichotomous; children) .....  | 90 |
| Analysis 1.7. Comparison 1: Web-based disease monitoring versus usual care, Outcome 7: Quality of life (adults) .....   | 91 |
| Analysis 1.8. Comparison 1: Web-based disease monitoring versus usual care, Outcome 8: Quality of life (adults; fixed-effect sensitivity analysis) .....  | 92 |
| Analysis 1.9. Comparison 1: Web-based disease monitoring versus usual care, Outcome 9: Medication adherence (continuous; adults) .....  | 92 |
| Analysis 1.10. Comparison 1: Web-based disease monitoring versus usual care, Outcome 10: Medication adherence (continuous; children) .....  | 93 |
| Analysis 1.11. Comparison 1: Web-based disease monitoring versus usual care, Outcome 11: Medication adherence (dichotomous; adults) .....   | 93 |
| Analysis 2.1. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 1: Flare-ups/relapse (dichotomous; adults) .....   | 94 |
| Analysis 2.2. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 2: Flare-ups/relapse (dichotomous; children) .....   | 95 |
| Analysis 2.3. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 3: Quality of life (children) .....  | 95 |
| Analysis 2.4. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 4: Number of episodes accessing healthcare (one or more hospital admissions; children) .....                   | 95 |
| Analysis 2.5. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 5: Medication adherence (adults) .....   | 96 |
| Analysis 2.6. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 6: Participant engagement (adults) .....   | 96 |
| Analysis 2.7. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 7: Rate of attendance/engagement with the intervention (scheduled consultations not cancelled; children) ..... | 96 |
| Analysis 2.8. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 8: Rate of attendance/engagement with the intervention (missed consultations; children) .....                  | 97 |
| Analysis 2.9. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 9: Rate of attendance of interactions with health professionals (children) .....                               | 97 |
| ADDITIONAL TABLES .....   | 98 |

---

|   |     |
|---|-----|
| APPENDICES .....                              | 128 |
| HISTORY .....                                 | 132 |
| CONTRIBUTIONS OF AUTHORS .....                | 132 |
| DECLARATIONS OF INTEREST .....                | 132 |
| SOURCES OF SUPPORT .....                      | 132 |
| DIFFERENCES BETWEEN PROTOCOL AND REVIEW ..... | 133 |

## [Intervention Review]

# Remote care through telehealth for people with inflammatory bowel disease

Morris Gordon<sup>1</sup>, Vassiliki Sinopoulou<sup>1</sup>, Svetlana Lakunina<sup>1</sup>, Teuta Gjuladin-Hellon<sup>1,2</sup>, Kelly Bracewell<sup>3</sup>, Anthony K Akobeng<sup>4</sup>

<sup>1</sup>School of Medicine, University of Central Lancashire, Preston, UK. <sup>2</sup>Centre for Guidelines, National Institute for Health and Care Excellence (NICE), Manchester, UK. <sup>3</sup>University of Central Lancashire, Preston, UK. <sup>4</sup>Pediatric Gastroenterology, Sidra Medicine, Doha, Qatar

**Contact:** Morris Gordon, [morris@betterprescribing.com](mailto:morris@betterprescribing.com).

**Editorial group:** Cochrane Gut Group.

**Publication status and date:** New, published in Issue 5, 2023.

**Citation:** Gordon M, Sinopoulou V, Lakunina S, Gjuladin-Hellon T, Bracewell K, Akobeng AK. Remote care through telehealth for people with inflammatory bowel disease. *Cochrane Database of Systematic Reviews* 2023, Issue 5. Art. No.: CD014821. DOI: [10.1002/14651858.CD014821.pub2](https://doi.org/10.1002/14651858.CD014821.pub2).

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. This is an open access article under the terms of the [Creative Commons Attribution Licence](https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

## ABSTRACT

### Background

People with inflammatory bowel disease (IBD) require intensive follow-up with frequent consultations after diagnosis. IBD telehealth management includes consulting by phone, instant messenger, video, text message, or web-based services. Telehealth can be beneficial for people with IBD, but may have its own set of challenges. It is important to systematically review the evidence on the types of remote or telehealth approaches that can be deployed in IBD. This is particularly relevant following the coronavirus disease 2019 (COVID-19) pandemic, which led to increased self- and remote-management.

### Objectives

To identify the communication technologies used to achieve remote healthcare for people with inflammatory bowel disease and to assess their effectiveness.

### Search methods

On 13 January 2022, we searched CENTRAL, Embase, MEDLINE, three other databases, and three trials registries with no limitations on language, date, document type, or publication status.

### Selection criteria

All published, unpublished, and ongoing randomised controlled trials (RCTs) that evaluated telehealth interventions targeted at people with IBD versus any other type of intervention or no intervention.

We did not include studies based on digital patient information resources or education resources, unless they formed part of a wider package including an element of telehealth. We excluded studies where remote monitoring of blood or faecal tests was the only form of monitoring.

### Data collection and analysis

Two review authors independently extracted data from the included studies and assessed their risk of bias. We analysed studies on adult and paediatric populations separately. We expressed the effects of dichotomous outcomes as risk ratios (RRs) and the effects of continuous

outcomes as mean differences (MDs) or standardised mean differences (SMDs), each with their 95% confidence intervals (CIs). We assessed the certainty of the evidence using GRADE methodology.

## Main results

We included 19 RCTs with a total of 3489 randomised participants, aged eight to 95 years. Three studies examined only people with ulcerative colitis (UC), two studies examined only people with Crohn's disease (CD), and the remaining studies examined a mix of IBD patients. Studies considered a range of disease activity states. The length of the interventions ranged from six months to two years. The telehealth interventions were web-based and telephone-based.

## Web-based monitoring versus usual care

Twelve studies compared web-based disease monitoring to usual care.

Three studies, all in adults, provided data on disease activity. Web-based disease monitoring ( $n = 254$ ) is probably equivalent to usual care ( $n = 174$ ) in reducing disease activity in people with IBD (SMD 0.09, 95% CI  $-0.11$  to  $0.29$ ). The certainty of the evidence is moderate.

Five studies on adults provided dichotomous data that we could use for a meta-analysis on flare-ups. Web-based disease monitoring ( $n = 207/496$ ) is probably equivalent to usual care ( $n = 150/372$ ) for the occurrence of flare-ups or relapses in adults with IBD (RR 1.09, 95% CI 0.93 to 1.27). The certainty of the evidence is moderate. One study provided continuous data. Web-based disease monitoring ( $n = 465$ ) is probably equivalent to usual care ( $n = 444$ ) for the occurrence of flare-ups or relapses in adults with CD (MD 0.00 events, 95% CI  $-0.06$  to  $0.06$ ). The certainty of the evidence is moderate. One study provided dichotomous data on flare-ups in a paediatric population. Web-based disease monitoring ( $n = 28/84$ ) may be equivalent to usual care ( $n = 29/86$ ) for the occurrence of flare-ups or relapses in children with IBD (RR 0.99, 95% CI 0.65 to 1.51). The certainty of the evidence is low.

Four studies, all in adults, provided data on quality of life. Web-based disease monitoring ( $n = 594$ ) is probably equivalent to usual care ( $n = 505$ ) for quality of life in adults with IBD (SMD 0.08, 95% CI  $-0.04$  to  $0.20$ ). The certainty of the evidence is moderate.

Based on continuous data from one study in adults, we found that web-based disease monitoring probably leads to slightly higher medication adherence compared to usual care (MD 0.24 points, 95% CI 0.01 to 0.47). The results are of moderate certainty. Based on continuous data from one paediatric study, we found no difference between web-based disease monitoring and usual care in terms of their effect on medication adherence (MD 0.00, 95% CI  $-0.63$  to  $0.63$ ), although the evidence is very uncertain. When we meta-analysed dichotomous data from two studies on adults, we found no difference between web-based disease monitoring and usual care in terms of their effect on medication adherence (RR 0.87, 95% CI 0.62 to 1.21), although the evidence is very uncertain.

We were unable to draw any conclusions on the effects of web-based disease monitoring compared to usual care on healthcare access, participant engagement, attendance rate, interactions with healthcare professionals, and cost- or time-effectiveness. The certainty of the evidence is very low.

## Authors' conclusions

The evidence in this review suggests that web-based disease monitoring is probably no different to standard care in adults when considering disease activity, occurrence of flare-ups or relapse, and quality of life. There may be no difference in these outcomes in children, but the evidence is limited. Web-based monitoring probably increases medication adherence slightly compared to usual care.

We are uncertain about the effects of web-based monitoring versus usual care on our other secondary outcomes, and about the effects of the other telehealth interventions included in our review, because the evidence is limited.

Further studies comparing web-based disease monitoring to standard care for the clinical outcomes reported in adults are unlikely to change our conclusions, unless they have longer follow-up or investigate under-reported outcomes or populations. Studies with a clearer definition of web-based monitoring would enhance applicability, enable practical dissemination and replication, and enable alignment with areas identified as important by stakeholders and people affected by IBD.

## PLAIN LANGUAGE SUMMARY

### The use of technology for remote care in inflammatory bowel disease

#### Key messages

- Remote care is probably the same as usual care (e.g. face-to-face care in clinics and hospitals) for improving inflammatory bowel disease symptoms in adults; there is limited evidence for children.
- Remote care is probably the same as usual care for avoiding relapses and flare-ups; the same may be true for children.
- Remote care is probably the same as usual care for improving quality of life in adults; there is limited evidence for children.

#### What is inflammatory bowel disease?

Inflammatory bowel disease refers to two main conditions that cause inflammation of the gut. These are ulcerative colitis and Crohn's disease. Ulcerative colitis only affects the large intestine. Crohn's disease can affect any part of the digestive tract, from mouth to bottom.

Inflammatory bowel disease mainly causes stomach pain or discomfort, diarrhoea that can be bloody, weight loss, and tiredness.

### **What did we want to find out?**

Providing care from a distance, also called telehealth, is becoming more common, especially since the coronavirus 2019 (COVID-19) pandemic. Using technology to provide remote care could benefit people with inflammatory bowel disease. Telehealth can take place via telephone, instant messaging, video, text message, web-based services, or other means.

We wanted to find which communication technologies are used for remote care in inflammatory bowel disease, how they are used, if they are accessible to everyone, and what are their benefits or drawbacks.

### **What did we do?**

We searched for randomised controlled trials (RCTs; studies where participants are randomly assigned to one of two or more treatment groups) comparing telehealth with any other treatment for people with inflammatory bowel disease. RCTs give us the highest standard of evidence.

We applied no limitations for age or type of remote care in our search, but we excluded studies that did not focus on providing care, such as studies providing only patient information or education. We also excluded studies that provided remote blood or stool test monitoring with no other type of remote monitoring.

### **What did we find?**

We found 19 relevant RCTs, which enrolled a combined total of 3489 people aged eight to 95 years. Remote care was delivered online (e.g. smartphone applications, websites) or by telephone.

Twelve studies compared web-based care to usual care, three compared telephone-based care to usual care, three compared web-based care to "sham" care, one compared web-based care to self-care, and one compared psychological and telephone support to usual care.

Web-based remote care is probably no different to usual care in adults for improving symptoms, avoiding relapses or flare-ups, and enhancing quality of life.

We also found that people who receive web-based care are probably less likely to skip their medicines compared to those that receive usual care. We are moderately certain about these results based on the current evidence.

The evidence on children is limited.

With the currently available information, we cannot make any judgements on other parameters such as access to care, whether people with inflammatory bowel disease approve of these programmes and are encouraged to attend appointments, to what degree clinical professionals are involved in them, and costs or time.

The evidence on other forms of remote care was also very limited.

### **What are the limitations of the evidence?**

One limitation of the evidence was that the RCTs provided unclear descriptions of the remote care programmes, which means that any organisation wishing to copy and adopt these interventions would have difficulty doing so. The descriptions of usual care (the alternative treatment group in many studies) were also unclear. This means that standard care might be different from one study to another, which could make our findings less accurate.

Few studies looked at forms of remote care other than web-based care.

Another limitation is that the different studies measured different results (outcomes) of treatment.

Finally, some studies used poor quality research methods.

### **What next?**

No further studies comparing web-based care to usual care in adults are necessary, unless they last for longer periods of time or give more details that would help clinicians adopt them anywhere in the world. This includes details on the type and number of staff needed, resources, equipment, costs, accessibility, and data security. More studies on children may be useful, as well as studies that examine differences based on sex and social or financial status. In any case, future studies should concentrate on measuring the results that matter most to people with inflammatory bowel disease and their care providers.

---

**How up-to-date is this review?**

This review is up-to-date as of January 2022.



## SUMMARY OF FINDINGS

### Summary of findings 1. Web-based disease monitoring compared to usual care

#### Web-based disease monitoring compared to usual care

**Patient or population:** people with inflammatory bowel disease

**Setting:** hospitals and tertiary centres, and remotely

**Intervention:** web-based disease monitoring

**Comparison:** usual care

| Outcomes   | Anticipated absolute effects* (95% CI)      |  | Relative effect (95% CI)         | Nº of participants (studies)  | Certainty of the evidence (GRADE)   | Comments  |
|--|---|--|----------------------------------|-------------------------------|-------------------------------------|---|
|  | Risk with usual care                        | Risk with web-based disease monitoring           |                                  |                               |                                     |   |
| <b>Disease activity (adults)</b><br>Follow-up: 12 months                 | —   | SMD 0.09 higher (0.11 lower to 0.29 higher)      | —                                | 428 participants (3 studies)  | ⊕⊕⊕⊖<br><b>Moderate<sup>a</sup></b> | Equivalent to a mean 36-point reduction on the CDAI and a mean 1.7-point reduction on the SCCAI |
| <b>Flare-ups/relapse (dichotomous; adults)</b><br>Follow-up: 6–12 months | <b>Study population</b>                     |  | <b>RR 1.09</b><br>(0.93 to 1.27) | 868 participants (5 studies)  | ⊕⊕⊕⊖<br><b>Moderate<sup>b</sup></b> | —   |
|  | 403 per 1000                                | 440 per 1000 (375 to 512)                        |                                  |                               |                                     |   |
| <b>Flare-ups/relapse (continuous; adults)</b><br>Follow-up: 12 months    | Mean number of flare-ups was 0.19 (SD 0.42) | MD 0.00 more flare-ups (0.06 fewer to 0.06 more) | —                                | 909 participants (1 study)    | ⊕⊕⊕⊖<br><b>Moderate<sup>a</sup></b> | —   |
| <b>Flare-ups/relapse (dichotomous; children)</b><br>Follow-up: 12 months | <b>Study population</b>                     |  | <b>RR 0.99</b><br>(0.65 to 1.51) | 170 participants (1 study)    | ⊕⊕⊖⊖<br><b>Low<sup>c</sup></b>      | —   |
|  | 337 per 1000                                | 334 per 1000 (219 to 509)                        |                                  |                               |                                     |   |
| <b>Quality of life (adults)</b><br>Follow-up: 12 months                  | —   | SMD 0.08 higher (0.04 lower to 0.20 higher)      | —                                | 1099 participants (4 studies) | ⊕⊕⊕⊖<br><b>Moderate<sup>d</sup></b> | Equivalent to a mean 22-point increase on the IBDQ scale  |

\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.

**CDAI:** Crohn's Disease Activity Index; **CI:** confidence interval; **IBDQ:** Inflammatory Bowel Disease Questionnaire; **MD:** mean difference; **RR:** risk ratio; **SCCAI:** Simple Clinical Colitis Activity Index; **SMD:** standardised mean difference; **SD:** standard deviation.

#### GRADE Working Group grades of evidence

**High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty:** we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty:** our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

**Very low certainty:** we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

<sup>a</sup> Downgraded once for risk of bias related to blinding.

<sup>b</sup> Downgraded once for risk of bias related to blinding, selective reporting, and other sources.

<sup>c</sup> Downgraded once for risk of bias related to blinding and imbalance in the numbers of participants reaching end of study, and once for imprecision due to low participant numbers.

<sup>d</sup> Downgraded once for risk of bias related to blinding and attrition.

## Summary of findings 2. Web-based disease monitoring compared to sham monitoring

### Web-based disease monitoring compared to sham monitoring

**Patient or population:** people with inflammatory bowel disease

**Setting:** hospitals and tertiary centres, and remotely

**Intervention:** web-based disease monitoring

**Comparison:** sham monitoring

| Outcomes  | Anticipated absolute effects* (95% CI)                                   |  | Relative effect (95% CI) | N° of participants (studies)    | Certainty of the evidence (GRADE)   | Comments          |
|---|--|--|--------------------------|---------------------------------|-------------------------------------|-------------------|
|   | Risk with sham monitoring  | Risk with web-based disease monitoring |                          |                                 |                                     |                   |
| Disease activity  | —  | —                                      | —                        | —                               | —                                   | No data available |
| Flare-ups/relapse                                       | —  | —                                      | —                        | —                               | —                                   | No data available |
| Quality of life (adults)<br>Follow-up: 6 months–2 years | 1 study reported no changes in QoL. Another study reached no conclusion. |  | —                        | 447 participants<br>(2 studies) | ⊕⊕⊕⊕<br><b>Very low<sup>a</sup></b> | —                 |

\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.  
**CI:** confidence interval; **QoL:** quality of life.

#### GRADE Working Group grades of evidence

**High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty:** we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty:** our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

**Very low certainty:** we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

<sup>a</sup> Downgraded once for serious risk of bias concerns (all domains) and twice for very serious imprecision due to very low event numbers.

### Summary of findings 3. Web-based disease monitoring compared to self-screening

#### Web-based disease monitoring compared to self-screening

**Patient or population:** people with inflammatory bowel disease

**Setting:** hospitals and tertiary centres, and remotely

**Intervention:** web-based disease monitoring

**Comparison:** self-screening

| Outcomes  | Anticipated absolute effects* (95% CI)                            |  | Relative effect (95% CI) | Nº of participants (studies)  | Certainty of the evidence (GRADE)   | Comments |
|---|---|--|--------------------------|-------------------------------|-------------------------------------|----------|
|   | Risk with self-screening  | Risk with web-based disease monitoring |                          |                               |                                     |          |
| <b>Disease activity (adults)</b><br>Follow-up: 24 weeks               | 1 study reported no differences in disease activity.              |  | —                        | 102 participants<br>(1 study) | ⊕⊕⊕⊕<br><b>Very low<sup>a</sup></b> | —        |
| <b>Flare-ups/relapse (dichotomous; adults)</b><br>Follow-up: 24 weeks | 1 study reported no differences in relapses.                      |  | —                        | 102 participants<br>(1 study) | ⊕⊕⊕⊕<br><b>Very low<sup>a</sup></b> | —        |
| <b>Quality of life (adults)</b><br>Follow-up: 24 weeks                | 1 study reported greater improvement in QoL in the control group. |  | —                        | 102 participants<br>(1 study) | ⊕⊕⊕⊕<br><b>Very low<sup>a</sup></b> | —        |

\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.  
**CI:** confidence interval; **QoL:** quality of life.

### GRADE Working Group grades of evidence

**High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty:** we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty:** our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

**Very low certainty:** we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

<sup>a</sup> Downgraded once due to serious risk of bias concerns (randomisation, blinding, and selective reporting), and twice for very serious imprecision (very low participant and event numbers).

### Summary of findings 4. Telephone-based disease monitoring compared to face-to-face monitoring

#### Telephone-based disease monitoring compared to face-to-face monitoring

**Patient or population:** people with inflammatory bowel disease

**Setting:** hospitals and tertiary centres, and remotely

**Intervention:** telephone-based disease monitoring

**Comparison:** face-to-face monitoring

| Outcomes  | Anticipated absolute effects* (95% CI)   |  | Relative effect (95% CI)         | N° of participants (studies) | Certainty of the evidence (GRADE)   | Comments |
|---|--|--|----------------------------------|------------------------------|-------------------------------------|----------|
|   | Risk with face-to-face monitoring  | Risk with telephone-based disease monitoring |                                  |                              |                                     |          |
| <b>Disease activity (adults)</b><br>Follow-up: 6 months                 | 1 study, whilst reporting no data on this outcome, mentioned there was no significant change.  |  | —                                | 60 participants (1 study)    | ⊕⊕⊕⊕<br><b>Very low<sup>a</sup></b> | —        |
| <b>Flare-ups/relapse (dichotomous; adults)</b><br>Follow-up: 6 months   | <b>Study population</b><br>286 per 1000                      334 per 1000<br>(134 to 586)  |  | <b>RR 1.17</b><br>(0.47 to 2.89) | 42 participants (1 study)    | ⊕⊕⊕⊕<br><b>Very low<sup>b</sup></b> | —        |
| <b>Flare-ups/relapse (dichotomous; children)</b><br>Follow-up: 6 months | <b>Study population</b><br>95 per 1000                      23 per 1000<br>(3 to 195)  |  | <b>RR 0.24</b><br>(0.03 to 2.05) | 86 participants (1 study)    | ⊕⊕⊕⊕<br><b>Very low<sup>b</sup></b> | —        |
| <b>Quality of life (adults)</b><br>Follow-up: 6 months                  | 1 study, whilst reporting no data on QoL, mentioned there was no significant change. Another study reported median QoL scores, which were not very different between groups. |  | —                                | 123 participants (2 studies) | ⊕⊕⊕⊕<br><b>Very low<sup>a</sup></b> | —        |

|                                   |   |   |   |                 |                                     |   |
|-----------------------------------|---|---|---|-----------------|-------------------------------------|---|
| <b>Quality of life (children)</b> | Mean of 106 points (SD 15.5) on the IMPACT QoL (35 lowest to 175 highest) | MD 7 points higher (0.29 lower to 14.29 higher) | — | 86<br>(1 study) | ⊕⊕⊕⊕<br><b>Very low<sup>b</sup></b> | — |
| Follow-up: 6 months               |   |   |   |                 |                                     |   |

**\*The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.

**CI:** confidence interval; **MD:** mean difference; **QoL:** quality of life; **RR:** risk ratio.

#### GRADE Working Group grades of evidence

**High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty:** we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty:** our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

**Very low certainty:** we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

<sup>a</sup> Downgraded once for serious risk of bias concerns related to blinding and selective reporting, and twice for very serious imprecision due to very low participant numbers and events.

<sup>b</sup> Downgraded one for serious risk of bias concerns related to blinding, and twice for very serious imprecision due to very low participant numbers.

### Summary of findings 5. Cognitive behavioural therapy manual and telephone support compared to usual care

#### Cognitive behavioural therapy manual and telephone support compared to usual care

**Patient or population:** people with inflammatory bowel disease

**Setting:** hospitals and tertiary centres, and remotely

**Intervention:** CBT manual and telephone support

**Comparison:** usual care

| Outcomes                 | Anticipated absolute effects* (95% CI) |  | Relative effect (95% CI) | Nº of participants (studies) | Certainty of the evidence (GRADE) | Comments          |
|--------------------------|--|--|--------------------------|------------------------------|-----------------------------------|-------------------|
|                          | Risk with usual care                   | Risk with CBT manual and telephone support |                          |                              |                                   |                   |
| <b>Disease activity</b>  | —                                      | —  | —                        | —                            | —                                 | No data available |
| <b>Flare-ups/relapse</b> | —                                      | —  | —                        | —                            | —                                 | No data available |
| <b>Quality of life</b>   | —                                      | —  | —                        | —                            | —                                 | No data available |

**\*The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). The comparison group risk has been calculated based on the data from the included studies.

**CBT:** cognitive behavioural therapy; **CI:** confidence interval.

**GRADE Working Group grades of evidence**

**High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty:** we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty:** our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

**Very low certainty:** we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

---

## BACKGROUND

### Description of the condition

Inflammatory bowel disease (IBD) is an umbrella term that encompasses three main disease subtypes that affect the gastrointestinal tract: ulcerative colitis (UC), Crohn's disease (CD), and IBD unclassified. IBS prevalence exceeds 0.3% in Europe, North America, and Oceania; and incidence is rapidly rising in newly industrialised countries (Ng 2017). It has no known cure but can be managed; therefore, it places a huge financial burden on healthcare systems (Ghosh 2015). Approximately 25% of cases are diagnosed before 18 years of age, and the main treatment modalities are pharmacological therapy, dietary therapy, and surgery. Guided management and care can improve disease activity, symptoms, clinical outcomes (e.g. need for surgery), and quality of life (QoL; Elkjaer 2012). After diagnosis, intensive follow-up and frequent consultations are required to optimise IBD care, at least for some stages of the disease course (Bernstein 2011).

### Description of the intervention

IBD telehealth management refers to the remote delivery of healthcare management from the healthcare professional to the person with IBD (McLean 2011). It includes consulting by phone, instant messenger, video, text message, or web-based services. Communication can be live, such as by telephone, or delayed, such as by email (McLean 2009). During a telehealth session, the person with IBD provides information about their condition and health status. The information becomes electronically available to the clinician or other healthcare professional, who uses it to provide feedback based on their professional judgement (McLean 2011; Sood 2007). Telehealth can be beneficial for certain subgroups of people with IBD who might face problems accessing traditional healthcare resources that require their physical presence, such as older people, people from socio-economically disadvantaged backgrounds, and people with physical or learning disabilities. However, these subgroups may face a separate set of barriers to accessing telehealth resources (Choi 2014; Forducey 2012; Rimmer 2013). Telehealth is not synonymous with telemedicine, which "refers to the use of live synchronised videoconferencing, allowing for interactive video communications between a provider and a patient" (Groom 2021).

### How the intervention might work

Telehealth consultations work similarly to face-to-face consultations; the only difference is that any procedure that requires the patient's physical presence cannot occur (e.g. blood tests or physical examination; Heida 2018). Therefore, while telehealth consultations might be a useful substitute when face-to-face consultations are not possible or recommended, it is unknown how effective they are compared to face-to-face consultations. The breadth of available telehealth options also means that each option has its own advantages and disadvantages.

Telehealth consultations may reduce potential barriers to multidisciplinary team communication across team members and organisations and achieve successful communication in real time. This could facilitate more timely data monitoring and sharing of questions and concerns voiced by the person with IBD among the entire multidisciplinary team, including the primary care professionals (Cross 2012).

### Why it is important to do this review

It is important to systematically review the evidence on the effects of remote or telehealth approaches that can be deployed for IBD care. This has become particularly relevant since the coronavirus 19 (COVID-19) pandemic and resulting need for increased self-management and remote management, which these interventions can facilitate (Al-Ani 2020). It is also key to ascertain the effective components of remote or telehealth packages so that they can be replicated and disseminated.

## OBJECTIVES

To identify the communication technologies used to achieve remote healthcare for people with inflammatory bowel disease and to assess their effectiveness.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

All published, unpublished, and ongoing randomised controlled trials (RCTs) that evaluated telecommunication technologies for the management of IBD versus face-to-face interventions or no intervention. Cross-over studies and cluster-RCTs were eligible for inclusion, but quasi-randomised trials (using inappropriate randomisation) were ineligible.

We did not include studies on digital patient information resources (e.g. information on IBD organisation websites, such as Crohn's and Colitis UK), or education resources alone, unless they formed part of a wider package that included an element of telehealth as defined in this review. A separate Cochrane Review is focussing on education resources for people with IBD (Gordon 2021a).

We excluded studies where remote monitoring of blood or faecal tests was the only form of monitoring.

#### Types of participants

People of all ages with a confirmed IBD diagnosis. Subsets such as CD, UC, or intermediate colitis were eligible.

#### Types of interventions

We included studies on IBD management interventions that took place via phone, instant messaging, video, text message, or web-based services, or any other means of remote communication, whether live (e.g. telephone conversations) or delayed (e.g. email).

We considered any control intervention, such as face-to-face interventions, no intervention. Studies that compared different telehealth interventions to each other were also eligible.

We aimed to perform separate analyses for trials that evaluated telehealth plus traditional consultations versus traditional consultations alone and trials that evaluated telehealth versus traditional consultations.

#### Types of outcome measures

Our review included dichotomous and continuous outcome measures. Study outcomes were irrelevant for determining study eligibility.



## Primary outcomes

- Disease activity at study end, using a recognised disease activity scoring system, measured clinically, endoscopically, or histologically, and as defined by study authors (separate for adults and children, if sufficient data available). We planned to analyse clinical, endoscopic, and histological data separately.
- Flare-ups or relapses at study end, measured clinically, endoscopically, or histologically, and as defined by study authors (separate for adults and children, if sufficient data available). We planned to analyse clinical, endoscopic, and histological data separately.
- QoL at study end, using validated scales or tools, and as defined by study authors (separate for adults and children, if sufficient data available)

## Secondary outcomes

- Number of episodes of accessing healthcare (outpatient, remote, or inpatient) at study end, as defined by study authors
- Medication adherence at study end, as defined and measured by study authors
- Participant engagement (adherence/compliance) with the intervention at study end, as defined by study authors
- Rate of attendance or engagement with any or all elements of the intervention (number of planned appointments attended, number of planned interactions attended) at study end, as defined by study authors
- Rate of attendance of interactions with healthcare professionals during the intervention (as part of the intervention or otherwise), as defined by study authors
- Costs or cost/time-effectiveness during study, as defined by study authors

## Qualitative outcomes

- Programme attributes (technology type, design, cost, user guidance, live contact, management of delayed contact, contact with other members of the multidisciplinary team, time to response, data security) during study
- Programme requirements (cost, software, infrastructure, training needs, access requirements (for the person with IBD and the healthcare provider)) during study

## Search methods for identification of studies

### Electronic searches

We searched the following databases from inception, applying no restrictions on the language of publication.

- Cochrane Central Register of Controlled Trials (CENTRAL; 2022, Issue 1) via Ovid Evidence-Based Medicine Reviews Database (EBMR; searched 13 January 2022; [Appendix 1](#))
- MEDLINE and MEDLINE ALL via Ovid (1946 to 13 January 2022; [Appendix 2](#))
- Embase via Ovid (1974 to 13 January 2022; [Appendix 3](#))
- PsycINFO via Ovid (1806 to 13 January 2022; [Appendix 4](#))
- CINAHL via EBSCO (1937 to 13 January 2022; [Appendix 5](#))
- AMED (Allied and Complementary Medicine database) via Ovid (1985 to 13 January 2022; [Appendix 6](#))

We searched the following trial registries by combining terms related to IBD and telehealth.

- Cochrane Gut Group Specialised Register
- ClinicalTrials.gov ([www.clinicaltrials.gov](http://www.clinicaltrials.gov); [Appendix 7](#))
- World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; [trialsearch.who.int/](http://trialsearch.who.int/); [Appendix 8](#))

### Searching other resources

As complementary search methods, we carefully checked the references of included studies and relevant systematic reviews for other potentially eligible studies. We sought unpublished trials by contacting experts in the field, and we scanned relevant conference abstracts that were identified in the search (Embase and CENTRAL) to capture any studies presented but not yet published in full.

We attempted to obtain translations of papers when necessary.

### Data collection and analysis

We carried out data collection and analysis according to the methods recommended in the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2020](#)).

### Selection of studies

Two review authors independently screened the titles and abstracts identified from the literature search, discarding studies that were clearly irrelevant. We obtained the full reports of all potentially eligible studies, and two review authors independently assessed them against our inclusion criteria. We resolved disagreements by discussion, or by consulting a third review author where necessary. We presented studies excluded at this or subsequent stages in the [Characteristics of excluded studies](#) table and recorded the main reason for exclusion. We outlined the selection process in a PRISMA flowchart ([Page 2021](#)).

### Data extraction and management

Two review authors independently extracted data from the included studies using piloted data extraction forms. We collected the following variables, where available.

- Trial setting: country and number of trial centres
- Trial registration details: registration number, date of registration, registered outcomes
- Methods: study design, total study duration, dates
- Participant characteristics: age, socio-demographics, ethnicity, disease status, disease type, diagnostic criteria, total number
- Eligibility criteria: inclusion and exclusion criteria
- Intervention and comparator: type of telehealth and control intervention, people delivering the intervention, resources required to deliver the intervention, time to response, people with access to the intervention, data security
- Outcomes: outcome definition, unit of measurement, time of collection
- Results: number of participants allocated to each group, missing participants, sample size
- Funding source and conflicts of interest



For studies requiring translation, we used online translation software or, if necessary, we sought translations by speakers of the relevant languages.

### Assessment of risk of bias in included studies

During data extraction, two review authors independently assessed all included studies for risk of bias, using the Cochrane risk of bias tool (RoB 1), as outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). RoB 1 includes the following risk of bias domains.

- Sequence generation (selection bias)
- Allocation concealment (selection bias)
- Blinding of participants and personnel (performance bias)
- Blinding of outcome assessment (detection bias)
- Incomplete outcome data (attrition bias)
- Selective reporting (reporting bias)
- Other bias

We judged the studies to be at low, high, or unclear risk of bias for each domain assessed.

After data extraction, two review authors compared the extracted data to discuss and resolve discrepancies before transferring the data to the [Characteristics of included studies](#) table in Review Manager Web (RevMan Web 2022).

We judged risk of bias for cluster-RCTs as prescribed in Section 16.3.2 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011).

### Measures of treatment effect

For dichotomous outcomes, we expressed the treatment effect as risk ratios (RRs) with corresponding 95% confidence intervals (CIs). For continuous outcomes, we expressed the treatment effect as mean differences (MDs) with 95% CIs. However, if studies assessed the same continuous outcome on a different scale, we estimated the treatment effect using the standardised mean difference (SMD). We presented SMDs as standard deviation (SD) units and interpreted them as follows: 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect.

### Unit of analysis issues

The participant was the unit of analysis. For studies comparing more than two intervention groups, we made multiple pair-wise comparisons between all possible pairs of intervention groups. To avoid double counting, we divided shared intervention groups evenly among the comparisons. For dichotomous outcomes, we divided both the number of events and the total number of participants. For continuous outcomes, we only divided the total number of participants, and left the means and SDs unchanged.

We pooled data from cross-over studies if they were reported separately before and after cross-over (we only used data from before cross-over). For cluster-RCTs, we only used study data if the study authors had used appropriate statistical methods for taking the clustering effect into account.

If studies reported dichotomous event data per episode instead of per participant, we contacted the study authors for further data to

avoid unit of analysis issues. If studies reported outcomes at several time points, we used the longest follow-up.

### Dealing with missing data

We contacted study authors to request missing data where necessary.

For analyses of dichotomous outcomes, we used the numbers randomised as denominators and numbers of events as numerators. For analyses of continuous outcomes, we used the sample numbers as reported by the study authors for each particular continuous outcome. If the sample numbers were not reported, we estimated them based on reported attrition percentages. We attempted to estimate missing SDs using relevant statistical tools and calculators if studies reported other variance measures.

Studies that did not report measures of variance were judged at high risk of selective reporting.

We used the same methods in our sensitivity analyses.

### Assessment of heterogeneity

We scrutinised studies to ensure they were clinically homogenous in terms of participants, interventions, comparators, and outcomes. To test for statistical heterogeneity, we used a  $\chi^2$  test, considering a P value below 0.1 indicative of heterogeneity. To quantify statistical heterogeneity, we used the  $I^2$  statistic, interpreting the values according to the following thresholds (Higgins 2020).

- 0% to 40%: might not be important
- 30% to 60%: may represent moderate heterogeneity
- 50% to 90%: may represent substantial heterogeneity
- 75% to 100%: considerable heterogeneity

We examined possible explanations for heterogeneity when sufficient data were available, including factors such as participant characteristics (e.g. age, sex), condition severity, healthcare system, and country.

Where we detected a considerable degree of statistical heterogeneity ( $I^2$  value above 75%), we did not pool the data in a meta-analysis. We also investigated possible sources of considerable statistical heterogeneity (e.g. clinical differences, risk of bias) and conducted sensitivity analyses where relevant. If we were unable to explain considerable statistical heterogeneity, we presented the results narratively.

### Assessment of reporting biases

We used an inclusive search strategy in an attempt to minimise reporting biases. Had we included 10 or more studies in a meta-analysis, we would have investigated publication bias by creating a funnel plot and visually inspecting funnel plot asymmetry, or by following other methods described in the *Cochrane Handbook of Systematic Reviews* (Higgins 2020). We would also have tested funnel plot asymmetry by performing a linear regression of the intervention effect estimate against its standard error, weighted by the inverse of the variance of the intervention effect estimate (Egger 1997).

## Data synthesis

We summarised the study characteristics narratively, then performed meta-analyses where two or more studies assessed similar populations, interventions, and outcomes. We planned to perform separate analyses of studies on paediatric populations, adult populations, and different sub-intervention types, using Review Manager Web ([RevMan Web 2022](#)). We synthesised data using the random-effects model. We pooled RRs for dichotomous outcomes and MDs or SMDs for continuous outcomes, alongside 95% CIs. When we were unable to carry out a meta-analysis (e.g. due to lack of uniformity in data reporting), we presented a narrative summary of the included studies.

We grouped qualitative outcomes by the key attributes defined in [Secondary outcomes](#), and presented them in additional tables. We also presented summary descriptive statistics (number of specific remote telehealth solutions used, mean costs, resources, etc.) to help readers ascertain the core attributes across studies. We presented these data narratively and in additional tables.

## Subgroup analysis and investigation of heterogeneity

Where we detected heterogeneity, we investigated possible causes and addressed them using methods described in [Higgins 2020](#).

For our primary outcomes, we presented our analyses separately based on age (adult/paediatric), and we undertook subgroup analyses based on disease type, which we considered the variable most likely to impact outcomes differently.

The statistical methods described in [Data synthesis](#) applied to the subgroup analyses.

## Sensitivity analysis

Where possible, we planned to undertake sensitivity analyses on the primary outcomes to assess whether the findings of the review were robust to the decisions made during the review process. In particular, we intended to exclude studies at high or unclear risk of selection and performance bias. Where analyses included studies with reported and estimated SDs, we planned to exclude those with estimated SDs, to assess whether this exclusion would affect the findings of the review. We investigated whether the choice of model (fixed-effect versus random-effects) impacted the results, and we explored heterogeneity in case of major inconsistencies between the results of the two models.

## Summary of findings and assessment of the certainty of the evidence

We presented the main results for all comparisons in summary of findings tables. We exported data for each comparison and primary outcome to GRADEpro software to assess the certainty of the evidence ([GRADEpro GDT](#)). We included all three primary outcomes in the summary of findings tables. We considered that the most important outcomes for decision-makers were those from the comparison 'web-based disease monitoring versus usual care'.

Based on risk of bias, inconsistency, imprecision, indirectness, and publication bias, we rated the certainty of the evidence for each outcome as high, moderate, low, or very low. The GRADE Working Group has defined these ratings as follows.

- High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
- Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
- Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

We justified all decisions to downgrade the certainty of the evidence using footnotes, and made comments to aid the reader's understanding of the review where necessary.

## RESULTS


### Description of studies

The [Characteristics of included studies](#) table, [Characteristics of excluded studies](#) table, [Characteristics of studies awaiting classification](#) table, and [Characteristics of ongoing studies](#) table provide detailed information.

### Results of the search

We completed our literature search on 13 January 2022, identifying 3946 records through database searching and three additional records from alternative sources. After removal of duplicates, 2622 unique records remained. After title and abstract screening, we retrieved 132 full-text articles; of these, 70 reports of 19 RCTs met our eligibility criteria. [Figure 1](#) presents the study selection process in a PRISMA flow diagram.

**Figure 1. Flow chart of study retrieval and selection.**



## Included studies

For details of study and participant characteristics, see [Table 1](#).

## Setting

Six studies were conducted in the USA ([Atreja 2018](#); [Cross 2012](#); [Cross 2019](#); [Reich 2019](#); [Siegel 2018](#); [Stunkel 2012](#)), one in Canada ([Chauhan 2016](#)), two in the UK ([Akobeng 2015](#); [Hughes 2017](#)), three in Denmark ([Ankersen 2019](#); [Carlsen 2017a](#); [Elkjaer 2010a](#)), one in China ([Wang 2020](#)), one in Spain ([Del Hoyo 2018](#)), two in the Netherlands ([de Jong 2017](#); [Heida 2018](#)), one in New Zealand ([McCombie 2020](#)), and one in Czechia ([Malickova 2020](#)). One study did not report the location ([Ley 2020](#)).

All studies were conducted in hospitals and tertiary centres. Nine studies were single-centre RCTs ([Akobeng 2015](#); [Ankersen 2019](#); [Atreja 2018](#); [Carlsen 2017a](#); [Chauhan 2016](#); [Del Hoyo 2018](#); [Malickova 2020](#); [Reich 2019](#); [Wang 2020](#)), and nine were multicentre RCTs ([Cross 2012](#); [Cross 2019](#); [de Jong 2017](#); [Elkjaer 2010a](#); [Heida 2018](#); [Hughes 2017](#); [McCombie 2020](#); [Siegel 2018](#); [Stunkel 2012](#)). One study provided no information in this regard ([Ley 2020](#)).

One study was a cluster-RCT ([Siegel 2018](#)).

## Participants

Participant age ranged from eight years ([Akobeng 2015](#)) to 95 years ([Elkjaer 2010a](#)). Three studies examined paediatric populations ([Akobeng 2015](#); [Carlsen 2017a](#); [Heida 2018](#)). All other studies were in adults (aged 16 years and older).

Three studies examined exclusively UC populations ([Cross 2012](#); [Elkjaer 2010a](#); [Ley 2020](#)), two studies examined exclusively CD populations ([Siegel 2018](#); [Wang 2020](#)), and the remaining studies examined a mix of IBD types.

Six studies included people with both active and inactive states of the disease ([Carlsen 2017a](#); [Cross 2012](#); [Cross 2019](#); [de Jong 2017](#); [Del Hoyo 2018](#); [Wang 2020](#)), six studies included people with an inactive state of the disease ([Akobeng 2015](#); [Heida 2018](#); [Ley 2020](#); [Malickova 2020](#); [McCombie 2020](#); [Reich 2019](#)), two studies included people with mild to moderate disease ([Elkjaer 2010a](#); [Stunkel 2012](#)), one study included people in remission or with low disease activity ([Ankersen 2019](#)), and four studies did not report on the activity of the disease ([Atreja 2018](#); [Chauhan 2016](#); [Hughes 2017](#); [Siegel 2018](#)).

Twelve studies reported trial registrations ([Akobeng 2015](#); [Ankersen 2019](#); [Atreja 2018](#); [Carlsen 2017a](#); [Cross 2012](#); [Cross 2019](#); [de Jong 2017](#); [Del Hoyo 2018](#); [Heida 2018](#); [Hughes 2017](#); [McCombie 2020](#); [Reich 2019](#)).

## Interventions

The studies evaluated the following interventions.

- Telephone consultations versus face-to-face consultations ([Akobeng 2015](#))
- Mobile phone application disease monitoring versus self-screening ([Ankersen 2019](#))
- Mobile phone application disease monitoring versus sham education application ([Atreja 2018](#), abstract only)
- Web-based disease monitoring versus usual care ([Carlsen 2017a](#))

- Telephone follow-up visits versus clinic follow-up visits ([Chauhan 2016](#), abstract only)
- Web-based care management portal versus usual care ([Cross 2012](#))
- Web-based care management portal weekly versus every other week versus usual care ([Cross 2019](#))
- Web-based care management portal versus usual care ([de Jong 2017](#))
- Remote web-based monitoring versus telephone-based monitoring versus usual care ([Del Hoyo 2018](#))
- Web-based education and self-treatment versus usual care ([Elkjaer 2010a](#))
- Automated email alerts and web-based telemonitoring versus usual care ([Heida 2018](#))
- Cognitive behavioural therapy (CBT) self-complete manual and telephone support versus usual care in waitlist ([Hughes 2017](#), abstract only)
- Web-based phone application for medication adherence versus sham application ([Ley 2020](#))
- Web-based application telemonitoring versus usual care ([Malickova 2020](#); [McCombie 2020](#))
- Web-based IBD-specific information and electronic reminders for medication adherence versus sham web-based information unrelated to IBD ([Reich 2019](#))
- Decision-aid online programme for choice of combination therapy versus usual care ([Siegel 2018](#), abstract only)
- Web-based application disease monitoring versus usual care ([Stunkel 2012](#), abstract only)
- Web-based disease monitoring and medication adherence versus usual care ([Wang 2020](#))

[Cross 2019](#) and [Del Hoyo 2018](#) were three-arm studies. All other studies had two arms.

## Outcomes

The length of the interventions ranged from eight weeks ([Hughes 2017](#)) to three years ([Siegel 2018](#)).

### Primary outcomes

#### Disease activity

Eight studies reported disease activity as an outcome. [Ankersen 2019](#) measured IBD activity using a colour-coded system based on the Harvey Bradshaw Index (HBI) for CD participants, the Simple Clinical Colitis Activity Index (SCCAI) for participants with UC/indeterminate colitis, and Total Inflammatory Burden Score (TIBS) for both populations. [Cross 2012](#) used the Seo Index to measure disease activity. [Cross 2019](#) and [McCombie 2020](#) used the HBI for CD participants and the SCCAI for UC participants. [Malickova 2020](#) used the HBI for CD participants and the partial Mayo score for UC participants. [Del Hoyo 2018](#) measured disease activity using faecal calprotectin (FC) levels, but provided no details in the report. [Chauhan 2016](#) and [Carlsen 2017a](#) stated that disease activity was an outcome but provided no data.

#### Flare-ups or relapse

Ten studies measured flare-ups or relapses. Seven studies reported the number of relapses in each intervention group over the study period ([Akobeng 2015](#); [Ankersen 2019](#); [Cross 2012](#); [Cross 2019](#); [Del](#)

Hoyo 2018; Heida 2018; McCombie 2020). de Jong 2017 and Elkjaer 2010a reported mean number of flare-ups during the study as continuous data. Malickova 2020 reported relapses that needed hospitalisation.

### Quality of life

Thirteen studies reported QoL (Akobeng 2015; Ankersen 2019; Atreja 2018; Chauhan 2016; Cross 2012; Cross 2019; de Jong 2017; Del Hoyo 2018; Elkjaer 2010a; Heida 2018; McCombie 2020; Reich 2019; Stunkel 2012). Four studies used the Inflammatory Bowel Disease Questionnaire (IBDQ; Cross 2012; Cross 2019; McCombie 2020; Stunkel 2012). Five studies used the Short Inflammatory Bowel Disease Questionnaire (SIBDQ; Ankersen 2019; Atreja 2018; de Jong 2017; Elkjaer 2010a; Reich 2019). Akobeng 2015 and Heida 2018 used the IMPACT questionnaire. Del Hoyo 2018 used the IBDQ-9, the EuroQol five-dimension questionnaire (EQ-5D), and Visual Analogue Scales (VAS). Carlsen 2017a and Chauhan 2016 did not report the method used to measure QoL.

### Secondary outcomes

#### Number of episodes of accessing healthcare

Nine studies reported the number of episodes of accessing healthcare (Akobeng 2015; Carlsen 2017a; Cross 2019; de Jong 2017; Del Hoyo 2018; Elkjaer 2010a; Heida 2018; Malickova 2020; McCombie 2020). Akobeng 2015 reported the number of participants in each group that had one or more hospital admissions. Carlsen 2017a reported total numbers of outpatient visits, on-demand outpatient visits, acute hospitalisations, planned outpatient visits, and contacts in total. Cross 2019 reported total encounters, IBD-related hospitalisations, non-IBD-related hospitalisations, non-invasive diagnostic tests, electronic encounters, and telephone encounters (per 100 participants per year). de Jong 2017 reported the mean number of hospital admissions and outpatient visits. Del Hoyo 2018 reported the number of outpatient visits. Elkjaer 2010a reported the number of acute and routine hospital visits per group. Heida 2018 reported face-to-face encounters with healthcare providers. Malickova 2020 reported the mean number of visits to doctors and IBD nurses and the mean number of hospitalisations per participant. McCombie 2020 reported the mean number of gastroenterologist appointments, surgical appointments, IBD hospitalisations, and nights in hospital.

#### Medication adherence

Seven studies measured medication adherence (Ankersen 2019; Carlsen 2017a; Cross 2012; de Jong 2017; Del Hoyo 2018; Ley 2020; Wang 2020). Ankersen 2019 and Carlsen 2017a used self-assessment questionnaires with the Medication Adherence Report Scale (MARS). Cross 2012, de Jong 2017, and Wang 2020 used the Morisky Medication Adherence Scale (MMAS). Del Hoyo 2018 used the Morisky-Green Index. Ley 2020 used the Medication Possession Ratio (MPR).

#### Participant engagement

Eleven studies studied participant engagement (Ankersen 2019; Carlsen 2017a; Cross 2019; Del Hoyo 2018; Elkjaer 2010a; Heida 2018; Hughes 2017; Malickova 2020; McCombie 2020; Reich 2019; Stunkel 2012). Ankersen 2019 reported participant satisfaction. Carlsen 2017a reported adherence as the number of entries in their web programme by participants. Cross 2019 defined adherence

as 80% or more completion of self-assessments. Del Hoyo 2018 measured adherence as compliance with more than 80% of checkups. Elkjaer 2010a assessed compliance via a compliance questionnaire. Heida 2018 reported compliance as more than 80% response to alerts. Hughes 2017 reported the percentage of participants completing at least one telephone session. McCombie 2020 reported the results of two system usability scales (SUS). Malickova 2020 reported non-compliance numbers without any further details. Reich 2019 reported the percentage of participants logging into their web application. Stunkel 2012 reported feedback from participants without providing further details.

#### Rate of attendance or engagement with any or all elements of the intervention

Only three studies reported attendance/engagement as number of planned appointments/interactions attended (Akobeng 2015; Carlsen 2017a; McCombie 2020). Akobeng 2015 reported the median number of consultations scheduled by the hospital and the median number of consultations attended per person. Carlsen 2017a reported the number of planned outpatient visits. McCombie 2020 reported the number of people completing FC readings.

#### Rate of attendance of interactions with healthcare professionals

Only Akobeng 2015 and Del Hoyo 2018 reported rate of interactions attended. Akobeng 2015 reported the percentage of participants who had at least one consultation allocated. Del Hoyo 2018 reported percentage of outpatient visits.

#### Costs or cost/time-effectiveness

Eight studies reported costs or cost/time-effectiveness (Akobeng 2015; Carlsen 2017a; Chauhan 2016; de Jong 2017; Del Hoyo 2018; Elkjaer 2010a; Heida 2018; Malickova 2020). Akobeng 2015 estimated costs to the UK National Health Service (NHS). Carlsen 2017a estimated economic gains. Chauhan 2016 reported the average parking and travel costs with an average loss of income. de Jong 2017 stated mean annual direct costs and mean annual savings. Del Hoyo 2018 used cost and effect data to obtain cost-effectiveness and cost-utility, but provided no specific details. Elkjaer 2010a converted the number of medications plus professional visits into financial savings for the department. Heida 2018 reported mean annual cost-saving. Malickova 2020 estimated the reduction on average annual costs between the groups.

### Qualitative synthesis

#### Type of Telehealth

Table 2 and Table 3 provide details of the contents of each intervention.

Three studies compared telephone consultations to usual care (Akobeng 2015; Chauhan 2016; Hughes 2017). Two studies compared web-based disease monitoring programmes to usual care (Carlsen 2017a; McCombie 2020). Four studies evaluated web-based care management programmes versus usual care (Cross 2012; Cross 2019; de Jong 2017; Siegel 2018). Two studies evaluated web-based monitoring together with automated email alerts versus usual care (Heida 2018; Malickova 2020). Ankersen 2019 investigated a mobile phone application for disease monitoring versus self-screening. Atreja 2018 compared a mobile phone application for disease monitoring to a patient education application. Elkjaer 2010a compared web-based online education and self-treatment to usual care. Ley 2020 compared a web-based



phone application for medication adherence to a sham application (containing educational materials and capability to record medication intake). Reich 2019 evaluated a web-based application with IBD-specific information and reminders for medication adherence versus a sham application. Stunkel 2012 evaluated a web-based application for disease monitoring versus websites with information regarding IBD. Wang 2020 evaluated nurse-led web-based disease monitoring and medication adherence application versus usual care. Del Hoyo 2018 evaluated remote web-based monitoring versus nurse-assisted telephone care versus usual care.

### Other components of the intervention

Seven studies reported educational components as part of the telehealth intervention (Cross 2012; Cross 2019; Elkjaer 2010a; Hughes 2017; Reich 2019; Siegel 2018; Wang 2020). Table 2 provides further details. Three studies measured FC as part of the diagnostic assessment (Heida 2018; Malickova 2020; McCombie 2020).

### Length of intervention, resources, access issues, data security

Length of the intervention varied between eight weeks (Heida 2018) and three years (Siegel 2018). For details, see Table 2.

Necessary resources were a mobile phone in 16 studies (Akobeng 2015; Ankersen 2019; Atreja 2018; Carlsen 2017a; Chauhan 2016; Cross 2012; Cross 2019; de Jong 2017; Del Hoyo 2018; Heida 2018; Hughes 2017; Ley 2020; Malickova 2020; McCombie 2020; Stunkel 2012; Wang 2020), a computer in four studies (de Jong 2017; Elkjaer 2010a; Malickova 2020; Reich 2019), and internet connection in seven studies (Atreja 2018; Carlsen 2017a; de Jong 2017; Del Hoyo 2018; Heida 2018; Malickova 2020; Reich 2019). Cross 2019 and McCombie 2020 stated that they provided devices to their participants. Cross 2019 required participants to have an electronic weight scale. Table 3 provides further details.

Not having access to a smartphone, computer, or internet was explicitly reported as an access issue in four studies (Akobeng 2015; Heida 2018; Malickova 2020; Reich 2019). Three studies reported language barrier as an access issue (Heida 2018; Malickova 2020; Reich 2019). Wang 2020 excluded people who were unable to use the web application. Stunkel 2012 excluded people with Blackberry phones. Reich 2019 excluded those with a degree of cognitive impairment that would impair participation. McCombie 2020 excluded people who were unable to provide written consent. Hughes 2017 excluded people with suicidal ideations. Table 3 provides further details.

Two studies commented on data security: Cross 2012 mentioned that the data transmitted from participants' homes was de-identified and encrypted, and Del Hoyo 2018 mentioned confidentiality measures to secure the data provided. Table 3 provides further details.

### Funding sources and conflicts of interest

Fourteen studies reported their sources of funding (Akobeng 2015; Ankersen 2019; Atreja 2018; Carlsen 2017a; Cross 2012; Cross 2019; de Jong 2017; Del Hoyo 2018; Elkjaer 2010a; Heida 2018; Ley 2020; McCombie 2020; Reich 2019; Wang 2020). Four studies were funded

via government grants (Akobeng 2015; Atreja 2018; Cross 2012; Cross 2019), nine studies by private sources (Ankersen 2019; Carlsen 2017a; de Jong 2017; Del Hoyo 2018; Heida 2018; Elkjaer 2010a; Ley 2020; Reich 2019; Wang 2020), and one study by a charity and non-profit research association (McCombie 2020).

Five studies provided no information regarding their source of funding (Chauhan 2016; Hughes 2017; Malickova 2020; Siegel 2018; Stunkel 2012).

Twelve studies made conflicts of interest declarations (Akobeng 2015; Ankersen 2019; Carlsen 2017a; Cross 2019; de Jong 2017; Del Hoyo 2018; Elkjaer 2010a; Heida 2018; Hughes 2017; Ley 2020; McCombie 2020; Reich 2019). Five studies declared no conflicts of interest (Carlsen 2017a; Cross 2019; Hughes 2017; McCombie 2020; Reich 2019), four studies declared that several authors received grants or non-financial support from private providers (Ankersen 2019; de Jong 2017; Heida 2018; Ley 2020), one study reported receiving research grants during the conduct of the study (Akobeng 2015), and two studies declared that several authors had connections to healthcare companies unrelated to the study (Del Hoyo 2018; Elkjaer 2010a).

Seven studies provided no conflicts of interest declarations (Atreja 2018; Chauhan 2016; Cross 2012; Malickova 2020; Siegel 2018; Stunkel 2012; Wang 2020).

### Excluded studies

We excluded 27 studies (42 records; see Characteristics of excluded studies). The main reason for exclusion was wrong intervention in 14 studies (Ankersen 2017; Carlsen 2017b; Elkjaer 2010b; Jambaulikar 2015; NCT01852097; NCT02265588; NCT02707068; NCT03486158; NCT03695783; Oser 2018; RBR-79dn4k; Sutton 2019; Tripp 2017; Zhang 2020), wrong population in one study (NCT00310362), and wrong study design in 12 studies (Camba 2013; Creed 2019; Del Hoyo 2021; Gray 2020; Greenley 2015; Krier 2011; Mastronardi 2020; Miloh 2017; Moss 2010; NCT04151420; NCT04165265; Snoei 2009).

### Studies awaiting classification

There are nine studies (10 records) awaiting classification (Bonnaud 2021; Hommel 2015; NCT02085083; NCT02694042; NCT03059186; NCT03186872; NCT04754620; NTR2892; NTR4648).


### Ongoing studies

We identified nine ongoing studies (10 records; ACTRN12617000389303; IRCT2020061304775; NCT03985800; NCT04207008; NCT04388865; NCT04653259; NCT04861597; Norton 2021; RBR-7t8fv7).

### Risk of bias in included studies

For a graphical presentation of the results of our risk of bias assessment, see Figure 2 and Figure 3. Further details can be found in the risk of bias tables (in the Characteristics of included studies table).

**Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.**



**Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.**

|                | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias): Study level | Blinding of outcome assessment (detection bias): Study level | Incomplete outcome data (attrition bias): Study level | Selective reporting (reporting bias) | Other bias |
|----------------|---|---|--|--|---|--------------------------------------|------------|
| Akobeng 2015   | +   | +                                       | -  | -  | +   | +                                    | +          |
| Ankersen 2019  | ?   | ?                                       | -  | -  | +   | ?                                    | +          |
| Atreja 2018    | ?   | ?                                       | ?  | ?  | ?   | ?                                    | ?          |
| Carlsen 2017a  | ?   | +                                       | -  | -  | +   | -                                    | +          |
| Chauhan 2016   | +   | +                                       | -  | -  | +   | ?                                    | +          |
| Cross 2012     | +   | +                                       | -  | +  | -   | +                                    | +          |
| Cross 2019     | +   | +                                       | -  | +  | +   | +                                    | +          |
| de Jong 2017   | +   | +                                       | -  | -  | +   | +                                    | +          |
| Del Hoyo 2018  | +   | +                                       | -  | -  | +   | +                                    | +          |
| Elkjaer 2010a  | +   | +                                       | -  | -  | +   | ?                                    | ?          |
| Heida 2018     | +   | +                                       | -  | -  | ?   | +                                    | +          |
| Hughes 2017    | ?   | ?                                       | -  | ?  | ?   | ?                                    | +          |
| Ley 2020       | ?   | ?                                       | +  | ?  | ?   | ?                                    | +          |
| Malickova 2020 | +   | ?                                       | -  | +  | +   | ?                                    | ?          |
| McCombie 2020  | +   | +                                       | -  | -  | +   | +                                    | +          |
| Reich 2019     | ?   | ?                                       | -  | ?  | ?   | +                                    | +          |
| Siegel 2018    | ?   | ?                                       | ?  | ?  | ?   | ?                                    | +          |
| Stunkel 2012   | ?   | ?                                       | ?  | ?  | ?   | ?                                    | ?          |



Figure 3. (Continued)

|              |   |   |   |   |   |   |   |
|--------------|---|---|---|---|---|---|---|
| Siegel 2018  | + | + | + | + | + | + | + |
| Stunkel 2012 | ? | ? | ? | ? | ? | ? | ? |
| Wang 2020    | + | + | - | ? | + | ? | + |

### Allocation

Ten studies clearly described random sequence generation and allocation concealment, so we judged them at low risk of selection bias in both domains (Akobeng 2015; Chauhan 2016; Cross 2012; Cross 2019; de Jong 2017; Del Hoyo 2018; Elkjaer 2010a; Heida 2018; McCombie 2020; Wang 2020). Seven studies provided insufficient information on random sequence generation and allocation concealment, so we judged them at unclear risk of selection bias (Ankersen 2019; Atreja 2018; Hughes 2017; Ley 2020; Reich 2019; Siegel 2018; Stunkel 2012). We considered Carlsen 2017a at unclear risk in relation to random sequence generation and low risk for allocation concealment (overall unclear risk of selection bias), and we judged Malickova 2020 at low risk regarding random sequence generation and unclear risk for allocation concealment (overall low risk of selection bias).

### Blinding

Due to the nature of the interventions, 15 studies could not blind participants and personnel and so were at high risk of performance bias (Akobeng 2015; Ankersen 2019; Carlsen 2017a; Chauhan 2016; Cross 2012; Cross 2019; de Jong 2017; Del Hoyo 2018; Elkjaer 2010a; Heida 2018; Hughes 2017; Malickova 2020; McCombie 2020; Reich 2019; Wang 2020). Only Ley 2020 was at low risk of performance bias, and we judged three studies at unclear risk (Atreja 2018; Siegel 2018; Stunkel 2012).

We considered three studies at low risk of detection bias as they mentioned or confirmed blinding of outcomes assessors (Cross 2012; Cross 2019; Malickova 2020). Seven studies provided insufficient information for judgement (Atreja 2018; Hughes 2017; Ley 2020; Reich 2019; Siegel 2018; Stunkel 2012; Wang 2020), and nine studies were at high risk because they confirmed or stated that assessors were unblinded (Akobeng 2015; Ankersen 2019; Carlsen 2017a; Chauhan 2016; de Jong 2017; Del Hoyo 2018; Elkjaer 2010a; Heida 2018; McCombie 2020).

### Incomplete outcome data

We considered eleven studies at low risk of attrition bias because they provided sufficient information to make a judgement (Akobeng 2015; Ankersen 2019; Carlsen 2017a; Chauhan 2016; Cross 2012; Cross 2019; de Jong 2017; Del Hoyo 2018; Elkjaer 2010a; Malickova 2020; McCombie 2020; Wang 2020). The remaining seven studies were at unclear risk as they provided insufficient information to make a clear judgement (Atreja 2018; Heida 2018; Hughes 2017; Ley 2020; Reich 2019; Siegel 2018; Stunkel 2012). We rated one study at high risk of attrition bias (Cross 2012).

### Selective reporting

We judged eight studies at low risk of reporting bias, as they reported all outcomes set out in their trial registrations (Akobeng 2015; Cross 2012; Cross 2019; de Jong 2017; Del Hoyo 2018; Heida 2018; McCombie 2020; Reich 2019). We considered one study at high risk, as the prioritisation of outcomes differed between the protocol

and the published manuscript (Carlsen 2017a). The remaining studies provided insufficient information for judgement (Ankersen 2019; Atreja 2018; Chauhan 2016; Elkjaer 2010a; Hughes 2017; Ley 2020; Malickova 2020; Siegel 2018; Stunkel 2012; Wang 2020).

### Other potential sources of bias

We rated fifteen studies at low risk of other potential sources of bias (Akobeng 2015; Ankersen 2019; Carlsen 2017a; Chauhan 2016; Cross 2012; Cross 2019; de Jong 2017; Del Hoyo 2018; Heida 2018; Hughes 2017; Ley 2020; McCombie 2020; Reich 2019; Siegel 2018; Wang 2020). Four studies provided insufficient information for judgement (Atreja 2018; Elkjaer 2010a; Malickova 2020; Stunkel 2012).

### Effects of interventions

See: **Summary of findings 1** Web-based disease monitoring compared to usual care; **Summary of findings 2** Web-based disease monitoring compared to sham monitoring; **Summary of findings 3** Web-based disease monitoring compared to self-screening; **Summary of findings 4** Telephone-based disease monitoring compared to face-to-face monitoring; **Summary of findings 5** Cognitive behavioural therapy manual and telephone support compared to usual care

#### 1. Web-based disease monitoring versus usual care

Twelve studies evaluated web-based disease monitoring versus usual care (Carlsen 2017a; Cross 2012; Cross 2019; de Jong 2017; Del Hoyo 2018; Elkjaer 2010a; Heida 2018; Malickova 2020; McCombie 2020; Siegel 2018; Stunkel 2012; Wang 2020). Two of these studies were in paediatric populations (Carlsen 2017a; Heida 2018).

#### Primary outcomes

**Summary of findings 1** presents the effect measures (where calculated) and GRADE judgements for the primary outcomes.

#### Disease activity

Five studies reported disease activity (Cross 2012; Cross 2019; Del Hoyo 2018; Malickova 2020; McCombie 2020).

Three studies provided data that we could use for meta-analysis (Cross 2012; Cross 2019; McCombie 2020). All three studies enrolled only adults. Web-based disease monitoring (n = 254) is probably equivalent to usual care (n = 174) in reducing disease activity in adults with IBD (SMD 0.09, 95% CI -0.11 to 0.29; **Analysis 1.1**). The certainty of the evidence is moderate, downgraded for risk of bias mainly due to lack of blinding. Subgroup comparison showed similar disease activity in the UC and CD groups. A fixed-effect sensitivity analysis showed no difference in the results (**Analysis 1.2**).

Del Hoyo 2018 and Malickova 2020 did not provide suitable data for meta-analysis. Del Hoyo 2018 measured disease activity only by proxy (FC levels) and reported no variance measure. At 24 weeks, the median FC level for clinical activity was 137 µg/g in the web-

based group and 230 µg/g in the control. [Malickova 2020](#) reported HBI mean scores of 3.48 in the web-based group and 2.71 in the control, and Partial Mayo mean scores of 2.71 in the web-based group and 2.57 in the control. We were unable to draw any conclusions from these results. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and for risk of bias concerns (lack of blinding, selective reporting, and other bias).

### Flare-ups or relapse

Seven studies reported flare-ups or relapse with suitable data for meta-analysis ([Cross 2012](#); [Cross 2019](#); [de Jong 2017](#); [Del Hoyo 2018](#); [Elkjaer 2010a](#); [Heida 2018](#); [McCombie 2020](#)). Six studies enrolled adults ([Cross 2012](#); [Cross 2019](#); [Del Hoyo 2018](#); [de Jong 2017](#); [Elkjaer 2010a](#); [McCombie 2020](#)), and one study enrolled children ([Heida 2018](#)).

Web-based disease monitoring (n = 207/496) is probably equivalent to usual care (n = 150/372) for the occurrence of flare-ups or relapses in adults with IBD (RR 1.09, 95% CI 0.93 to 1.27; 5 studies; [Analysis 1.3](#)). We downgraded the certainty of the evidence to moderate for risk of bias (lack of blinding, reporting bias, and other bias). Subgroup comparison showed no major differences between the mixed IBD, UC, and CD groups. A fixed-effect sensitivity analysis showed no difference in the results ([Analysis 1.4](#)).

[de Jong 2017](#) provided continuous data for flare-ups or relapses. Web-based disease monitoring (n = 465) is probably equivalent to usual care (n = 444) for the occurrence of flare-ups or relapses in adults with CD (MD 0.00 events, 95% CI -0.06 to 0.06; [Analysis 1.5](#)). We downgraded the certainty of the evidence to moderate for lack of blinding.

[Heida 2018](#) evaluated a paediatric population of mixed CD and UC patients. Web-based disease monitoring (n = 28/84) may be equivalent to usual care (n = 29/86) for the occurrence of flare-ups or relapses in children with IBD (RR 0.99, 95% CI 0.65 to 1.51; [Analysis 1.6](#)). We downgraded the certainty of the evidence to low for imprecision (low participant numbers) and risk of bias concerns (lack of blinding and imbalance in number of participants reaching end of study between the two groups).

[Table 4](#) provides further details.

### Quality of life

Eight studies measured QoL ([Cross 2012](#); [Cross 2019](#); [de Jong 2017](#); [Del Hoyo 2018](#); [Elkjaer 2010a](#); [Heida 2018](#); [McCombie 2020](#); [Stunkel 2012](#)).

Four studies on adults provided data that we could use for a meta-analysis ([Cross 2012](#); [Cross 2019](#); [de Jong 2017](#); [McCombie 2020](#)). Web-based disease monitoring (n = 594) is probably equivalent to usual care (n = 505) for QoL in adults with IBD (SMD 0.08, 95% CI -0.04 to 0.20; [Analysis 1.7](#)). We downgraded the certainty of the evidence by one level to moderate for risk of bias concerns (lack of blinding and attrition). Subgroup comparison showed no major differences between mixed IBD, UC, and CD.

A fixed-effect sensitivity analysis showed no difference in the results ([Analysis 1.8](#)).

[Stunkel 2012](#) reported an IBDQ mean of 172.9 (undefined measure of variance 26.8) for the web-based group and 165.9 (undefined

measure of variance 24.7) for the control group. [Del Hoyo 2018](#) reported an IBDQ-9 mean of 53 and EQ-5D mean of 1 for the web-based group, and an IBDQ-9 mean of 53 and EQ-5D mean of 1 for the control group, without measures of variance. [Elkjaer 2010a](#) provided only commentary on the results of the outcome ("Disease specific QoL was improved in the web-group, as well as general health, vitality, role emotional, and social functioning, compared to control group"). [Heida 2018](#) provided mean IMPACT changes of 1.32 for the web-based group and -0.32 for the control group, without a measure of variance. The study authors also commented that 54% of participants in the web-based group and 44% in the control group reported positive changes. We were unable to reach any conclusions based on these data. We downgraded the certainty of the evidence for all of the above findings to very low for imprecision (very low participant numbers) and risk of bias concerns (all domains).

[Table 4](#) provides more details.

### Secondary outcomes

#### Number of episodes of accessing healthcare

Eight studies reported number of episodes of accessing healthcare ([Carlsen 2017a](#); [Cross 2019](#); [de Jong 2017](#); [Del Hoyo 2018](#); [Elkjaer 2010a](#); [Heida 2018](#); [Malickova 2020](#); [McCombie 2020](#)); however, no meta-analysis was possible owing to substantial differences between studies in the types of healthcare access reported, methodology, and reporting of the data. We were unable to draw any conclusions on the effects of web-based disease monitoring compared to usual care on healthcare access. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (all domains). [Table 5](#) provides further details.

#### Medication adherence

Five studies reported medication adherence ([Carlsen 2017a](#); [Cross 2012](#); [de Jong 2017](#); [Del Hoyo 2018](#); [Wang 2020](#)). Four studies provided data suitable for meta-analysis: continuous data in [de Jong 2017](#) and [Carlsen 2017a](#), and dichotomous data in [Cross 2012](#) and [Del Hoyo 2018](#).

The analysis of continuous data from [de Jong 2017](#) showed that web-based disease monitoring (n = 340) compared to usual care (n = 331) probably leads to slightly higher medication adherence in adults (MD 0.24 points, 95% CI 0.01 to 0.47; [Analysis 1.9](#)). We downgraded the certainty of the evidence by one level to moderate for risk of bias due to lack of blinding.

The analysis of continuous data from [Carlsen 2017a](#) showed no difference between web-based disease monitoring (n = 15) and usual care (n = 18) in terms of their effect on medication adherence in children, although the results are very uncertain (MD 0.00, 95% CI -0.63 to 0.63; [Analysis 1.10](#)). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias (lack of blinding).

Meta-analysis of the dichotomous data showed no difference between web-based disease monitoring (n = 26/46) and usual care (n = 28/43) in terms of their effect on medication adherence in adults, although the results are very uncertain (RR 0.87, 95% CI 0.62 to 1.21; 2 studies; [Analysis 1.11](#)). We downgraded the certainty of the evidence to very low for imprecision (very low numbers of events) and risk of bias concerns (lack of blinding

and attrition). Subgroup comparison showed no major differences between mixed IBD and UC.

Wang 2020 reported MMAS scores of less than six points for 22 participants in the web-based group and 42 in the control group, and scores of more than or equal to six points for 98 participants in the web-based group and 77 in the control group at six months. We were unable to draw any conclusions from these data. We downgraded the certainty of the evidence to very low for imprecision (low event numbers) and risk of bias concerns (blinding and selective reporting).

Table 5 provides further details.

### Participant engagement

Eleven studies reported or commented on participant engagement (Ankersen 2019; Carlsen 2017a; Cross 2019; Del Hoyo 2018; Elkjaer 2010a; Heida 2018; Hughes 2017; Malickova 2020; McCombie 2020; Reich 2019; Stunkel 2012); however, no meta-analysis was possible owing to substantial differences between studies in the types of participant engagement reported, methodology, and reporting of the data. We were unable to draw any conclusions on the effects of web-based disease monitoring compared to usual care on participant engagement. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (all domains). Table 5 provides further details.

### Rate of attendance or engagement with any or all elements of the intervention

Three studies reported attendance or engagement with the intervention (Akobeng 2015; Carlsen 2017a; McCombie 2020); however, meta-analysis was not possible owing to differences in how studies reported this outcome. We were unable to draw any conclusions on the effects of web-based disease monitoring compared to usual care on attendance or engagement rate. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). Table 5 provides further details.

### Rate of attendance of interactions with healthcare professionals

Akobeng 2015 and Del Hoyo 2018 reported attendance of interactions with healthcare professionals; however, meta-analysis was not possible owing to differences in how the two studies reported this outcome. We were unable to draw any conclusions on the effects of web-based disease monitoring compared to usual care on rate of attendance of interactions with healthcare professionals. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). Table 5 provides further details.

### Costs or cost/time-effectiveness

Eight studies provided estimations of costs or cost/time-effectiveness (Akobeng 2015; Carlsen 2017a; Chauhan 2016; de Jong 2017; Del Hoyo 2018; Elkjaer 2010a; Heida 2018; Malickova 2020); however, meta-analysis was not possible owing to differences in how studies reported this outcome. We were unable to draw any conclusions on the effects of web-based disease monitoring compared to usual care on costs or cost/time-effectiveness. We downgraded the certainty of the evidence to very

low for imprecision (very low participant numbers) and risk of bias concerns (all domains). Table 5 provides further details.

Owing to lack of data, we were unable to perform subgroup and sensitivity analyses prespecified in our protocol.

## 2. Web-based disease monitoring versus sham monitoring

Three studies evaluated web-based disease monitoring versus sham monitoring (Atreja 2018; Ley 2020; Reich 2019). We were unable to perform meta-analyses for any primary or secondary outcomes (Summary of findings 2).

### Primary outcomes

#### Disease activity

No studies reported disease activity.

#### Flare-ups or relapse

No studies reported flare-ups or relapse.

#### Quality of life

Atreja 2018 provided QoL results only for the web-based group and not the sham group, while Reich 2019 provided QoL means at six months but without variance measures. We were unable to draw any conclusions on the effects of web-based disease monitoring compared to sham monitoring on QoL. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (all domains). Table 4 provides further details.

### Secondary outcomes

#### Number of episodes of accessing healthcare

No studies reported healthcare access.

#### Medication adherence

Ley 2020 provided medication adherence means at study end but without any variance measures. We were unable to draw any conclusions on the effects of web-based disease monitoring compared to sham monitoring on medication adherence. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selection bias, blinding, attrition bias, and reporting bias). Table 5 provides further details.

### Participant engagement

Reich 2019 reported rates of participants logging onto their web application (monthly, weekly, and every other week). We were unable to draw any conclusions on the effects of web-based disease monitoring compared to sham monitoring on participant engagement. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selection bias, blinding, and attrition bias). Table 5 provides further details.

### Rate of attendance or engagement with any or all elements of the intervention

No studies reported attendance or engagement rate.

### Rate of attendance of interactions with healthcare professionals

No studies reported interactions with professionals.

## Costs or cost/time-effectiveness

No studies reported costs or cost/time-effectiveness.

## 3. Web-based disease monitoring versus self-screening

One study evaluated web-based disease monitoring versus self-screening (Ankersen 2019). We were unable to perform meta-analyses for any primary or secondary outcomes (Summary of findings 3).

### Primary outcomes

#### Disease activity

The authors of Ankersen 2019 devised their own classification system for disease activity, presenting SCCAI, HBI, and TIBS mean scores without variance on their "traffic light" classification over one year. We were unable to draw any conclusions on the effects of web-based disease monitoring compared to self-screening on disease activity. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selection bias, blinding, and reporting bias). Table 4 provides further details.

#### Flare-ups or relapse

Ankersen 2019 reported combined moderate and severe relapse numbers based on SCCAI and FC levels; however, the denominator in this calculation (total number of patients) far exceeded the number of people randomised, so it was unclear if these relapses were based on randomised data. We were unable to draw any conclusions on the effects of web-based disease monitoring compared to self-screening on relapses or flare-ups. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selection bias, blinding, and reporting bias). Table 4 provides further details.

#### Quality of life

Ankersen 2019 reported mean changes in QoL in the two groups, but it was unclear if these groups comprised the randomised participants. We were unable to draw any conclusions on the effects of web-based disease monitoring compared to self-screening on QoL. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selection bias, blinding, and reporting bias). Table 4 provides further details.

### Secondary outcomes

#### Number of episodes of accessing healthcare

Ankersen 2019 did not report healthcare access.

#### Medication adherence

Ankersen 2019 reported median (interquartile range (IQR)) adherence values for the two groups, but it was unclear if these groups comprised the randomised participants. We were unable to draw any conclusions on the effects of web-based disease monitoring compared to self-screening on medication adherence. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selection bias, blinding, and reporting bias). Table 5 provides further details.

## Participant engagement

Ankersen 2019 reported no "statistical difference between the two intervention groups on any of the seven yes/no questions assessing patient satisfaction". We were unable to draw any conclusions on the effects of web-based disease monitoring compared to self-screening on participant engagement. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selection bias, blinding, and reporting bias). Table 5 provides further details.

### Rate of attendance or engagement with any or all elements of the intervention

Ankersen 2019 did not report attendance or engagement rate.

### Rate of attendance of interactions with healthcare professionals

Ankersen 2019 did not report interactions with professionals.

## Costs or cost/time-effectiveness

Ankersen 2019 did not report costs or cost/time-effectiveness.

## 4. Telephone-based disease monitoring versus face-to-face monitoring

Three studies evaluated telephone-based disease monitoring versus face-to-face monitoring: two enrolled adults (Chauhan 2016; Del Hoyo 2018), and one enrolled children (Akobeng 2015).

### Primary outcomes

Summary of findings 4 presents the effect measures (where calculated) and GRADE judgements for the primary outcomes.

#### Disease activity

Two studies reported disease activity, but neither provided data suitable for meta-analysis (Chauhan 2016; Del Hoyo 2018; Table 4).

Chauhan 2016 reported no significant change. Del Hoyo 2018 measured disease activity only by proxy (FC levels) and provided no variance measure. We were unable to draw any conclusions on the effects of telephone-based disease monitoring compared to face-to-face monitoring on disease activity. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (selective reporting). Table 4 provides further details.

#### Flare-ups or relapse

All three studies reported flare-ups or relapse (Akobeng 2015; Chauhan 2016; Del Hoyo 2018).

Del Hoyo 2018 provided data suitable for meta-analysis from an adult population. We found no difference between telephone-based disease monitoring ( $n = 7/21$ ) and face-to-face monitoring ( $n = 6/21$ ) in terms of their effect on the occurrence of flare-ups or relapses in adults with IBD, but the results are very uncertain (RR 1.17, 95% CI 0.47 to 2.89; Analysis 2.1). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding).

Akobeng 2015 provided data suitable for meta-analysis from a paediatric population. We found no difference between telephone-based disease monitoring ( $n = 1/44$ ) and face-to-face monitoring ( $n = 4/42$ ) in terms of their effect on the occurrence of flare-ups or



relapses in children with IBD, but the results are very uncertain (RR 0.24, 95% CI 0.03 to 2.05; [Analysis 2.2](#)). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding).

[Chauhan 2016](#) reported "no significant change" but provided no data. We were unable to draw any conclusions from this information. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding and selective reporting).

[Table 4](#) provides further details.

### Quality of life

All three studies reported QoL ([Akobeng 2015](#); [Chauhan 2016](#); [Del Hoyo 2018](#)).

[Akobeng 2015](#) provided data suitable for meta-analysis from a paediatric population. It is unclear whether telephone-based disease monitoring (n = 44) compared to face-to-face monitoring (n = 42) affects QoL in children with IBD (MD 7.00 points, 95% CI -0.29 to 14.29; [Analysis 2.3](#)). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding).

[Del Hoyo 2018](#) reported QoL means without measures of variance. We were unable to draw any conclusions based on these data. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding and selective reporting).

[Chauhan 2016](#) reported "no significant change" but provided no data. We were unable to draw any conclusions from this information. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding and selective reporting).

[Table 4](#) provides further details.

### Secondary outcomes

#### Number of episodes of accessing healthcare

[Akobeng 2015](#) and [Del Hoyo 2018](#) reported number of episodes of accessing healthcare.

[Akobeng 2015](#) reported numbers of participants in each consultation group that had one or more hospital admissions due to IBD. It is unclear whether telephone-based disease monitoring (n = 1/44) compared to face-to-face monitoring (n = 1/42) affects the number of episodes of accessing healthcare in children with IBD (RR 0.95, 95% CI 0.06 to 14.77; [Analysis 2.4](#)). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding).

[Del Hoyo 2018](#) reported the number of outpatient visits and telephone consultations. We were unable to draw any conclusions from these data. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). [Table 5](#) provides further details.

#### Medication adherence

Only [Del Hoyo 2018](#) reported numbers of participants adhering to their medication. It is unclear whether telephone-based disease

monitoring (n = 7/21) compared to face-to-face monitoring (n = 14/21) affects medication adherence in adults with IBD (RR 0.50, 95% CI 0.25 to 0.98; [Analysis 2.5](#)). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). [Table 5](#) provides further details.

#### Participant engagement

Only [Del Hoyo 2018](#) reported participant engagement, specifically the number of participants who adhered to more than 80% of checkups planned in the study protocol. It is unclear whether telephone-based disease monitoring (n = 20/21) compared to face-to-face monitoring (n = 19/21) affects participant engagement in adults with IBD (RR 1.05, 95% CI 0.89 to 1.25; [Analysis 2.6](#)). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). [Table 5](#) provides further details.

#### Rate of attendance or engagement with any or all elements of the intervention

Only [Akobeng 2015](#) reported attendance or engagement rate, specifically the number of scheduled consultations that each participant missed. It is unclear whether telephone-based disease monitoring (n = 36) compared to face-to-face monitoring (n = 40) affects attendance or engagement rate in children with IBD (MD 1.00, 95% CI 0.48 to 1.52; [Analysis 2.8](#)). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). [Table 5](#) provides further details.

#### Rate of attendance of interactions with healthcare professionals

Only [Akobeng 2015](#) reported attendance of interactions with healthcare professions, specifically the number of participants who attended at least one scheduled consultation before the 12-month follow-up. It is unclear whether telephone-based disease monitoring (n = 36/44) compared to face-to-face monitoring (n = 40/42) affects the rate of attendance of interactions with healthcare professionals in children with IBD (RR 0.86, 95% CI 0.74 to 1.00; [Analysis 2.9](#)). We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). [Table 5](#) provides further details.

#### Costs or cost/time-effectiveness

All three studies provided narrative estimates on costs or time-effectiveness ([Akobeng 2015](#); [Chauhan 2016](#); [Del Hoyo 2018](#)). We were unable to draw any conclusions on the effects of telephone-based disease monitoring compared to face-to-face monitoring on cost or cost/time-effectiveness. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (lack of blinding). [Table 5](#) provides further details.

### 5. Cognitive behavioural therapy manual and telephone support versus usual care

One study evaluated CBT manual and telephone support versus usual care ([Hughes 2017](#)).

We were unable to perform meta-analyses for any primary or secondary outcomes ([Summary of findings 5](#)).

## Primary outcomes

### Disease activity

Hughes 2017 did not report disease activity.

### Flare-ups of relapse

Hughes 2017 did not report flare-ups or relapse.

### Quality of life

Hughes 2017 did not report QoL.

## Secondary outcomes

### Number of episodes of accessing healthcare

Hughes 2017 did not report healthcare access.

### Medication adherence

Hughes 2017 did not report medication adherence.

### Participant engagement

Hughes 2017 reported rates of participants completing at least one telephone session only for the intervention group. We were unable to draw any conclusions on the effects of CBT manuals and telephone support compared to usual care on participant engagement. We downgraded the certainty of the evidence to very low for imprecision (very low participant numbers) and risk of bias concerns (randomisation, blinding, attrition, and selective reporting).

### Rate of attendance or engagement with any or all elements of the intervention

Hughes 2017 did not report attendance or engagement rate.

### Rate of attendance of interactions with healthcare professionals

Hughes 2017 did not report interactions with professionals.

### Costs or cost/time-effectiveness

Hughes 2017 did not report costs or cost/time-effectiveness.

## DISCUSSION

### Summary of main results

This review included a wide range of interventions in a very contemporaneous area of interest. Since 2020, almost all people with IBD have had some elements of their care delivered by telehealth, but this approach had already formed a part of IBD healthcare provision for some time.

The studies included in this review demonstrate the different means employed to deliver remote healthcare to people with IBD. Web-based disease monitoring was the most commonly studied intervention and was compared to standard or usual care in 12 studies, with just three adding a sham or control web application to the control group. A single study compared web-based disease monitoring with self-screening, three studies compared telephone-based disease monitoring with face-to-face monitoring, and one study evaluated a CBT manual combined with telephone support versus usual care.

Most studies compared a form of remote telehealth to normal or usual care, but descriptions of normal care were limited, and

no studies specified whether standard care groups were offered remote care, formally or informally.

The analysis for the most common comparison (web-based monitoring versus usual care) produced the following results.

- There is probably no difference between the interventions in IBD disease activity in adults.
- There is probably no difference between the interventions in IBD flare-ups or relapse in adults.
- There may be no difference between the interventions in IBD flare-ups or relapse in children.
- There is probably no difference between the interventions in QoL in adults.
- Web-based monitoring compared to usual care probably improves medication adherence slightly in adults.

The poor reporting of other outcomes measures severely limited the scope for meta-analysis, and the certainty of evidence was very low.

### Overall completeness and applicability of evidence

Further clarification on the specifics of the web-based monitoring would support better replication and dissemination (Table 2; Table 3). Unlike pharmacological intervention reviews, reviews of this type should establish not only whether an intervention is effective or safe, but also what specific components of the intervention are effective. Most studies included in this review do not provide this information. Lack of detail is a recognised problem in non-pharmacological trial reporting. An analysis of non-pharmacological intervention trials found that 61% of reports did not provide details of the primary intervention, although trial authors forwarded this information on request in 72% of cases (Hoffman 2013). In this review, we received only minimal information from study authors when we contacted them. It is important that future studies rectify this gap in the evidence base.

The choice of outcomes in the included studies was another concern. The primary outcomes appeared somewhat arbitrary and involved many clinical measures. For pharmacological studies, national governing bodies often mandate the primary outcomes, but as this is not the case for studies of non-pharmacological interventions, the analysis in this review is limited. In addition, follow-up duration was generally short.

Most studies used web-based disease monitoring as the focus for remote care. Few studies evaluated other remote approaches. It appears that many ongoing studies are focusing on other forms of remote care (possibly as a result of the COVID-19 pandemic), and future updates of this review will likely include these interventions.

We excluded studies where remote monitoring of blood or faecal tests was the only form of monitoring, as this was a proxy for direct patient outcomes. This could be considered an incomplete aspect of our review and a potential focus of a new review.

Finally, standard care was a frequent comparator in the included studies, but no studies provided clear descriptions of standard care in terms of the content, form, frequency, and professionals involved. Without this information, it is unclear to what extent each intervention differed from its respective control. As a result, the completeness and utility of the evidence is limited.

## Quality of the evidence

There were significant issues related to risk of bias in the studies included in this review. Despite our requests to authors of included studies, we received few data to change our judgements in these key areas.

Most studies did not blind participants, personnel, or outcome assessors, but this can be considered acceptable given the context of the review. As we explained in a previous review ([Gordon 2022](#)), research has demonstrated that even in double-blind trials, participant expectancies can limit the validity of the design; assessing participants' beliefs about their treatment could help to overcome this issue ([Colagiuri 2010](#)). Nevertheless, blinding remains a concern and a potential limitation of the included studies in this review, and we have downgraded the certainty of the evidence for all our outcomes accordingly.

Reporting of the interventions themselves is another source of potential bias, as it is difficult to determine what specific interventions each study delivered. As discussed in [Overall completeness and applicability of evidence](#), unclear reporting is a recognised problem within non-pharmacological intervention studies ([Hoffman 2013](#)), and within health education systematic reviews ([Gordon 2016](#)), although the GRADE approach does not explicitly identify this issue ([Gordon 2020](#)). Lack of detail in the reporting of interventions constitutes the most serious problem with the evidence base, limiting the utility of our outcomes, because these interventions cannot be replicated or disseminated.

The outcome of paediatric flare-ups or relapses for web-based disease monitoring compared to usual care was downgraded twice for imprecision (low participant numbers) and risk of bias concerns (blinding and attrition).

All reported primary outcomes for telephone-based disease monitoring compared to face-to-face monitoring were downgraded three times for serious imprecision (very low participant numbers) and risk of bias concerns.

The only secondary outcome we were able to meta-analyse was medication adherence for web-based disease monitoring compared to usual care. We considered the evidence for this outcome based on continuous data in adults to be of moderate certainty, downgrading once for risk of bias; and we considered the evidence based on continuous data in children and the evidence based on dichotomous data in adults to be of very low certainty, downgrading for very serious imprecision and risk of bias concerns.

## Potential biases in the review process

Clinical heterogeneity is a major concern in this review. Most studies included people with both CD and UC at different disease states. Had we excluded studies that did not differentiate between CD and UC (most studies), we would have lost a key source of evidence in this area. Nevertheless, this clearly introduces a source of bias.

Although some studies analysed IBD populations as one cohort while others analysed UC and CD populations separately, and despite the mix of disease states in the included studies, we do not consider indirectness to be an issue. The constituents of the interventions were homogenous in their scope for web-based monitoring, and varied only in the type of telehealth method adopted. There is no clinical evidence to suggest indirectness

between subgroups of IBD and disease state. However, we recognise the variation in the methods used by the included studies may be a limitation of this review. Our outcomes are direct measures for efficacy and safety in IBD treatment.

We decided to only include studies where the remote component was the primary focus and not part of a larger package, and we may have missed studies with relevant evidence as a result.

## Agreements and disagreements with other studies or reviews

This is the first Cochrane Review on remote care for people with IBS.

One systematic review from 2014 concluded that distance management of IBD significantly decreased clinic visit utilisation but did not significantly affect relapse rates or hospital admission rates ([Huang 2014](#)). Another systematic review, published in 2022, concluded that digital health technologies may be effective in decreasing healthcare utilisation and costs, though may not improve risk of relapse, QoL, or treatment adherence in people with IBD ([Nguyen 2022](#)). Similarly, we found no effect on relapse rates and QoL in comparison to usual care, but we had insufficient evidence to judge clinic visits, hospital admissions, and costs. The evidence we found on medication adherence was heterogeneous, with one meta-analysis suggesting telehealth may be non-inferior to usual care (though the evidence is very uncertain), and another suggesting telehealth is probably slightly better than usual care.

The international guidelines for IBD provide no evidence base to support the use of remote telehealth as a standalone or replacement intervention, only as an addendum to normal care ([Feuerstein 2020](#); [Feuerstein 2021](#); [Forducey 2012](#); [Ko 2019](#); [Lamb 2019](#)).

## AUTHORS' CONCLUSIONS

### Implications for practice

The evidence in this review demonstrates that web-based disease monitoring is probably no different to standard care when considering disease activity, occurrence of flare-ups or relapse, and quality of life in adults with inflammatory bowel disease (IBD), and it probably improves medication adherence slightly. Evidence in children is limited.

The effects of web-based disease monitoring versus usual care on the remaining secondary outcomes are unclear, as are the effects of the other telehealth interventions included in our review, as there are insufficient high-quality data.

### Implications for research

For the comparison web-based monitoring versus standard care, we consider that further studies are unlikely to change the findings of this review. Several outcomes demonstrate that the intervention is no more effective than standard care.

Longer-term studies with outcome measures after some years could provide more relevant findings for a chronic disease such as IBD. Additionally, future studies should provide more detailed reports of the interventions to allow practical dissemination and replication. This includes details on the type and number of staff needed, resources, equipment, costs, accessibility, and data

security. Further studies on children could be useful, as well as studies that examine differences in efficacy between subgroups (e.g. sex or socio-economic status).

There is also a need to investigate the impact of other forms of remote telehealth, including those reported in this review in small numbers. Nine ongoing studies are currently examining other remote care strategies.

## ACKNOWLEDGEMENTS

Editorial contributions:

Cochrane Gut group supported the authors in the development of this systematic review. The following people conducted the editorial process for this article:

- Sign-off Editor (final editorial decision): Michael Brown, Michigan State University College of Human Medicine, USA
- Managing Editor (selected peer reviewers, collated peer-reviewer comments, provided editorial guidance to authors, edited the article): Marwah Anas El-Wegoud, Cochrane Central Editorial Service
- Editorial Assistant (conducted editorial policy checks and supported editorial team): Lisa Wydrzynski, Cochrane Central Editorial Service
- Copy Editor (copy editing and production): Julia Turner, c/o Cochrane Central Production Service
- Peer-reviewers (provided comments and recommended an editorial decision): Miles Sparrow, Alfred Health (clinical review); Raymond K Cross, MD, MS, AGAF, FACP, University of Maryland School of Medicine (clinical review); Robert Hirten, MD, Icahn School of Medicine at Mount Sinai (clinical review); Alysia De Nino, MPH (consumer review); Nuala Livingstone, Cochrane Evidence Production and Methods Directorate (methods review). Two additional peer reviewers provided search peer-review and clinical peer-review but chose not to be publicly acknowledged.



## REFERENCES

### References to studies included in this review

#### Akobeng 2015 {published data only}

\* Akobeng AK, O'Leary N, Vail A, Brown N, Widiatmoko D, Fagbemi A, et al. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. *EBioMedicine* 2015;**2**(9):1251-6.

NCT02319798. Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease. [clinicaltrials.gov/ct2/show/NCT02319798](https://clinicaltrials.gov/ct2/show/NCT02319798) (first received 18 December 2014).

#### Ankersen 2019 {published data only}

Ankersen DV, Marker D, Weimers P, Burisch J, Munkholm P. DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice. *Journal of Crohn's and Colitis* 2018;**12** Suppl 1:S052-3.

\* Ankersen DV, Weimers P, Marker D, Bennedsen M, Saboori S, Paridaens K, et al. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial. *World Journal of Gastroenterology* 2019;**25**(40):6158-71.

NCT02492555. Is relapse rate reduced by home monitoring of IBD patients tightly or on demand by FC and disease activity? [clinicaltrials.gov/ct2/show/NCT02492555](https://clinicaltrials.gov/ct2/show/NCT02492555) (first received 8 July 2015).

#### Atreja 2018 {published data only}

Atreja A, Khan S, Otobo E, Rogers J, Ullman T, Grinspan A, et al. Impact of real world home-based remote monitoring on quality of care and quality of life in IBD patients: interim results of pragmatic randomized trial. *Gastroenterology* 2017;**152**(5):S600-1.

\* Atreja A, Khan S, Otobo E, Rogers J, Ullman T, Grinspan A, et al. P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. *Journal of Crohn's and Colitis* 2017;**11** Suppl 1:S362-3.

Atreja A, Khan S, Rogers JD, Otobo E, Patel NP, Ullman T, et al. Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. *JMIR research protocols* 2015;**4**(1):e23.

Atreja A, Khan S, Szigethy E, Otobo E, Shroff H, Chang H, et al. Improved quality of care for IBD patients using HealthPROMISE App: a randomized, control trial: P-003. *Official Journal of the American College of Gastroenterology* 2018;**113**:S1.

Atreja A, Otobo E, Szigethy E, Kohli A, Shroff H, Chang H, et al. P057 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomized control trial. *Inflammatory Bowel Diseases* 2018;**24** Suppl 1:S21-2.

Atreja A, Otobo E, Szigethy E, Shroff H, Chang H, Keefer L, et al. DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: a randomised control trial. *Journal of Crohn's and Colitis* 2018;**12** Suppl 1:S077-8.

Atreja A, Szigethy E, Otobo E, Chang HL, Keefer L, Rogers J, et al. 17-improved quality of care and quality of life for IBD patients using HealthPROMISE app: a randomized, control trial. *Gastroenterology* 2018;**154**(6):S-6.

NCT02322307. Trial on impact of HealthPROMISE mobile app on inflammatory bowel disease care and quality of life. [clinicaltrials.gov/ct2/show/NCT02322307](https://clinicaltrials.gov/ct2/show/NCT02322307) (first received 23 December 2014).

#### Carlsen 2017a {published data only}

Carlsen K, Houen G, Jakobsen C, Kallemose T, Paerregaard A, Riis LB, et al. Individualized infliximab treatment guided by patient-managed ehealth in children and adolescents with inflammatory bowel disease. *Inflammatory bowel diseases* 2017;**23**(9):1473-82.

Carlsen K, Jakobsen C, Hansen LF, Paerregaard A, Kallemose T, Houen G, et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. *Journal of Crohn's & Colitis* 2016;**10**:S53-4.

Carlsen K, Jakobsen C, Hansen LF, Paerregaard A, Kallemose T, Houen G, et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. *Journal of Pediatric gastroenterology and Nutrition* 2016;**62** Suppl 1:131.

Carlsen K, Jakobsen C, Hansen LF, Paerregaard A, Kallemose T, Riis LB, et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. *Journal of Crohn's & Colitis* 2016;**10**:S421-2.

Carlsen K, Jakobsen C, Hansen LF, Paerregaard A, Riis LB, Munkholm PS, et al. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. *Journal of Crohn's and Colitis* 2016;**10**:S53.

\* Carlsen K, Jakobsen C, Houen G, Kallemose T, Paerregaard A, Riis LB, et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. *Inflammatory Bowel Diseases* 2017;**23**(3):357-65.

NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. [clinicaltrials.gov/ct2/show/NCT01860651](https://clinicaltrials.gov/ct2/show/NCT01860651) (first received 15 February 2019).

#### Chauhan 2016 {published data only}

Chauhan U, Armstrong D, Farbod Y, Halder SL, Kaasalainen S, Marshall JK, et al. Telephone vs. clinic follow-up in the

management of patients with inflammatory bowel disease: a nurse practitioner led study. *Gastroenterology* 2016;**1**:S235.

Chauhan U, Armstrong D, Halder S, Marshall J, Tse F, Pinto Sanchez M, et al. Telephone versus clinic follow-up in management of patients with inflammatory bowel disease. *Canadian Journal of Gastroenterology and Hepatology* 2016;**2016**:A257.

\* Chauhan U, Armstrong D, Halder SL, Marshall JK, Tse F, Sanchez MP, et al. Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. *Journal of Crohn's and Colitis* 2016;**493**:S505.

#### Cross 2012 {published data only}

Cross R, Cheevers N, Rustgi A, Hanahan A, Steele AG, Lydecker A, et al. T1240 A randomized, controlled trial of home telemanagement in patients with ulcerative colitis. *Gastroenterology* 2010;**5**(138):S-519.

\* Cross RK, Cheevers N, Rustgi A, Langenberg P, Finkelstein J. Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). *Inflammatory bowel diseases* 2012;**18**(6):1018-25.

Cross RK, Finkelstein J. Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. *Clinical Trials* 2009;**6**(6):649-57.

NCT00620126. The home telemanagement (UC HAT) trial for patients with ulcerative colitis. [clinicaltrials.gov/ct2/show/NCT00620126](http://clinicaltrials.gov/ct2/show/NCT00620126) (first received 21 February 2008).

#### Cross 2019 {published data only}

Abutaleb A, Buchwald A, Chudy-Onwugaje K, Langenberg P, Regueiro M, Schwartz DA, et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. *Inflammatory Bowel Diseases* 2018;**24**(20):2191-7.

Bilgrami Z, Abutaleb A, Chudy-Onwugaje K, Cross R. TU1747-Effect of telemedicine for inflammatory bowel disease (tele-IBD) on patient activation and general self-efficacy. *Gastroenterology* 2019;**156**(6):S-1109.

Bilgrami Z, Abutaleb A, Chudy-Onwugaje K, Langenberg P, Regueiro M, Schwartz DA, et al. Effect of TELEmedicine for inflammatory bowel disease on patient activation and self-efficacy. *Digestive diseases and sciences* 2020;**65**(1):96-103.

Cross RK, Jambaulikar G, Langenberg P, Tracy JK, Collins JF, Katz J, et al. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial. *Contemporary Clinical Trials* 2015;**42**:132-44.

\* Cross RK, Langenberg P, Regueiro M, Schwartz DA, Tracy JK, Collins JF, et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). *Official Journal of the American College of Gastroenterology* 2019;**114**(3):472-82.

Jambaulikar G, Langenberg P, Katz J, Quinn C, Flasar M, Regueiro M, et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD). *American Journal of Gastroenterology* 2014;**109** Suppl 2:S521.

NCT01692743. Telemedicine in patients with inflammatory bowel disease (TELE-IBD). [clinicaltrials.gov/ct2/show/NCT01692743](http://clinicaltrials.gov/ct2/show/NCT01692743) (first received 25 September 2012).

Quinn CC, Chard S, Roth EG, Eckert JK, Russman KM, Cross RK. The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants' perceptions. *Journal of Medical Internet Research* 2019;**21**(6):e14165.

Schliep M, Chudy-Onwugaje K, Abutaleb A, Langenberg P, Regueiro M, Schwartz DA, et al. P040 Text message-based telemedicine does not improve quality of life or depressive symptoms in IBD patients. *Gastroenterology* 2019;**156**(3):S28-9.

Schliep M, Chudy-Onwugaje K, Abutaleb A, Langenberg P, Regueiro M, Schwartz DA, et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared with standard care at tertiary referral centers. *Crohn's & Colitis 360* 2020;**2**(1):otaa002.

Sivasailam B, Cross RK, Ghazi L, Patil SA, Quezada SM, Russman K, et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD) decreases inflammatory bowel disease (IBD)-related hospitalizations. *Inflammatory Bowel Diseases* 2018;**24** Suppl 1:S60-1.

#### de Jong 2017 {published data only}

NCT02173002. Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controlled trial. [clinicaltrials.gov/ct2/show/NCT02173002](http://clinicaltrials.gov/ct2/show/NCT02173002) (first received 24 June 2014).

de Jong M, Van Der Meulen A, Romberg-Camps M, Becx M, Cilissen M, Maljaars J, et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: a pragmatic randomized multicenter trial with myIBDcoach. *Gastroenterology* 2012;**5**:S186.

de Jong M, van Der Meulen-De Jong A, Romberg-Camps M, Becx M, Maljaars JPW, Cilissen M, et al. Personalised care with the telemedicine tool myibdcoach is cost-effective. A cost-utility analysis of the myibdcoach trial. *United European Gastroenterology Journal* 2018;**6**(8):A649.

de Jong M, van der Meulen-de Jong A, Romberg-Camps M, Becx M, Markus T, Maljaars J, Mahmmod N, et al. Telemedicine for inflammatory bowel disease patients with MyIBDcoach: description of the myIBDcoach trial. *Journal of Crohn's & Colitis* 2016;**10**:S198.

de Jong M, van der Meulen-de Jong A, Romberg-Camps M, Degens J, Becx M, Markus T, et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. *Inflammatory Bowel Diseases* 2017;**23**(4):485-93.

de Jong MJ, Boonen A, van der Meulen-de AE, Romberg-Camps MJ, van Bodegraven AA, Mahmod N, et al. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. *Clinical Gastroenterology and Hepatology* 2020;**18**(8):1744-52.

de Jong MJ, van der Meulen-de AE, Romberg-Camps MJ, Becx MC, Maljaars JP, Cilissen M, et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. *Lancet* 2017;**390**(10098):959-68.

#### **Del Hoyo 2018** {published data only}

Aguas M, Del Hoyo J, Faubel R, Munoz D, Dominguez D, Bastida G, et al. A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): results of a randomised controlled clinical trial. *Journal of Medical Internet Search* 2018;**12**:S214.

Aguas M, Del Hoyo J, Faubel R, Muñoz D, Domínguez D, Bastida G, et al. A web-based telemanagement system for patients with complex inflammatory bowel disease: protocol for a randomized controlled clinical trial. *JMIR Research Protocols* 2018;**7**(12):e9639.

Aguas M, Del Hoyo J, Faubel R, Muñoz D, Domínguez D, Bastida G, et al. P301 Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: a randomised controlled trial. *Journal of Crohn's and Colitis* 2018;**12** Suppl 1:S252-3.

Aguas M, Del Hoyo J, Muñoz D, Faubel R, Barrios A, Navarro B, et al. P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial. *Journal of Crohn's and Colitis* 2017;**11** Suppl 1:no pagination.

Del Hoyo J, Nos P, Bastida G, Faubel R, Muñoz D, Garrido-Marín A, et al. Telemonitoring of Crohn's disease and ulcerative colitis (TECCU): cost-effectiveness analysis. *Journal of Medical Internet Research* 2019;**21**(9):e15505.

\* Del Hoyo J, Nos P, Faubel R, Muñoz D, Domínguez D, Bastida G, et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. *Journal of Medical Internet Research* 2018;**20**(11):e11602.

Del Hoyo J, Nos P, Faubel R, Muñoz D, Domínguez D, Bastida G, et al. A web-based telemanagement system for patients with complex inflammatory bowel disease (TECCU): results of a randomized controlled clinical trial. *Gastroenterology* 2018;**154**(6):S797.

NCT02943538. Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU). clinicaltrials.gov/ct2/show/NCT02943538 (first received 24 October 2016).

del Hoyo J, Nos P, Faubel R, Muñoz D, Domínguez D, Bastida G, et al. Mo1783-Effects of telemonitoring on safety and healthcare costs with a web platform (teccu) in complex IBD patients: a randomized clinical trial. *Gastroenterology* 2018;**154**(6):S-800.

#### **Elkjaer 2010a** {published data only}

\* Elkjaer M, Shuhaibar M, Burisch J, Bailey Y, Scherfig H, Laugesen B, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. *Gut* 2010;**59**(12):1652-61.

Elkjaer M. E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. *Danish Medical Journal* 2012;**59**(7):B4478.

#### **Heida 2018** {published data only}

Heida A, Dijkstra A, Groen H, Kobold AM, Verkade H, van Rheenen P. Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. *Trials* 2015;**16**(1):1.

Heida A, Dijkstra A, Kobold A, Kindermann A, Kokke F, de Meij T, et al. Telemonitoring versus usual care: a multicenter trial among teenagers with inflammatory bowel disease. *Journal of Pediatric Gastroenterology and Nutrition* 2017;**65** Suppl 1:S3.

\* Heida A, Dijkstra A, Muller Kobold A, Rossen JW, Kindermann A, Kokke F, et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. *Journal of Crohn's and Colitis* 2018;**12**(4):432-41.

#### **Hughes 2017** {published data only}

\* Hughes LD, Fischer A, Goodliffe S, Irving PM, Moss-Morris R. PTH-101 A manualised intervention to reduce psychological distress in inflammatory bowel disease: a pilot randomised controlled feasibility trial. *Gut* 2017;**66** Suppl 2:A256-7.

#### **Ley 2020** {published data only}

\* Ley D, Martin B, Caldera F. Use of an iphone application to increase adherence in patients with ulcerative colitis in remission: a randomized controlled trial. *Inflammatory Bowel Diseases* 2020;**26**(5):e33-4.

#### **Malickova 2020** {published data only}

Malickova K, Pesinova V, Bortlik M, Duricova D, Machkova N, Hrubá V, et al. P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. *Journal of Crohn's and Colitis* 2020;**14** Suppl 1:S352-3.

\* Malickova K, Pesinova V, Bortlik M, Duricova D, Machkova N, Hrubá V, et al. Telemedicine and inflammatory bowel disease: results of the IBD assistant pilot project [Telemedicina a idiopatické střevní záněty – výsledky pilotního projektu IBD Asistent]. *Gastroenterology & Hepatology* 2020;**74**(1):18-27.

#### **McCombie 2020** {published data only}

\* McCombie A, Walmsley R, Barclay M, Ho C, Langlotz T, Regenbrecht H, Gray A, et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. *Inflammatory bowel diseases* 2020;**26**(7):1098-109.

Walmsley RS, McCombie A, Barclay M, Ho C, Visessio N, Brown S, Schulz M. Non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. *Congress of the ECCO 2019*;no volume:no pagination.

#### Reich 2019 {published data only}

\* Reich J, Canakis A, Shankar D, Harrington J, Apte M, Weinberg J, et al. The use of an EHR patient portal (MyChart-Epic) in patients with inflammatory bowel disease. *Crohn's & Colitis 360* 2019;**1**(3):otz039.

Reich J, Harrington JE, Shankar D, Jones E, Weinberg J, Norohna A, et al. The use of an EMR patient portal (MYCHART-EPIC) in patients with inflammatory bowel disease: preliminary results of a randomized clinical trial: 609. *Official Journal of the American College of Gastroenterology* 2018;**113**:S349.

#### Siegel 2018 {published data only}

\* Siegel CA, Thompson KD, Siegel LS, MacKenzie T, Dubinsky M. Crohn's disease decision aid leads to more patients choosing combination therapy in a cluster randomized controlled trial. *Journal of Crohn's and Colitis* 2018;**12** Suppl 1:S076-7.

#### Stunkel 2012 {published data only}

\* Stunkel L, Karia K, Okoji O, Warren R, Jean T, Jacob V, et al. Impact on quality of life of a smart device mobile application in patients with inflammatory bowel disease: 1575. *Official Journal of the American College of Gastroenterology* 2012;**107**:S635-6.

#### Wang 2020 {published data only}

\* Wang K, Peng N, Qi J, Sun L, Gong J, Zhu W. Efficacy of a nurse-led WeChat follow-up program on adherence to azathioprine in Crohn's disease patients: a randomized controlled trial [基于护士主导的微信平台改善克罗恩病人硫唑嘌呤服药依从性的研究]. *Chinese Nursing Research* 2020;**34**(5):828-34.

### References to studies excluded from this review

#### Ankersen 2017 {published data only}

Ankersen DV, Marker D, Weimers P, Burisch J, Munkholm P. Home monitoring of disease activity and fecal calprotectin in adult patients with inflammatory bowel disease-interim analysis of 68 patients. *United European Gastroenterology Journal* 2017;**5**(5):A287.

#### Camba 2013 {published data only}

Camba AH, Carrillo M, Ramos L, Alonso I, Alvarez-Buylla NH, Fernandez OA, et al. E-mail reminders and adherence rates to medical treatment in patients with inflammatory bowel disease. *Journal of Crohn's and Colitis* 2013;**7**:S112.

Camba AH, Carrillo-Palau M, Ramos L, Alonso-Abreu I, Hernandez N, Alarcon O, et al. E-mail reminders and adherence rates to medical treatment in patients with inflammatory bowel disease. *Gastroenterology* 2013;**5**(144):S779.

#### Carlsen 2017b {published data only}

Carlsen K, Houen G, Jakobsen C, Kallemose T, Paerregaard A, Riis LB, et al. Individualized infliximab treatment guided by

patient-managed eHealth in children and adolescents with inflammatory bowel disease. *Inflammatory Bowel Diseases* 2017;**23**(9):1473-82.

Carlsen K, Houen G, Jakobsen C, Kallemose T, Paerregaard A, Riis LB, et al. Individualized infliximab treatment guided by patient-managed eHealth in children and adolescents with inflammatory bowel disease. *Inflammatory Bowel Diseases* 2017;**23**(9):1473-82.

Carlsen K, Jakobsen C, Hansen LF, Paerregaard A, Kallemose T, Houen G, et al. Self-administered telemedicine empowers paediatric and adolescent patients with inflammatory bowel disease. *Journal of Crohn's and Colitis* 2016;**10**:S53-4.

Carlsen K, Jakobsen C, Hansen LF, Paerregaard A, Kallemose T, Riis LB, et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. *Journal of Crohn's and Colitis* 2016;**10**:S421-2.

Carlsen K, Jakobsen C, Hansen LF, Paerregaard A, Riis LB, Munkholm PS, Wewer V. Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease. *Journal of Crohn's and Colitis* 2016;**10**:S53.

Carlsen K, Jakobsen C, Houen G, Kallemose T, Paerregaard A, Riis LB, et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. *Inflammatory Bowel Diseases* 2017;**23**(3):357-65.

NCT01860651. Web-based monitoring in children and adolescents with inflammatory bowel disease. [clinicaltrials.gov/ct2/show/NCT01860651](https://clinicaltrials.gov/ct2/show/NCT01860651) (first received 23 May 2013).

#### Creed 2019 {published data only}

Creed E, Clark K. Virtual biologics clinic for IBD patients improving patient and service experience. *BMJ* 2019;**68**:A234.

#### Del Hoyo 2021 {published data only}

Del Hoyo J, Aguas M. Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial. *Clinical Gastroenterology and Hepatology* 2021;**19**(1):206-7.

#### Elkjaer 2010b {published data only}

Elkjaer M, Burisch J, Avnstrom S, Lyng E, Munkholm P. Development of a web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. *European Journal of Gastroenterology & Hepatology* 2010;**22**(6):695-704.

#### Gray 2020 {published data only}

Gray WN, Wagoner ST, Schaefer MR, Reed B, Morgan P, Holbrook E, et al. Transition to adult IBD care: a pilot multi-site, telehealth hybrid intervention. *Journal of Pediatric Psychology* 2020;**j18**:7801773.

#### Greenley 2015 {published data only}

Greenley R, Kunz J, Gumidyala A, Nguyen E, Pouloupoulos N, Thomason M, et al. P-173 Improving oral medication adherence



in adolescents with IBD: year 3 results of the PHONE trial. *Inflammatory Bowel Diseases* 2013;**19 Suppl 1**:S95.

Greenley R, Nguyen E, Kunz J, Gumidyala A, Thomason M, Walter J, et al. O-10 Improving oral medication adherence in pediatric IBD by teaching problem solving skills: year 2 results of the PHONE trial. *Inflammatory Bowel Diseases* 2012;**Suppl 1**:S6.

Greenley R, Nguyen E, Kunz J, Gumidyala A, Thomason M, Walter J, et al. P-160 Improving oral medication adherence in pediatric IBD by teaching problem solving skills: year 2 results of the PHONE trial. *Inflammatory Bowel Diseases* 2012;**18 Suppl 1**:S79-80.

Greenley R, Nguyen E, Kunz JH, Biank V, Blank, E, Miranda A, et al. Phone intervention to improve pediatric oral medication adherence: preliminary acceptability and feasibility: P-148. *Inflammatory Bowel Diseases* 2011;**17 Suppl 2**:S57.

Greenley RN, Gumidyala AP, Nguyen E, Plevinsky JM, Pouloupoulos N, Thomason MM, et al. Can you teach a teen new tricks? Problem solving skills training improves oral medication adherence in pediatric patients with inflammatory bowel disease participating in a randomized trial. *Inflammatory Bowel Diseases* 2015;**21**(11):2649-57.

NCT01237847. A brief intervention to improve adherence in teens with inflammatory bowel disease (PHONE). [clinicaltrials.gov/ct2/show/NCT01237847](https://clinicaltrials.gov/ct2/show/NCT01237847) (first received 10 November 2010).

#### **Jambaulikar 2015** {published data only}

Jambaulikar GD, Lee J, Aholoukpe M, Regueiro M, Schwartz DA, Ghazi LJ, et al. Internal locus of control and increased self-efficacy are associated with higher quality of life in patients with inflammatory bowel disease. *Gastroenterology* 2015;**148**(4):S841.

#### **Krier 2011** {published data only}

Krier M, Kaltenbach T, McQuaid K, Soetikno R. Potential use of telemedicine to provide outpatient care for inflammatory bowel disease. *Official Journal of the American College of Gastroenterology* 2011;**106**(12):2063-7.

Krier MJ, Kaltenbach TR, McQuaid KR, Soetikno RM. Broadening the access to specialized IBD care using a consumer grade affordable telemedicine system. *Gastroenterology* 2010;**138 Suppl 1**:S473.

NCT01296841. Telemedicine to provide inflammatory bowel disease outpatient care. [clinicaltrials.gov/ct2/show/study/NCT01296841](https://clinicaltrials.gov/ct2/show/study/NCT01296841) (first received 16 February 2011).

#### **Mastronardi 2020** {published data only}

Mastronardi M, Curlo M, Polignano M, Vena N, Rossi D, Giannelli G. Remote monitoring empowerment of patients with IBDs during the SARS-CoV-2 pandemic. *Healthcare* 2020;**8**(4):337.

#### **Miloh 2017** {published data only}

Miloh T, Shub M, Montes R, Ingebo K, Silber G, Pasternak B. Text messaging effect on adherence in children with inflammatory

bowel disease. *Journal of Pediatric Gastroenterology and Nutrition* 2017;**64**(6):939-42.

#### **Moss 2010** {published data only}

Chaudhary N, Junior J, Tukey M, Falchuk KR, Cheifetz A, Moss AC. S1053 Impact of a patient support program on mesalamine adherence in patients with ulcerative colitis. *Gastroenterology* 2009;**136**(5):A178.

Moss AC, Chaudhary N, Tukey M, Junior J, Cury D, Falchuk KR, et al. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis—a prospective study. *Journal of Crohn's and Colitis* 2010;**4**(2):171-5.

#### **NCT00310362** {published data only}

NCT00310362. Use of telehealth in-home messaging to improve GI (gastrointestinal) endoscopy completion rates. [clinicaltrials.gov/ct2/show/NCT00310362](https://clinicaltrials.gov/ct2/show/NCT00310362) (first received 3 April 2006).

#### **NCT01852097** {published data only}

NCT01852097. An online intervention to address barriers to IBD medication adherence [A pilot randomised controlled trial to determine the feasibility, acceptability and effectiveness of a CBT based online intervention to address practical and perceptual barriers to medication adherence in inflammatory bowel disease]. [clinicaltrials.gov/ct2/show/NCT01852097](https://clinicaltrials.gov/ct2/show/NCT01852097) (first received 13 May 2013).

#### **NCT02265588** {published data only}

NCT02265588. Healthy approach to physical and psychological problems in youngsters with IBD (HAPPY-IBD). [clinicaltrials.gov/ct2/show/NCT02265588](https://clinicaltrials.gov/ct2/show/NCT02265588) (first received 16 October 2014).

#### **NCT02707068** {published data only}

NCT02707068. Quality Of Life Tool for IBD [Quality Of Life Tool for IBD (QOLITI): pilot testing of a self-administered intervention to target psychological distress in inflammatory bowel disease]. [clinicaltrials.gov/ct2/show/NCT02707068](https://clinicaltrials.gov/ct2/show/NCT02707068) (first received 14 March 2016).

#### **NCT03486158** {published data only}

NCT03486158. The CalproSmartNOR Study – a new clinical tool for monitoring patients with inflammatory bowel disease. [clinicaltrials.gov/ct2/show/study/NCT03486158](https://clinicaltrials.gov/ct2/show/study/NCT03486158) (first received 3 April 2018).

#### **NCT03695783** {published data only}

NCT03695783. The IBD&me randomized controlled trial [Impact of a web-based decision aid on shared decision-making in patients with inflammatory bowel disease: the ibd&me randomized controlled trial]. [clinicaltrials.gov/ct2/show/NCT03695783](https://clinicaltrials.gov/ct2/show/NCT03695783) (first received 3 April 2018).

#### **NCT04151420** {published data only}

NCT04151420. Real life remote monitoring of mild, moderate and severe infectious complications in ibd by patient reported assessment. [clinicaltrials.gov/ct2/show/NCT04151420](https://clinicaltrials.gov/ct2/show/NCT04151420) (first received 5 November 2019).

**NCT04165265** {published data only}

NCT04165265. The use of web-app constant-care in patients with acute severe ulcerative colitis treated with rescue therapy. [clinicaltrials.gov/ct2/show/NCT04165265](https://clinicaltrials.gov/ct2/show/NCT04165265) (first received 15 November 2019).

**Oser 2018** {published data only}

Oser M, Szigethy E, Wallace ML, Weaver EK, Culp A, Kogan J, Regueiro MD. Randomized adaptive trial of digital behavioral program for anxiety and depression in ibd patient centered medical home. *Gastroenterology* 2018;**154**(6):S-153.

**RBR-79dn4k** {published data only}

RBR-79dn4k. Effect of a program on drug use in patients with Ulcerative Colitis [Impact of an intervention program on nonadherence to drugs in ulcerative colitis patients: randomized clinical trial]. [ensaiosclinicos.gov.br/rg/RBR-79dn4k](https://ensaiosclinicos.gov.br/rg/RBR-79dn4k) (first received 1 February 2020).

**Snoei 2009** {published data only}

Snoei L, van Bodegraven A, Oldenburg B, Stijnen T, Kaptein AA. Prototype evaluation of a self-management Internet diary for patients with ulcerative colitis. *Patient Preference and Adherence* 2009;**3**(101475748):179-87.

**Sutton 2019** {published data only}

Sutton RT, Wierstra K, Huang VW. Knowledge translation dataset: an e-health intervention for pregnancy in inflammatory bowel disease. *Data in Brief* 2019;**23**(101654995):103647.

**Tripp 2017** {published data only}

Tripp DA, Verreault P, Gates J, Ropeleski M, Beyak M. Development and piloting of a cognitive-behavioral selfmanagement program for patients with inflammatory bowel disease: an early stage update. *Gastroenterology* 2017;**152**(5):S799.

**Zhang 2020** {published data only}

Zhang Y, Pi B, Xu X, Li Y, Chen X, Yang N. Influence of narrative medicine-based health education combined with an online patient mutual assistance group on the health of patients with inflammatory bowel disease and arthritis. *Psychology Research and Behavior Management* 2020;**13**(101514563):1-10.

**References to studies awaiting assessment**
**Bonnaud 2021** {published data only}

Bonnaud G, Haennig A, Altwegg R, Caron B, Boivineau L, Zallot C, et al. Real-life pilot study on the impact of the telemedicine platform EasyMICI-MaMICI® on quality of life and quality of care in patients with inflammatory bowel disease. *Scandinavian Journal of Gastroenterology* 2021;**56**(5):530-6.

**Hommel 2015** {published data only}

Hommel KA, Gray WN, Hente E, Loreaux K, Ittenbach RF, Maddux M, et al. The Telehealth Enhancement of Adherence to Medication (TEAM) in pediatric IBD trial: design and methodology. *Contemporary Clinical Trials* 2015;**43**:105-13.

NCT01536509. Improving medication adherence in pediatric inflammatory bowel disease (TEAM). [clinicaltrials.gov/ct2/show/NCT01536509](https://clinicaltrials.gov/ct2/show/NCT01536509) (first received 22 February 2012).

**NCT02085083** {published data only}

NCT02085083. Improving outcomes in the pediatric to adult care transition in inflammatory bowel disease (IMPACT-IBD). [clinicaltrials.gov/ct2/show/NCT02085083](https://clinicaltrials.gov/ct2/show/NCT02085083) (first received 12 March 2014).

**NCT02694042** {published data only}

NCT02694042. Mission is remission®: how can a disease self-management website change care? [clinicaltrials.gov/ct2/show/NCT02694042](https://clinicaltrials.gov/ct2/show/NCT02694042) (first received 29 February 2016).

**NCT03059186** {published data only}

NCT03059186. A gratitude intervention in improving well-being and coping in people living with inflammatory bowel disease. [clinicaltrials.gov/ct2/show/NCT03059186](https://clinicaltrials.gov/ct2/show/NCT03059186) (first received 23 February 2017).

**NCT03186872** {published data only}

NCT03186872. Improving quality of care with a digital behavioral program in ibd patient centered medical home. [clinicaltrials.gov/ct2/show/NCT03186872](https://clinicaltrials.gov/ct2/show/NCT03186872) (first received 14 June 2017).

**NCT04754620** {published data only}

NCT04754620. Distant management of Crohn's disease by smartphones is feasible and effective additionally it reduces the costs. [clinicaltrials.gov/ct2/show/NCT04754620](https://clinicaltrials.gov/ct2/show/NCT04754620) (first received 15 February 2021).

**NTR2892** {published data only}

NTR2892. Adherence as a lifetime effort [Promoting recall of information and treatment adherence]. [www.trialregister.nl/trial/2753](https://www.trialregister.nl/trial/2753) (first received 11 May 2011).

**NTR4648** {published data only}

NTR4648. Improving adherence in ulcerative colitis patients on 5-ASA. <https://www.trialregister.nl/trial/4406> (first received 17 June 2014).

**References to ongoing studies**
**ACTRN12617000389303** {published data only}

ACTRN12617000389303. Teleconsulting versus normal consulting in the care of inflammatory bowel disease in rural Southern District Health Board patients. [Establishing the role of Teleconsulting in the care of chronic conditions in rural areas of the Southern District Health Board (SDHB): A randomised controlled trial (RCT) in patients with inflammatory bowel disease]. [www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372543&isReview=true](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372543&isReview=true) (first received 16 March 2017).

**IRCT2020061304775** {published data only}

IRCT2020061304775N1. Designing a mobile-based inflammatory bowel disease management system by using gamification techniques and determining its effectiveness on disease activity index, mental health and quality of life

[Evaluation of the effectiveness of mobile-based inflammatory bowel disease management system by using gamification techniques on disease activity index, mental health and quality of life]. [www.irct.ir/trial/59842](http://www.irct.ir/trial/59842) (first received 16 November 2021).

#### **NCT03985800** {published data only}

NCT03985800. Specialty medical homes to improve outcomes for patients with IBD and behavioral health conditions. [clinicaltrials.gov/ct2/show/NCT03985800](https://clinicaltrials.gov/ct2/show/NCT03985800) (first received 14 June 2019).

#### **NCT04207008** {published data only}

NCT04207008. Trial of a decision support intervention for adolescents and young adults with ulcerative colitis (iBDecide). [clinicaltrials.gov/ct2/show/NCT04207008](https://clinicaltrials.gov/ct2/show/NCT04207008) (first received 20 December 2019).

#### **NCT04388865** {published data only}

NCT04388865. Patient Automated Text Hovering for IBD (PATH-IBD). [clinicaltrials.gov/ct2/show/NCT04388865](https://clinicaltrials.gov/ct2/show/NCT04388865) (first received 14 May 2020).

#### **NCT04653259** {published data only}

NCT04653259. Digital nutrition therapy for patients with IBD (LYFEMD). [clinicaltrials.gov/ct2/show/NCT04653259](https://clinicaltrials.gov/ct2/show/NCT04653259) (first received 4 December 2020).

#### **NCT04861597** {published data only}

NCT04861597. Digital behavioral interventions in inflammatory bowel disease. [clinicaltrials.gov/ct2/show/NCT04861597](https://clinicaltrials.gov/ct2/show/NCT04861597) (first received 27 April 2021).

#### **Norton 2021** {published data only}

ISRCTN71618461. A supported online self-management for symptoms of fatigue, pain and urgency/incontinence in people with inflammatory bowel disease: the IBD-BOOST trial [A randomised controlled trial of supported online self-management for symptoms of fatigue, pain and urgency/incontinence in people with inflammatory bowel disease: the IBD-BOOST trial]. [www.isrctn.com/ISRCTN71618461](http://www.isrctn.com/ISRCTN71618461) (first received 2 September 2019).

Norton C, Syred J, Kerry S, Artom M, Sweeney L, Hart A, et al. Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial. *Trials* 2021;**22**(1):1-18.

#### **RBR-7t8fv7** {published data only}

RBR-7t8fv7. Clinical trial of the effectiveness of telephone nursing care to individuals with inflammatory bowel disease. [ensaiosclinicos.gov.br/rg/RBR-7t8fv7](https://ensaiosclinicos.gov.br/rg/RBR-7t8fv7) (first received 25 July 2016).

### **Additional references**

#### **Al-Ani 2020**

Al-Ani AH, Prentice RE, Rentsch CA, Johnson D, Ardalan Z, Heerasing N, et al. Prevention, diagnosis and management

of COVID-19 in the IBD patient. *Alimentary Pharmacology & Therapeutics* 2020;**52**(1):54-72.

#### **Bernstein 2011**

Bernstein KI, Promislow S, Carr R, Rawsthorne P, Walker JR, Bernstein CN. Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. *Inflammatory Bowel Diseases* 2011;**17**(2):590-8.

#### **Choi 2014**

Choi NG, Marti CN, Bruce ML, Hegel MT, Wilson NL, Kunik ME. Six-month postintervention depression and disability outcomes of in-home telehealth problem-solving therapy for depressed, low-income homebound older adults. *Depression and Anxiety* 2014;**31**(8):653-61.

#### **Colagiuri 2010**

Colagiuri B. Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity. *Clinical Trials* 2010;**7**(3):246-55.

#### **Cross 2012**

Cross RK, Cheevers N, Rustgi A, Langenberg P, Finkelstein J. Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). *Inflammatory Bowel Diseases* 2012;**18**(6):1018-25.

#### **Eady 2008**

Eady AM, Wilczynski NL, Haynes RB. PsycINFO search strategies identified methodologically sound therapy studies and review articles for use by clinicians and researchers. *Journal of Clinical Epidemiology* 2008;**61**(1):34-40.

#### **Egger 1997**

Egger M, Smith GD, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**(7109):629-34. [DOI: [10.1136/bmj.315.7109.629](https://doi.org/10.1136/bmj.315.7109.629)]

#### **Elkjaer 2012**

Elkjaer M. E-health: web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. *Danish Medical Journal* 2012;**59**(59):B4478.

#### **Feuerstein 2020**

Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. *Gastroenterology* 2020;**158**(5):1450-61.

#### **Feuerstein 2021**

Feuerstein JD, Ho EY, Schmidt E, Singh H, Falck-Ytter Y, Sultan S, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. *Gastroenterology* 2021;**160**(7):2496-508.

#### **Fordeucey 2012**

Fordeucey PG, Glueckauf RL, Bergquist TF, Maheu MM, Yutsis M. Telehealth for persons with severe functional disabilities and

their caregivers: facilitating self-care management in the home setting. *Psychological Services* 2012;**9**(2):144.

## Ghosh 2015

Ghosh N, Premchand P. A UK cost of care model for inflammatory bowel disease. *Frontline Gastroenterology* 2015;**6**(3):169-74.

## Gordon 2016

Gordon M. Are we talking the same paradigm? Considering methodological choices in health education systematic review. *Medical Teacher* 2016;**38**:746-50.

## Gordon 2020

Gordon M, Guyatt G. Assessment of evidence quality in inflammatory bowel disease guidance: the use and misuse of GRADE. *Gastroenterology* 2020;**159**:1209-15.

## Gordon 2021a

Gordon M, Sinopoulou V, Akobeng AK, Lakunina S, Gjuladin-Hellon T. Patient education interventions for the management of inflammatory bowel disease. *Cochrane Database of Systematic Reviews* 2021, Issue January. Art. No: CD013854. [DOI: [10.1002/14651858.CD013854](https://doi.org/10.1002/14651858.CD013854)]

## Gordon 2022

Gordon M, Sinopoulou V, Tabbers M, Rexwinkel R, de Bruijn C, Dovey T, et al. Psychosocial interventions for the treatment of functional abdominal pain disorders in children: a systematic review and meta-analysis. *JAMA Pediatrics* 2022;**176**(4):no pagination.

## GRADEpro GDT [Computer program]

GRADEpro Guideline Development Tool [Software]. Version Accessed March 2021. McMaster University (developed by Evidence Prime, Inc), 2020. Available from [www.grade-pro.org](http://www.grade-pro.org).

## Groom 2021

Groom LL, McCarthy MM, Stimpfel AW, Brody AA. Telemedicine and telehealth in nursing homes: an integrative review. *Journal of the American Medical Directors Association* 2021;**22**(9):1784-801.

## Hedges

Search Strategies for EMBASE in Ovid Syntax. [hiru.mcmaster.ca/hiru/HIRU\\_Hedges\\_EMBASE\\_Strategies.aspx](http://hiru.mcmaster.ca/hiru/HIRU_Hedges_EMBASE_Strategies.aspx).

## Heida 2018

Heida A, Dijkstra A, Muller Kobold A, Rossen JW, Kindermann A, Kokke F, et al. Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. *Journal of Crohn's and Colitis* 2018;**12**(4):432-41.

## Higgins 2011

Higgins JP, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [training.cochrane.org/handbook/archive/v5.1/](http://training.cochrane.org/handbook/archive/v5.1/).

## Higgins 2020

Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 6.1 (updated September 2020). Cochrane, 2021. Available from [training.cochrane.org/handbook/archive/v6.1/](http://training.cochrane.org/handbook/archive/v6.1/).

## Hoffman 2013

Hoffmann T C, Eructi C, Glasziou P P. Poor description of non-pharmacological interventions: analysis of consecutive sample of randomised trials. *BMJ* 2013;**347**:f3755.

## Huang 2014

Huang VW, Reich KM, Fedorak RN. Distance management of inflammatory bowel disease: systematic review and meta-analysis. *World Journal of Gastroenterology* 2014;**20**(3):829.

## Ko 2019

Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. *Gastroenterology* 2019;**156**(3):748-64.

## Lamb 2019

Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019;**68** Suppl 3:s1-s106.

## Lefebvre 2022

Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Marshall C, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 6.3 (updated February 2022). Cochrane, 2022. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).

## McLean 2009

McLean S, Sheikh A. Does telehealthcare offer a patient-centred way forward for the community-based management of long-term respiratory disease? *Primary Care Respiratory Journal* 2009;**18**(3):125-6.

## McLean 2011

McLean S, Protti D, Sheikh A. Telehealthcare for long-term conditions. *BMJ* 2011;**342**:d120.

## Ng 2017

Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet* 2017;**390**(10114):2769-78.

## Nguyen 2022

Nguyen NH, Martinez I, Atreya A, Sitapati AM, Sandborn WJ, Ohno-Machado L, et al. Digital health technologies for remote monitoring and management of inflammatory bowel disease: a systematic review. *The American Journal of Gastroenterology* 2022;**117**:78-97.



## Page 2021

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *BMJ* 2021;**372**(160):no pagination.

## RevMan Web 2022 [Computer program]

Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at [revman.cochrane.org](http://revman.cochrane.org).

## Rimmer 2013

Rimmer JH, Wang E, Pellegrini CA, Lullo C, Gerber BS. Telehealth weight management intervention for adults with physical disabilities: a randomized controlled trial. *American Journal of Physical Medicine & Rehabilitation* 2013;**92**(12):1084-94.

## Sood 2007

Sood S, Mbarika V, Jugoo S, Dookhy R, Doarn CR, Prakash N, et al. What is telemedicine? A collection of 104 peer-reviewed

perspectives and theoretical underpinnings. *Telemedicine and e-Health* 2007;**13**(5):573-90.

## Wong 2006

Wong SS, Wilczynski NL, Haynes RB. Optimal CINAHL search strategies for identifying therapy studies and review articles. *Journal of Nursing Scholarship* 2006;**38**(2):194-9. [DOI: [10.1111/j.1547-5069.2006.00100.x](https://doi.org/10.1111/j.1547-5069.2006.00100.x)]

## References to other published versions of this review

### Gordon 2021b

Gordon M, Sinopoulou V, Akobeng AK, Lakunina S, Gjuladin-Hellon T, Bracewell K. Remote care through telehealth for people with inflammatory bowel disease. *Cochrane Database of Systematic Reviews* 2021, Issue 4. Art. No: CD014821. [DOI: [10.1002/14651858.CD014821](https://doi.org/10.1002/14651858.CD014821)]

\* Indicates the major publication for the study

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies [ordered by study ID]

#### Akobeng 2015

##### Study characteristics

|              |   |
|--------------|---|
| Methods      | <p><b>Study design:</b> prospective RCT</p> <p><b>Study duration:</b> July 2010–June 2013</p> <p><b>Setting:</b> Royal Manchester Children's Hospital, Manchester, UK, a regional Paediatric Gastroenterology referral centre</p>   |
| Participants | <p><b>State of disease at beginning of study:</b> all in remission</p> <p><b>Disease type:</b></p> <ul style="list-style-type: none"> <li>IG: UC or indeterminate colitis (n = 8), CD (n = 36)</li> <li>CG: UC or indeterminate colitis (n = 7), CD (n = 35)</li> </ul> <p><b>Inclusion criteria:</b></p> <ul style="list-style-type: none"> <li>Diagnosis of IBD by established clinical, endoscopic, histological, and radiological criteria</li> <li>Clinical remission, defined as an aPCDAI score ≤ 10 for people with CD, or PUCAI score ≤ 10 for those with UC and indeterminate colitis</li> </ul> <p><b>Exclusion criteria:</b></p> <ul style="list-style-type: none"> <li>Active disease (aPCDAI ≥ 15 or PUCAI ≥ 15)</li> <li>Unwillingness to provide informed consent</li> </ul> <p><b>Age at beginning of study:</b></p> <ul style="list-style-type: none"> <li>All participants: 8–16 years</li> <li>IG: median 13.9 years (IQR 12.1–15.9)</li> <li>CG: median 13.8 years (IQR 11.2–15.3)</li> </ul> <p><b>Sex:</b></p> |

#### Remote care through telehealth for people with inflammatory bowel disease (Review)

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

**Akobeng 2015** (Continued)

- IG: 30 boys, 14 girls
- CG: 24 boys, 18 girls

**Number randomised:**

- IG: 44
- CG: 42

**Number reaching end of study:**

- IG: 27
- CG: 28

|               |   |
|---------------|---|
| Interventions | <p><b>IG:</b> telephone consultations with gastroenterology doctor; parents and participants advised to be together for the appointment (as in face-to-face consultations)</p> <p><b>CG:</b> routine appointments in hospital as usual</p>  |
| Outcomes      | <p><b>Duration of follow-up:</b> 24 months</p> <p><b>Primary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• QoL at 12 months (measured by the IMPACT questionnaire)</li> </ul> <p><b>Secondary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Participant and parent satisfaction with consultations (assessed with the Consultation Satisfaction Questionnaire (CSQ))</li> <li>• Number of disease relapses (defined by the aPCDAI or PUCAI)</li> <li>• Anthropometric measures (BMI, height, and weight z-scores)</li> <li>• Number of hospital admissions</li> <li>• Proportion of consultations attended</li> <li>• Duration of consultations</li> <li>• Costs to the UK National Health Service (NHS)</li> </ul> |
| Notes         | <p><b>Funding source:</b> "The project was funded by Research for Patient Benefit Programme, UK National Institute for Health Research (grant number PB-PG-0408-16218)."</p> <p><b>Conflicts of interest:</b> "The authors report grants from Research for Patient Benefit Programme, UK National Institute for Health Research, during the conduct of the study"</p> <p><b>Contact with study authors:</b> no emails sent</p>  |

**Risk of bias**

| Bias   | Authors' judgement | Support for judgement  |
|--|--------------------|--|
| Random sequence generation (selection bias)                              | Low risk           | Computer-generated randomisation scheme.   |
| Allocation concealment (selection bias)                                  | Low risk           | Quote: "The assignment schedule was held centrally and allocation was performed by staff of the hospital's pharmacy department independent from the trial team." |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk          | Masking not possible because of the nature of the interventions.   |

**Akobeng 2015** (Continued)

|  |           |   |
|--|-----------|---|
| Blinding of outcome assessment (detection bias)<br>Study level | High risk | Masking not possible because of the nature of the interventions.                    |
| Incomplete outcome data (attrition bias)<br>Study level        | Low risk  | Attrition and reasons balanced between the groups.                                  |
| Selective reporting (reporting bias)                           | Low risk  | The trial was registered. Reported outcomes match the protocol and methods section. |
| Other bias   | Low risk  | No baseline imbalance.  |

**Ankersen 2019**
**Study characteristics**

|              |   |
|--------------|---|
| Methods      | <p><b>Study design:</b> prospective, open-label, 1:1 RCT</p> <p><b>Study duration:</b> July 2015–August 2016</p> <p><b>Setting:</b> outpatient clinic at the Department of Gastroenterology, North Zealand University Hospital, Denmark</p>   |
| Participants | <p><b>State of disease at beginning of study:</b> remission (<math>\text{SCCAI} \leq 2</math> or <math>\text{HBI} &lt; 5</math>) or with mild-to-moderate disease activity (<math>\text{SCCAI} 3\text{--}4</math> or <math>\text{HBI} 5\text{--}16</math>)</p> <p><b>Disease type per IG/CG:</b></p> <ul style="list-style-type: none"> <li>IG: UC or indeterminate colitis (<math>n = 8</math>), CD (<math>n = 36</math>)</li> <li>CG: UC or indeterminate colitis (<math>n = 7</math>), CD (<math>n = 35</math>)</li> </ul> <p><b>Inclusion criteria:</b></p> <ul style="list-style-type: none"> <li>Age <math>\geq 18</math> years or older</li> <li>IBD according to Copenhagen diagnostic criteria</li> <li>Use of any medical IBD therapy</li> <li>Remission (<math>\text{SCCAI} \leq 2</math> or <math>\text{HBI} &lt; 5</math>) or mild-to-moderate disease activity (<math>\text{SCCAI} 3\text{--}4</math> or <math>\text{HBI} 5\text{--}16</math>)</li> <li>Ability to speak Danish</li> <li>Having a smartphone</li> </ul> <p><b>Exclusion criteria:</b></p> <ul style="list-style-type: none"> <li>Unwillingness to provide informed consent</li> </ul> <p><b>Age at beginning of study:</b></p> <ul style="list-style-type: none"> <li>IG: mean 48.4 years (SD 16.0); mean age at diagnosis was 37.3 years (SD 14.9)</li> <li>CG: mean 44.9 years (SD 15.2); mean age at diagnosis was 32.0 years (SD 13.1)</li> </ul> <p><b>Sex:</b></p> <ul style="list-style-type: none"> <li>IG: 24 men (48%), 26 women (52%)</li> <li>CG: 26 men (50%), 26 women (50%)</li> </ul> <p><b>Number randomised:</b></p> <ul style="list-style-type: none"> <li>IG: 50</li> </ul> |

**Ankersen 2019** (Continued)

- CG: 52

**Number reaching end of study:**

- IG 45
- CG: 43

|               |   |
|---------------|---|
| Interventions | <p><b>IG:</b> mobile phone application Constant Care. If participants experienced a recurrence of disease visualised on constant care web application (web-app), they should contact the electronic care (eCare) personnel by phone or via the personal web-wall, for an early consultation to assess the need for treatment adjustment or diagnostic investigation. The eCare nurses performed daily web ward rounds in close collaboration with a medical doctor.</p> <p><b>CG:</b> self-screening every 3 months</p>   |
| Outcomes      | <p><b>Duration of follow-up:</b> 1 year</p> <p><b>Primary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>1-year disease course (traffic light system based on HBI, SCCAI, FC and TIBS). 2 internal assessors characterised the individual disease courses as follows. <ul style="list-style-type: none"> <li>Chronic continuous course: red throughout 1 year</li> <li>Chronic continuous course: yellow throughout 1 year</li> <li>Chronic continuous course: red and yellow throughout 1 year</li> <li>Continuous remission course: green throughout 1 year</li> <li>Intermittent course: green, yellow, and red throughout 1 year</li> <li>Intermittent course: green with a single relapse (yellow or red) throughout 1 year</li> </ul> </li> <li>Relapse</li> <li>Disease-related quality of life measured with the SIBDQ</li> </ul> <p><b>Secondary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>Medical adherence measured by a self-assessment questionnaire (MARS)</li> </ul>                      |
| Notes         | <p><b>Funding source:</b> not reported</p> <p><b>Conflicts of interest:</b> "Ankersen DV has received grants from Ferring Pharmaceuticals, Crohn Colitis patient society Denmark, North Zealand University Hospital and nonfinancial support from Calpro AS; Weimers P has received grants from Ferring lægemidler and Tillotts Pharma AG as well as nonfinancial support from Janssen- Cilag A/S, Calpro AS, and Vifor Pharma Nordiska AB; Marker D has received non-financial support from Calpro AS and Pharmacosmos; Bennedsen M has received other financial support from AbbVie, Tillotts, Takeda, MSD and Pfizer; Saboori S has received non-financial support from Janssen-Cilag and Salofalk; Paridaens K is an employee of Ferring Pharmaceuticals; Burisch J has received grants from AbbVie, Takeda, Tillotts Pharma and personal fees from AbbVie, Janssen-Cilag, Celgene, Samsung Bioepis, MSD, Pfizer and Takeda; Munkholm P has none to declare."</p> <p><b>Contact with study authors:</b> we emailed the study authors on 17 October 2021 but received no response.</p> |

**Risk of bias**

| Bias  | Authors' judgement | Support for judgement  |
|---|--------------------|--|
| Random sequence generation (selection bias) | Unclear risk       | <p>Quote: "Patients were randomized to either be screened for disease activity whenever they felt necessary (OD group) or scheduled to be screened every 3M".</p> <p>Comment: insufficient information to make a judgement and no response to email request for clarification.</p> |

**Ankersen 2019** (Continued)

|  |              |  |
|--|--------------|--|
| Allocation concealment (selection bias)                                  | Unclear risk | Insufficient information to make a judgement and no response to email request for clarification.   |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk    | Quote: "This study was a 1-year open-label randomized trial (1:1) of adult IBD patients using the constant care platform for self-monitoring of disease activity." |
| Blinding of outcome assessment (detection bias)<br>Study level           | High risk    | Quote: "This study was a 1-year open-label randomized trial (1:1) of adult IBD patients using the constant care platform for self-monitoring of disease activity." |
| Incomplete outcome data (attrition bias)<br>Study level                  | Low risk     | Reasons for dropouts are stated and are balanced. Stated drop-out number in intervention and control groups.   |
| Selective reporting (reporting bias)                                     | Unclear risk | Trial registration offers limited information on outcomes, though outcomes are reported with appropriate data and are as expected.                                 |
| Other bias   | Low risk     | No baseline imbalance or other sources apparent.   |

**Atreja 2018**
**Study characteristics**

|              |  |
|--------------|--|
| Methods      | <p><b>Study design:</b> prospective phase III, single-centre, pragmatic RCT</p> <p><b>Study duration:</b> 2 years (104 weeks), protocol registration date 18 February 2015</p> <p><b>Setting:</b> recruitment in outpatient and inpatient facilities in Mount Sinai Health System, NY, USA</p>   |
| Participants | <p><b>State of disease at beginning of study:</b> insufficient information in abstract and protocol</p> <p><b>Disease type:</b> mixed</p> <p><b>Inclusion criteria:</b></p> <ul style="list-style-type: none"> <li>• Age ≥ 18 years</li> <li>• Having a mobile phone or access to the internet at home</li> <li>• Ability to complete a web-based questionnaire in English</li> </ul> <p><b>Exclusion criteria:</b></p> <ul style="list-style-type: none"> <li>• Inability to communicate with the investigators and comply with the study requirements</li> <li>• Short bowel syndrome or stoma</li> <li>• A condition or disease that, in the opinion of the investigators, may make it difficult for the person to use the HealthPROMISE app (e.g. advanced dementia)</li> </ul> <p><b>Age at beginning of study:</b> adults</p> <p><b>Sex:</b> 163 men (50.9%), 157 women (49.1%)</p> <p><b>Number randomised:</b></p> <p>IG: 162</p> <p>CG: 158</p> |

**Atreja 2018** (Continued)

**Number reaching end of study:** 315 (total)

|               |   |
|---------------|---|
| Interventions | <b>IG:</b> HealthPROMISE app: participants track QoL and symptoms every 2 weeks, providers use the visual data to improve care<br><br><b>CG:</b> usual care + IBD education app   |
| Outcomes      | <b>Duration of follow-up:</b> 104 weeks<br><br><b>Primary outcomes as defined by study authors:</b> <ul style="list-style-type: none"> <li>Improvement in quality indicators from AGA outpatient quality metrics</li> </ul> <b>Secondary outcomes as defined by study authors:</b> <ul style="list-style-type: none"> <li>SIBDQ</li> <li>Emergency visits and hospitalisations</li> <li>Change in generic QoL score (EQ-5D)</li> <li>Predictors of HEALTHPROMISE app utilisation</li> </ul>   |
| Notes         | <b>Funding source:</b> "The app was developed in-house at Sinai AppLab. The study is supported by the Crohn's & Colitis Foundation of America (grant #253624) and the National Institutes of Health (5K23 DK97451-02) with Ashish Atreja as the principal investigator."<br><br><b>Conflicts of interest:</b> not reported<br><br><b>Contact with study authors:</b> we sent emails for further clarification on 20 January 2021 and on 6 July 2021. The authors responded that the manuscript was under preparation for publication, providing no further clarification. |

**Risk of bias**

| Bias   | Authors' judgement | Support for judgement  |
|--|--------------------|--|
| Random sequence generation (selection bias)                              | Unclear risk       | Insufficient information in abstract and protocol to make a judgement.   |
| Allocation concealment (selection bias)                                  | Unclear risk       | Insufficient information in abstract and protocol to make a judgement.   |
| Blinding of participants and personnel (performance bias)<br>Study level | Unclear risk       | Insufficient information in abstract and protocol to make a judgement.   |
| Blinding of outcome assessment (detection bias)<br>Study level           | Unclear risk       | Insufficient information in abstract and protocol to make a judgement.   |
| Incomplete outcome data (attrition bias)<br>Study level                  | Unclear risk       | Insufficient information in abstract and protocol to make a judgement.   |
| Selective reporting (reporting bias)                                     | Unclear risk       | The trial was registered. Insufficient information to make a judgement as not all outcomes had been published at the time of the review. |
| Other bias   | Unclear risk       | Insufficient information in abstract and protocol to make a judgement.   |



## Carlsen 2017a

### Study characteristics

|               |  |
|---------------|--|
| Methods       | <p><b>Study design:</b> prospective, open-label, 1:1 RCT</p> <p><b>Study duration:</b> 2 years</p> <p><b>Setting:</b> outpatient clinic at the Pediatric Department, Hvidovre University Hospital, Denmark</p>   |
| Participants  | <p><b>State of disease at beginning of study:</b></p> <ul style="list-style-type: none"> <li>IG: UC in remission (n = 14), mild UC (n = 5); CD in remission (n = 2), mild CD (n = 5), moderate CD (n = 0), severe CD (n = 1)</li> <li>CG: UC in remission (n = 9), mild UC (n = 4); CD in remission (n = 5), mild CD (n = 6), moderate CD (n = 2), severe CD (n = 0)</li> </ul> <p><b>Disease type:</b></p> <ul style="list-style-type: none"> <li>IG: CD (n = 8), UC (n = 19)</li> <li>CG: CD (n = 13), UC (n = 13)</li> </ul> <p><b>Inclusion criteria:</b></p> <ul style="list-style-type: none"> <li>IBD diagnosis according to Copenhagen and Porto criteria</li> <li>Age 10–17 years</li> <li>Proficiency in Danish</li> <li>Access to the internet</li> <li>Nonbiological treatment (oral or topical) or no treatment for IBD</li> </ul> <p><b>Exclusion criteria:</b></p> <ul style="list-style-type: none"> <li>Insufficient Danish language skills</li> <li>Lack of intellectual capacity</li> <li>Growth retardation</li> <li>No access to the internet</li> <li>Biological treatment for IBD</li> </ul> <p><b>Age at beginning of study:</b></p> <ul style="list-style-type: none"> <li>IG: mean 15.1 years (SD 1.82)</li> <li>CG: mean 14.7 years (SD 2.11)</li> </ul> <p><b>Sex:</b></p> <ul style="list-style-type: none"> <li>IG: 10 boys, 17 girls</li> <li>CG: 12 boys, 14 girls</li> </ul> <p><b>Number randomised:</b></p> <ul style="list-style-type: none"> <li>IG: 27</li> <li>CG: 26</li> </ul> <p><b>Number reaching end of study:</b></p> <ul style="list-style-type: none"> <li>IG: 15</li> <li>CG: 18</li> </ul> |
| Interventions | <p><b>IG:</b> paediatric/adolescent version of eHealth web-based monitoring tool. Traffic light system based on self-reported symptoms and FC. Paediatric QoL, school absence, and weight and height measures were added. A message tool was available for participants to write to the IBD team for non-urgent matters.</p>   |

## Carlsen 2017a (Continued)

**CG:** hospital's IBD care guidelines (standard IBD care in Denmark), with outpatient visits every third month, including blood samples and FC. In addition, participant-completed MARS and VAS, PUCAI/aPCDAI, days of school absence since last visit, and IMPACT III questionnaires.

|          |   |
|----------|---|
| Outcomes | <p><b>Duration of follow-up:</b> 2 years</p> <p><b>Primary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Disease activity (self-reported symptoms using PUCAI or aPCDAI)</li> <li>• Relapse according to PUCAI and aPCDAI</li> <li>• Health-related QoL measured with IMPACT III</li> <li>• Absence from school</li> </ul> <p><b>Secondary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Total number of outpatient visits</li> <li>• Medical adherence according to MARS</li> <li>• Evaluation and adherence to the eHealth programme (number of entries of symptom scores and FC samples)</li> <li>• Socioeconomic perspectives (reduced school absence and fewer outpatient visits)</li> </ul> |
| Notes    | <p><b>Funding source:</b> "European Crohn's and Colitis Organization, Queen Louise's Hospital Foundation, TrygFoundation, CALPRO A/S, Tillotts Pharma, Capital Region Denmark, Alice and Frimodts Foundation, Ulcerative Colitis and Crohn's Danish Patient Society, and Merck Sharp and Dome"</p> <p><b>Conflicts of interest:</b> "V. Wewer: Advisory Board, MSD Denmark. A. Paerregaard: Advisory Board Nestle; Speaker fee (2015) Abbvie. The remaining authors have no conflict of interest to disclose"</p> <p><b>Contact with study authors:</b> no emails sent</p>  |

### Risk of bias

| Bias   | Authors' judgement | Support for judgement   |
|--|--------------------|---|
| Random sequence generation (selection bias)                              | Unclear risk       | Quote: "Patients were consecutively randomised by closed envelopes representing one of the 2 groups."   |
| Allocation concealment (selection bias)                                  | Low risk           | Envelopes handled by a person not involved in the study group and blinded to the person enrolling patients.   |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk          | Open-label study.   |
| Blinding of outcome assessment (detection bias)<br>Study level           | High risk          | Open-label study.   |
| Incomplete outcome data (attrition bias)<br>Study level                  | Low risk           | <p>The drop-out rate reported in the published paper is 20/53 (IG: 12/27 (44%); CG: 8/26 (31%)). There are no major differences and the reasons for drop-outs are stated and are balanced.</p> <p>In the trial registration, enrolment is stated as 103 (IG: 56; CG: 47), but this seems to include a separate population of people in treatment with biological infusions.</p> |

## Carlsen 2017a (Continued)

|                                      |           |   |
|--------------------------------------|-----------|---|
| Selective reporting (reporting bias) | High risk | The trial was registered. There is a difference in prioritisation of outcomes between the protocol (medication adherence) and published manuscript (disease activity). Disease activity and QoL not appropriately reported. |
| Other bias                           | Low risk  | No baseline differences reported by study authors, but differences of PCDAI and PUCAI in remission between groups at baseline.  |

## Chauhan 2016

### Study characteristics

|               |   |
|---------------|---|
| Methods       | <b>Study design:</b> prospective RCT<br><b>Study duration:</b> 6 months<br><b>Setting:</b> outpatient clinic at McMaster Medical Centre, Canada   |
| Participants  | <b>State of disease at beginning of study:</b> not reported<br><b>Disease type:</b> mixed, no further information provided<br><b>Inclusion criteria</b> <ul style="list-style-type: none"> <li>People with IBD assigned 3 months after their current appointment</li> </ul> <b>Exclusion criteria:</b> not reported<br><b>Age at beginning of study:</b> not reported<br><b>Sex:</b> not reported<br><b>Number randomised:</b> 60 in total, not reported per IG/CG<br><b>Number reaching end of study:</b> not reported |
| Interventions | <b>IG:</b> telephone follow-up visit by an IBD nurse practitioner 3 months after participant's current appointment<br><b>CG:</b> clinic follow-up visit by an IBD nurse practitioner  |
| Outcomes      | <b>Duration of follow-up:</b> 6 months<br><b>Primary outcomes as defined by study authors:</b> <ul style="list-style-type: none"> <li>Disease activity: CRP, HBI (CD) or Partial Mayo Score (UC)</li> <li>Health-related QoL using SIBDQ</li> </ul> <b>Secondary outcomes as defined by study authors:</b> <ul style="list-style-type: none"> <li>Change in disease activity</li> <li>Participant satisfaction using Patient Satisfaction Questionnaire</li> </ul>  |
| Notes         | <b>Funding source:</b> not reported<br><b>Conflicts of interest:</b> not reported<br><b>Contact with study authors:</b> we send an email on 10 October 2021 and the study authors responded. The trial was under review in the journal, but we adjusted the risk of bias section with the results provided.   |

## Chauhan 2016 (Continued)

### Risk of bias

| Bias   | Authors' judgement | Support for judgement  |
|--|--------------------|--|
| Random sequence generation (selection bias)                              | Low risk           | Participants randomised 1:1 using a computer-generated randomisation list and sealed envelopes.  |
| Allocation concealment (selection bias)                                  | Low risk           | Participants randomised 1:1 using a computer-generated randomisation list and sealed envelopes.  |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk          | Quote: "The participants and investigators were blinded using the sealed envelopes numbered chronologically for every participant (i.e. patient 001, patient 002, etc.). These sealed envelopes contained the treatment allocations (telephone follow-up or clinic follow-up) and were produced by a colleague researcher who was not involved in this study. This blinding of participants and investigators was maintained up until the participants have consented. Upon consenting, the corresponding sealed envelope was opened, and the participant and investigators became aware of the group allocation." |
| Blinding of outcome assessment (detection bias)<br>Study level           | High risk          | Quote: "Upon consenting, the corresponding sealed envelope was opened, and the participant and investigators became aware of the group allocation."  |
| Incomplete outcome data (attrition bias)<br>Study level                  | Low risk           | Reasons for dropouts stated, and dropout rate and reasons evenly distributed between the groups.   |
| Selective reporting (reporting bias)                                     | Unclear risk       | Study authors state "We reported all primary and secondary outcomes as per our ethics approved study protocol"; however, the protocol is not available, and the trial was not registered.  |
| Other bias   | Low risk           | More people with CD than with UC. Remaining baseline information was equal.  |

## Cross 2012

### Study characteristics

|              |   |
|--------------|---|
| Methods      | <b>Study design:</b> prospective RCT<br><br><b>Study duration:</b> November 2007–February 2010<br><br><b>Setting:</b> University of Maryland, Baltimore, and the gastroenterology clinic of the Veterans Affairs, Maryland Health Care System (VAMHCS), MD, USA   |
| Participants | <b>State of disease at beginning of study:</b> <ul style="list-style-type: none"> <li>IG: active UC 40%, UC in remission 60%</li> <li>CG: active UC 32%, UC in remission 68%</li> </ul> <b>Disease type:</b> UC<br><br><b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>UC diagnosis confirmed by standard clinical, endoscopic, and histologic criteria</li> <li>Age ≥ 18 years</li> </ul> <b>Exclusion criteria:</b> |

### Remote care through telehealth for people with inflammatory bowel disease (Review)

## Cross 2012 (Continued)

- Inability to comply with study protocol
- Previous colectomy with ileostomy or colectomy with ileoanal anastomosis
- History of colonic dysplasia or colorectal cancer
- Uncontrolled medical or psychiatric disease
- Inability or unwillingness to provide consent
- Age < 18 years
- Other forms of colitis

### Age at beginning of study:

- IG: mean 41.7 years (SD13.9)
- CG: mean 40.3 years (SD 14.4)
- Overall: mean 41.1 years (SD14.0)

### Sex:

- IG: 10 men, 15 women
- CG: 7 men, 15 women

### Number randomised:

- IG: 25
- CG: 22

### Number reaching end of study:

- IG: 14
- CG: 18

|                     |  |
|---------------------|--|
| Interventions       | <p><b>IG:</b> home telemanagement in UC (UC HAT, comprising a home unit, a decision support server, and a web-based clinician portal)</p> <p><b>CG:</b> individualised written action plan at the time of group assignment without reinforcement, based on current evidence-based guidelines and including scheduled and as-needed clinic visits or calls, and educational fact sheets about UC</p>  |
| Outcomes            | <p><b>Duration of follow-up:</b> 12 months</p> <p><b>Primary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Clinical disease activity using Seo Index scores</li> <li>• QoL using IBDQ</li> </ul> <p><b>Secondary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Medication adherence using MMAS. To evaluate percentage adherence, the study authors dichotomised the variable (adherent/non-adherent)</li> </ul> |
| Notes               | <p><b>Funding source:</b> "Broad Medical Research Program (BRMP-0190), University of Maryland General Clinical Research Center Grant (M01 RR16500), General Clinical Research Centers Program, National Center for Research Resources (NCRR), NIH, and the Baltimore Education and Research Foundation."</p> <p><b>Conflicts of interest:</b> not reported</p> <p><b>Contact with study authors:</b> we sent an email on 17 October 2021 and received additional information.</p>                  |
| <b>Risk of bias</b> |  |
| <b>Bias</b>         | <b>Authors' judgement</b> <b>Support for judgement</b>   |

## Cross 2012 (Continued)

|  |           |  |
|--|-----------|--|
| Random sequence generation (selection bias)                              | Low risk  | Random permuted block design with randomly varied block sizes.   |
| Allocation concealment (selection bias)                                  | Low risk  | Quote: "Group assignment was concealed and was not revealed to the patient or the research team members until after all baseline data were collected."; "We did computer randomization stratified by disease activity at enrollment (active or inactive). The group assignments were made using sealed envelopes." |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk | Participants not masked to their group assignments   |
| Blinding of outcome assessment (detection bias)<br>Study level           | Low risk  | Research staff at study visits blinded to treatment allocation of participants for subsequent visits.  |
| Incomplete outcome data (attrition bias)<br>Study level                  | High risk | 8/22 (36.3%) children in the IG discontinued the intervention, compared to 1/19 (5.3%) in the CG.  |
| Selective reporting (reporting bias)                                     | Low risk  | The trial was registered and the outcomes were appropriately presented.  |
| Other bias   | Low risk  | IBDQ scores significantly higher at baseline in CG than in IG; however, this is of questionable clinical significance given the nature of the IBDQ system. No other imbalance.   |

## Cross 2019

### Study characteristics

|              |  |
|--------------|--|
| Methods      | <p><b>Study design:</b> prospective, 3-arm, parallel RCT</p> <p><b>Study duration:</b> September 2021–September 2016</p> <p><b>Setting:</b> University of Maryland, Baltimore, MD, USA; University of Pittsburgh, PA, USA; and Vanderbilt University, Nashville, TN, USA</p>   |
| Participants | <p><b>State of disease at beginning of study:</b> IBD in remission (n = 200) and active IBD (n = 148)</p> <p><b>Disease type:</b></p> <ul style="list-style-type: none"> <li>IG1: CD (n = 79), UC (n = 36)</li> <li>IG2: CD (n = 78), UC (n = 38)</li> <li>CG: CD (n = 79), UC (n = 38)</li> </ul> <p><b>Inclusion criteria:</b></p> <ul style="list-style-type: none"> <li>Age ≥ 18 years</li> <li>Diagnosis of CD, UC, or indeterminate colitis according to Lennard-Jones classification</li> <li>≥ 1 IBD flare-up in 2 years prior to baseline visit (increase in IBD symptoms sufficient to warrant a change in medication dose or addition of a medication)</li> </ul> <p><b>Exclusion criteria:</b></p> <ul style="list-style-type: none"> <li>Inability to speak/read English</li> </ul> |

### Remote care through telehealth for people with inflammatory bowel disease (Review)



## Cross 2019 (Continued)

- Inability to comply with study protocol
- Presence of an ileostomy, colostomy, ileoanal pouch anastomosis, or ileorectal anastomosis
- Imminent surgery
- History of short bowel syndrome
- Uncontrolled medical/psychiatric disease
- Pregnancy
- Remission lasting  $\geq 2$  years

### Age at beginning of study:

- IG1: mean 40.1 years (SD 13.2)
- IG2 36.4 years (SD 11.5)
- CG 40.1 years (SD 11.7)

### Sex:

- IG1: 48 men, 67 women
- IG2: 50 men, 66 women
- CG: 53 men, 64 women

### Number randomised:

- IG1: 115
- IG2: 116
- CG: 117

### Number reaching end of study:

- IG1 88
- IG2 81
- CG 90

|               |  |
|---------------|--|
| Interventions | <p><b>IG1:</b> participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check bodyweight and to receive educational content. Participants receive self-action plans after each self-testing session. Alerts are generated to the nurse co-ordinator if certain clinical criteria are met.</p> <p><b>IG2:</b> participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check bodyweight and to receive educational content. Participants receive self-action plans after each self-testing session. Alerts are generated to the nurse co-ordinator if certain clinical criteria are met.</p> <p><b>CG:</b> standard of care for participants modelled after the standard of care at all 3 study sites. Comprehensive assessment, a guideline concordant therapy plan, scheduled and as-needed clinic visits, scheduled and as-needed telephone calls, and administration of educational fact sheets about disease-specific topics when appropriate.</p> |
| Outcomes      | <p><b>Duration of follow-up:</b> 12 months</p> <p><b>Primary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Change in disease activity score and remission rates measures with HBI and SCCAI</li> <li>• Change in disease-specific QoL scores (IBDQ)</li> </ul> <p><b>Secondary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Change in healthcare utilisation (number of hospitalisations, surgeries, emergency room visits, office visits, endoscopic procedures, non-endoscopic procedures, IV therapeutics, non-invasive diagnostic tests, electronic and telephone encounters)</li> </ul>  |

## Cross 2019 (Continued)

Notes

**Funding source:** Agency for Healthcare Research and Quality (1R01HS018975-01A1) and the University of Maryland General Clinical Research Centers Program.

**Conflicts of interest:** authors declared no conflict of interest

**Contact with study authors:** we sent an email on 17 October 2021 and received additional information.

### Risk of bias

| Bias   | Authors' judgement | Support for judgement  |
|--|--------------------|--|
| Random sequence generation (selection bias)                              | Low risk           | Permuted block randomisation with randomly varied block sizes.   |
| Allocation concealment (selection bias)                                  | Low risk           | Quote: "[...] the randomization arm assignments for each of the 4 (UC remission, UC active disease, CD remission, and CD active disease) strata were sent to the Cooperative Studies Program (CSP) Coordinating Center at the Veterans Affairs in Perry Point, MD, and entered into their interactive voice response system."  |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk          | Quote: "Investigators and staff were blinded to the randomization order, but patients, staff, and providers were not masked to group assignment."  |
| Blinding of outcome assessment (detection bias)<br>Study level           | Low risk           | Quote: "Investigators and staff were blinded to the randomization order, but patients, staff, and providers were not masked to group assignment."<br><br>Comment: according to the trial registration ( <a href="https://clinicaltrials.gov/ct2/show/NCT01692743">clinicaltrials.gov/ct2/show/NCT01692743</a> ) this study is single-blind (outcome assessors)<br><br>Response from authors: "The research staff was blind to the study group during the outcomes assessment." |
| Incomplete outcome data (attrition bias)<br>Study level                  | Low risk           | Balanced attrition and reasons for withdrawals thoroughly explained by the authors in our correspondence (27 October 2021). 48 participants in the intervention group discontinued and were accounted for in the published paper, while 42 participants were lost to follow-up in the control group.   |
| Selective reporting (reporting bias)                                     | Low risk           | In the 2015 published protocol for the study, there are more secondary outcomes than reported in the results. Most were reported in 3 publications referenced in this RCT, including all those relevant to this review.<br><br>The outcomes match with the trial registration (NCT01692743).   |
| Other bias   | Low risk           | No baseline imbalances.  |

## de Jong 2017

### Study characteristics

Methods

**Study design:** prospective RCT

**Study duration:** July 2014–July 2016

**de Jong 2017** (Continued)

**Setting:** 4 hospitals in the Netherlands: 2 academic hospitals (Maastricht University Medical Centre and Leiden University Medical Centre), and 2 large, non-academic, regional hospitals (Zuyderland Medical Centre, Sittard, and St Antonius Hospital, Nieuwegein)

**Participants**
**State of disease at beginning of study:**

- IG: in remission (n = 394), active (n = 71)
- CG: in remission (n = 380), active (n = 64)

**Disease type:**

- IG: CD (n = 282), UC (n = 183)
- CG: CD (n = 262), UC (n = 182)

**Inclusion criteria:**

- IBD diagnosis according to Lennard-Jones criteria
- Age 18–75 years
- Access to internet by computer, tablet, or smartphone
- Dutch proficiency

**Exclusion criteria:**

- Inability to read or understand the informed consent form
- Lack of internet access by computer, tablet, or smartphone
- Hospital admission within 2 weeks before inclusion
- Ileoanal pouch or ileorectal anastomosis

**Age at beginning of study:**

- IG: mean 44.0 years (SD 14.1)
- CG: mean 44.1 years (SD 14.2)

**Sex:**

- IG: 194 men, 271 women
- CG: 180 men, 264 women

**Number randomised:**

- IG: 465
- CG: 444

**Number reaching end of study:**

- IG: 438
- CG: 443

**Interventions**

**IG:** myIBDcoach is a secured webpage with an HTML application for tablet or smartphone and monthly monitoring modules, which contain questions regarding disease activity, medication use, treatment adherence, treatment satisfaction, and side effects, including infections. Also includes questions on factors affecting disease (including nutritional status, smoking, stress, life events, anxiety and depression, social support, physical exercise, and self-management skills), and patient-reported outcome measures on QoL and work productivity.

**CG:** standard care with routine follow-up visits according to the local protocol, with an opportunity to schedule an extra visit if symptoms relapsed.

**Outcomes**

**Duration of follow-up:** 12 months

**Primary outcomes as defined by study authors:**

## de Jong 2017 (Continued)

- Number of outpatient visits and telephone consultations with gastroenterologists and nurses
- Patient-reported quality of care via VAS scores on patient satisfaction with healthcare, patients' experiences contacting their healthcare providers, and the extent to which healthcare meets patients' expectations

**Secondary outcomes as defined by study authors:**

- Medication adherence measured with the 8-item MMAS
- QoL measured with SIBDQ
- Self-efficacy, defined as the perception of one's ability to engage in skills required to master a new challenge despite obstacles, measured with the 29-item inflammatory bowel disease self-efficacy scale (IBD-SES)
- Disease-related and medication-related knowledge assessed on a VAS
- Smoking behaviour with a categorical question (non-smoker, active-smoker, or ex-smoker)
- Numbers of relapses, defined as flares if symptoms suggestive of disease activity resulted in a dose escalation or initiation of a new drug to induce remission
- IBD-related hospital admissions, emergency visits, surgeries, and corticosteroid use

## Notes

**Funding source:** academic incentive fund of the Maastricht University Medical Centre (31962340B)

**Conflicts of interest:** Quote. "MJdJ reports non-financial support from Merck Sharpe & Dohme, outside the submitted work. AEvdM-dJ reports grants and non-financial support from Takeda, personal fees from AbbVie, and non-financial support from Tramedico, all outside the submitted work. AAvB reports personal fees from AbbVie, MSD, Ferring, Tramedico, Takeda, Pfizer, and Janssen, all outside the submitted work. GD reports speaker's fees from Shire, AbbVie, and Takeda, and a grant for investigator-initiated research from Takeda, all outside the submitted work. AAM reports grants from Grünenthal, Zon MW GGG (government), Will Pharma, BioActor, Pentax Europe, Falk Pharma, and Almiral Pharma, all outside the submitted work. AB received research grants to her department from AbbVie, Amgen, and Merck, and advisory board honoraria from Janssen and Sandoz, all unrelated to the current work. MJP reports personal fees from AbbVie, Ferring, Janssen, and Takeda, and grants from Falk, all outside the submitted work. All other authors declare no competing interests."

**Contact with study authors:** we sent an email on 17 October 2021 and received additional information.

**Risk of bias**

| Bias   | Authors' judgement | Support for judgement  |
|--|--------------------|--|
| Random sequence generation (selection bias)                              | Low risk           | Randomisation VIA ALEA Screening and Enrolment Application Software using the minimisation method, stratified for medical centre, IBS subtype (CD or UC), and treatment (no medication or Mesalazine; immunosuppressive drugs; or biological therapy). |
| Allocation concealment (selection bias)                                  | Low risk           | Enrolment via the software mentioned above.  |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk          | Open-label study.  |
| Blinding of outcome assessment (detection bias)<br>Study level           | High risk          | Open-label study.  |

## de Jong 2017 (Continued)

|   |          |  |
|---|----------|--|
| Incomplete outcome data (attrition bias)<br>Study level | Low risk | Attrition low in both groups. There were more reasons reported for dropping out of the IG (18/456) than the CG (1/444); however, this is unlikely to have affected the outcomes. |
| Selective reporting (reporting bias)                    | Low risk | Outcomes stated match the trial registration.  |
| Other bias  | Low risk | No baseline imbalances.  |

## Del Hoyo 2018

### Study characteristics

|              |  |
|--------------|--|
| Methods      | <p><b>Study design:</b> prospective, 3-arm RCT</p> <p><b>Study duration:</b> May 2014–December 2016</p> <p><b>Setting:</b> IBD Unit of La Fe University and Polytechnic Hospital (tertiary referral centre), Valencia, Spain</p>   |
| Participants | <p><b>State of disease at beginning of study:</b> Remission: 30, based on the HBI and the partial Mayo scores. The other 33 apparently were not in remission.</p> <p>CD: IG1 6/ IG2 9/ CG 10</p> <p>UC: IG1 2 / IG2 1 / CG 2</p> <p><b>Disease type:</b></p> <ul style="list-style-type: none"> <li>IG1: CD (n = 13), UC (n = 8)</li> <li>IG2: CD (n = 13), UC (n = 8)</li> <li>CG: CD (n = 14), UC (n = 7)</li> </ul> <p><b>Inclusion criteria:</b></p> <ul style="list-style-type: none"> <li>Age ≥ 18 years</li> <li>IBD diagnosis according to internationally accepted criteria</li> <li>Initiation of therapy with corticosteroids, immunosuppressants, and biological agents due to disease activity</li> <li>Provision of written informed consent to participate in the study</li> </ul> <p><b>Exclusion criteria:</b></p> <ul style="list-style-type: none"> <li>Inability to speak and read Spanish</li> <li>Inability to manage a mobile phone or tablet or the internet, or not having a telephone line</li> <li>Participation in other clinical trials during the inclusion period</li> <li>Uncontrolled medical or psychiatric disease</li> <li>Presence of ileorectal or ileal pouch-anal anastomosis</li> <li>Receipt of definitive ileostomy</li> <li>Perianal disease</li> <li>Pregnancy</li> </ul> <p><b>Age at beginning of study:</b></p> <ul style="list-style-type: none"> <li>IG1: median 40.91 years (range 24–60)</li> <li>IG2: median 41.32 years (range 19–66)</li> <li>CG: median 39.31 years (range 22–61)</li> </ul> |

## Del Hoyo 2018 (Continued)

### Sex:

- IG1: 12 men, 9 women
- IG2: 9 men, 12 women
- CG: 12 men, 9 women

### Number randomised:

- IG1: 21
- IG2: 21
- CG: 21

### Number reaching end of study:

- IG1 20
- IG2 18
- CG 19

|                     |  |
|---------------------|--|
| Interventions       | <p><b>IG1:</b> nursing care by telephone: participants had periodic health status assessments delivered through structured interviews; clinical activity self-recorded at home. Nurses modified medication or follow-up schedule with support of medical staff according to results of the interview.</p> <p><b>IG2:</b> Telemonitoring of CD and UC (TECCU): a web-based telemanagement system with an http app (NOMHADhome) for mobile phones, tablets, and computers. Participants completed questionnaires on the platform related to symptoms and adverse effects. Alerts and action plans were established based on this information and the medical staff adjusted therapy accordingly. Through the platform, participants also received advice, reminders, educational material about their disease, and information on prevention.</p> <p><b>CG:</b> usual care provided in the IBD Outpatient Clinic</p>   |
| Outcomes            | <p><b>Duration of follow-up:</b> 24 weeks</p> <p><b>Primary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Clinical remission of participants using HBI for CD and Mayo Index for UC</li> </ul> <p><b>Secondary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Health-related QoL measured by the generic EuroQol (EQ-5D) questionnaire</li> <li>• Health-related QoL measured by the specific SIBDQ</li> <li>• Participant satisfaction measured by a satisfaction questionnaire designed for the study</li> <li>• Therapeutic adherence measured by the validated Morisky-Green questionnaire</li> <li>• Urgent and scheduled visits and urgent hospital admissions captured directly through hospital information system</li> <li>• Number of surgical interventions related to the pathology</li> <li>• Work activity and productivity measured by a validated questionnaire</li> <li>• Mortality</li> <li>• Directs health costs</li> </ul> |
| Notes               | <p><b>Funding source:</b> "grants from the Instituto de Salud Carlos III-Fondo de Investigaciones Sanitarias (FIS PI12/00277) and cofunded by FEDER (Fondo Europeo de Desarrollo Regional)"</p> <p><b>Conflicts of interest:</b> "DD is the general manager of Connected Health Services."</p> <p><b>Contact with study authors:</b> no emails sent</p>  |
| <b>Risk of bias</b> |  |
| <b>Bias</b>         | <b>Authors' judgement</b> <b>Support for judgement</b>   |

## Remote care through telehealth for people with inflammatory bowel disease (Review)

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.



## Del Hoyo 2018 (Continued)

|  |           |  |
|--|-----------|--|
| Random sequence generation (selection bias)                              | Low risk  | Quote: "[...] block randomization method through a Web-based tool [...] in order to generate a random-allocation sequence and ensure allocation concealment."  |
| Allocation concealment (selection bias)                                  | Low risk  | Quote: "[...] block randomization method through a Web-based tool [...] in order to generate a random-allocation sequence and ensure allocation concealment."  |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk | Quote: "Neither the patients nor the researchers were masked to the intervention"  |
| Blinding of outcome assessment (detection bias)<br>Study level           | High risk | Quote: "[...] the results were analyzed by an independent statistician who was blinded to group identification."<br><br>Comment: However, all clinical outcome measures were analysed by staff who were not masked as per above. |
| Incomplete outcome data (attrition bias)<br>Study level                  | Low risk  | Low and balanced attrition and reasons for attrition.  |
| Selective reporting (reporting bias)                                     | Low risk  | Outcomes stated match the trial registration.  |
| Other bias   | Low risk  | No baseline imbalance.   |

## Elkjaer 2010a

### Study characteristics

|              |   |
|--------------|---|
| Methods      | <b>Study design:</b> prospective RCT<br><br><b>Study duration:</b> NR<br><br><b>Setting:</b> Herlev and Amager Hospitals, Copenhagen, Denmark; and Adelaide and Meath Hospital in Dublin, Ireland   |
| Participants | <b>State of disease at beginning of study:</b> SCCAI <ul style="list-style-type: none"> <li>IG: Denmark: median 1 (range 0–10); Ireland: median 1 (range 0–9)</li> <li>CG: Denmark: median 1 (range 0–11); Ireland: median 2 (range 0–7)</li> </ul> <b>Disease type:</b> UC<br><br><b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Age 18–69 years</li> <li>Mild/moderate UC diagnosed based on Copenhagen diagnostic criteria</li> <li>Treatment with 5-ASA at 1 of the study centres</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>Acute phase of comorbid conditions (rheumatoid arthritis, chronic lung disease, coronary heart disease, chronic pancreatitis)</li> <li>Drug (narcotic) dependence or substance abuse</li> </ul> |

**Elkjaer 2010a** (Continued)

- Use of immunomodulators (azathioprine, 6-mercaptopurine, methotrexate or antitumour necrosis factor (TNF) therapy)
- Frequent treatment (> 6 months/year or 2 treatments/year) with high dose of systemic corticosteroids to enter remission
- Likely requirement of IBD surgery during the study period
- Previous IBD surgery
- Pregnancy or breastfeeding
- Inability to read or understand the informed consent form or use a computer

**Age at beginning of study:**

- IG: Denmark: median 41 years (range 21–69); Ireland: median 42 years (range 18–68)
- CG: Denmark: median 48 years (range 21–69); Ireland: median 48 years (range 19–95)

**Sex:**

- IG: Denmark: 57 men, 60 women; Ireland: 32 men, 20 women
- CG: Denmark: 35 men, 81 women; Ireland: 20 men, 28 women

**Number randomised:**

- IG: Denmark: 117; Ireland: 52
- CG: Denmark: 116; Ireland: 48

**Number reaching end of study:**

- IG: Denmark: 89; Ireland: 41
- CG: Denmark: 97; Ireland: 38

|               |  |
|---------------|--|
| Interventions | <p><b>IG:</b> web-based programme (<a href="http://www.constant-care.dk">www.constant-care.dk</a>). Participants who relapsed were requested to log on daily and complete the disease activity score (SCCAI) until they entered the green zone. In any event, they had to log on once a week until 4 weeks after the initiation of relapse. Participants were asked to fill in the SIBDQ at the beginning and the end of each relapse. Once remission was achieved, participants had to use the programme once a month until the next relapse occurred.</p> <p><b>CG:</b> conventional treatment and follow-up in the IBD outpatient clinic, including routine appointments or as-needed appointments if participants were experiencing relapse symptoms. The attending physician evaluated the need for blood tests to monitor inflammation, and the need for sigmoido- or colonoscopy. Participants who relapsed filled in the SCCAI and SIBDQ in paper format 7 days after remission and sent it to the investigator.</p> |
| Outcomes      | <p><b>Duration of follow-up:</b> 12 months</p> <p><b>Primary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Compliance questionnaire with 5 questions: easy access to prescription, ability of relapse recognition, following the physician's advice, ability to self-initiate acute treatment, and adherence to 5-ASA treatment (5-ASA refill compared with results from the e-prescription pharmacy database)</li> <li>• Disease outcome (SCCAI)</li> <li>• IBD knowledge and QoL <ul style="list-style-type: none"> <li>◦ Disease specific QoL (SIBDQ)</li> <li>◦ CCKNOW (multiple choice questionnaire)</li> <li>◦ SF-36 (Denmark) or SF-12 (Ireland)</li> <li>◦ HADS</li> </ul> </li> <li>• Safety (adverse events)</li> <li>• Cost (number of outpatients visits, hospitalisation, and phone/online consultation)</li> </ul> <p><b>Secondary outcomes as defined by study authors:</b> not reported</p>  |

## Elkjaer 2010a (Continued)

### Notes

**Funding source:** "PM is member of the advisory boards in Ferring, Tillots, MSD and Swedish Orphan. ME is member of the advisory board in Swedish Orphan. HS is member of the advisory board in Swedish Orphan. CO'M is on the International Advisory Board of Abbott, MSD, and Shire Pharmaceutical Company. He has unrestricted educational grants from Abbott and MSD"

**Conflicts of interest:** "Colitis Crohn Patient Organisation, Moran's Foundation, Vibeke Binder & Povl Riis' Foundation, Bayer Health Care Funding, Augustinus Foundation, Munkholms Foundation, Tillotts Funding, Scientific Council at Herlev Hospital, Prof. Fagerhol Research Foundation, Aase & Einar Danielsen Foundation, Ole Trock-Jansen & Hustrus Foundation, and European Crohn Colitis Organisation."

**Contact with study authors:** we sent an email on 17 October 2021 but received no response.

### Risk of bias

| Bias   | Authors' judgement | Support for judgement   |
|--|--------------------|---|
| Random sequence generation (selection bias)                              | Low risk           | Quote: "Eligible patients, who had signed the informed consent form, were randomly allocated to the interventional (web) or to the control group by use of randomisation program" |
| Allocation concealment (selection bias)                                  | Low risk           | Quote: "Each randomisation number was placed in a closed, consecutively numbered envelope by two nurses not involved in the study."   |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk          | Quote: "This study was a 1-year open-label randomized trial (1:1) of adult IBD patients using the constant care platform for self-monitoring of disease activity."                |
| Blinding of outcome assessment (detection bias)<br>Study level           | High risk          | Quote: "This study was a 1-year open-label randomized trial (1:1) of adult IBD patients using the constant care platform for self-monitoring of disease activity."                |
| Incomplete outcome data (attrition bias)<br>Study level                  | Low risk           | Balanced drop-out rates and reasons for drop-out reported for each group are balanced.  |
| Selective reporting (reporting bias)                                     | Unclear risk       | No trial registration available, but all outcomes stated in the methods section are reported.   |
| Other bias   | Unclear risk       | Significantly higher age and more women in CG ( $p < 0.05$ ) in both groups with no explanation.  |

## Heida 2018

### Study characteristics

|              |   |
|--------------|---|
| Methods      | <b>Study design:</b> prospective RCT<br><b>Study duration:</b> April 2013–July 2016<br><b>Setting:</b> 11 centres (6 tertiary care hospitals and 5 large regional general hospitals) in the Netherlands |
| Participants | <b>State of disease at beginning of study:</b> remission<br><b>Disease type:</b> <ul style="list-style-type: none"> <li>IG: UC (<math>n = 45</math>), CD (<math>n = 39</math>)</li> </ul>               |

### Remote care through telehealth for people with inflammatory bowel disease (Review)

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

**Heida 2018** (Continued)

- CG: UC (n = 44), CD (n = 42)

**Inclusion criteria:**

- Age 10–19 years
- IBD in clinical remission at baseline for  $\geq 3$  months, diagnosed according to Revised Porto criteria > 6 months before enrolment
- Access to a telephone, the internet, and an email address
- Good knowledge of the Dutch language

**Exclusion criteria:**

- Treatment with anti-TNF monoclonal antibodies
- Ileostomy or ileoanal pouch
- Any other comorbidity requiring frequent hospital visits

**Age at beginning of study:**

- IG: median 15 years (range 12–16)
- CG: median 15 years (range 13–17)

**Sex:**

- IG: 64 boys, 20 girls
- CG: 45 boys, 41 girls

**Number randomised:**

- IG: 84
- CG: 86

**Number reaching end of study:**

- IG: 48
- CG: 72

|               |  |
|---------------|--|
| Interventions | <p><b>IG:</b> IBD-live web app. Participants received automated email alerts to fill in the symptom score (PUCAI, PCDAI) and to send in a stool sample to the hospital laboratory; results were uploaded on the IBD-live website and cumulated in a colour-coded disease flare risk stratification that was visible to the participant and the local IBD team.</p> <p><b>CG:</b> regular checks in the consultation room as before the trial, regardless of how well the participant was; the interval varied according to the physician's discretion.</p>   |
| Outcomes      | <p><b>Duration of follow-up:</b> 52 weeks</p> <p><b>Primary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Cumulative incidence of disease flares per group, defined as disease activity requiring therapy intensification (including steroid therapy, exclusive enteral nutrition, aminosalicylate dose escalation or introduction of anti-TNF antibodies)</li> </ul> <p><b>Secondary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Change in QoL measured with IBD-specific IMPACT-III questionnaire</li> <li>• Cost-effectiveness measured by direct and indirect medical and non-medical costs</li> <li>• Compliance to the home telemonitoring programme defined as being compliant to <math>\geq 80\%</math> of the alerts</li> </ul> |
| Notes         | <p><b>Funding source:</b> "ZonMw Health Care Efficiency Research [grant number 837001001], Innovation Fund Dutch Insurance Companies [grant number B12-204-2509], and NutsOhra Fund [grant number 1301-002]. RKW is supported by the Netherlands Organization for Scientific Research [NWO] [grant number 016.136.308]. Reagents for the Quantum Blue® calprotectin point-of-care tests were an unre-</p>  |

## Heida 2018 (Continued)

stricted donation by Bühlmann Laboratories AG. An unrestricted start-up grant for the development of the web-based programme IBD-live was awarded by Ferring Pharmaceuticals BV. Neither funding company had a role in the design of this study, nor in the execution, analyses, interpretation of the data or decision to submit results."

**Conflicts of interest:** "PFvR, AH and AMK received funding for joint research projects from BÜHLMANN Laboratories and CisBio Bioassays. All other authors had no support from any organization."

### Risk of bias

| Bias   | Authors' judgement | Support for judgement  |
|--|--------------------|--|
| Random sequence generation (selection bias)                              | Low risk           | Quote: "Computer generated random sequence 1:1 ratio stratified by research site and disease type [...]"   |
| Allocation concealment (selection bias)                                  | Low risk           | Allocation concealment was ensured, as the study website did not release the randomisation code until the participant had been recruited into the trial.         |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk          | Quote: "The nature of the intervention did not allow blinding of participants, care providers or outcome assessors."   |
| Blinding of outcome assessment (detection bias)<br>Study level           | High risk          | Quote: "The nature of the intervention did not allow blinding of participants, care providers or outcome assessors."   |
| Incomplete outcome data (attrition bias)<br>Study level                  | Unclear risk       | Imbalance in the participants reaching the end of the study; high number of non- or insufficient compliance in IG (36/84). Reason for non-compliance not stated. |
| Selective reporting (reporting bias)                                     | Low risk           | Appropriate selection of outcomes that matches the trial registration.   |
| Other bias   | Low risk           | Overrepresentation of males in IG compared with CG, but other characteristics were balanced and no other concerns.   |

## Hughes 2017

### Study characteristics

|              |   |
|--------------|---|
| Methods      | <b>Study design:</b> prospective RCT<br><b>Study duration:</b> not reported<br><b>Setting:</b> Hospital clinics (Guy's and St Thomas') and online through the Crohn's and Colitis UK website  |
| Participants | <b>State of disease at beginning of study:</b> not reported<br><b>Disease type:</b> unclear<br><b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• IBD diagnosis</li> <li>• Age &gt; 18 years</li> <li>• Ability to read and understand English fluently</li> <li>• Informed consent</li> </ul> |

## Hughes 2017 (Continued)

### Exclusion criteria:

- Suicidal ideations

### Age at beginning of study:

- IG: mean 38 years (SD 11.9)
- CG: mean 43 years (SD 13.7)

### Sex:

- IG: 13 men, 19 women
- CG: 10 men, 21 women

### Number randomised:

- IG: 32
- CG: 31

**Number reaching end of study:** 54 (85%) in total (per group unclear)

|               |  |
|---------------|--|
| Interventions | <p><b>IG:</b> Quality Of Life Tool for IBD (QOLITI): cognitive-behavioural therapy-inspired manual providing information, guidance for setting goals for behaviour change, and accompanying tasks to aid implementation. to be completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals. Participants also receive 30-minute telephone support sessions with a healthcare professional, at 2, 4 and 6 weeks after randomisation.</p> <p><b>CG:</b> waitlist: after study completion, the control group receive the same manual, but without telephone support sessions.</p>   |
| Outcomes      | <p><b>Duration of follow-up:</b> 8 weeks</p> <p><b>Primary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Acceptability <ul style="list-style-type: none"> <li>◦ Change in numbers of participants throughout the trial</li> </ul> </li> <li>• Feasibility</li> <li>• Effectiveness <ul style="list-style-type: none"> <li>◦ Change in depression</li> <li>◦ Change in anxiety</li> <li>◦ Change in generic QoL</li> <li>◦ Change in IBD-specific QoL</li> </ul> </li> </ul> <p><b>Secondary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Retrospective appraisal of the intervention (i.e. content and layout) through semi-structured qualitative interviews</li> <li>• Change in fatigue</li> <li>• Change in illness perception</li> <li>• Change in disease activity</li> </ul> |
| Notes         | <p><b>Funding source:</b> not reported</p> <p><b>Conflicts of interest:</b> none</p> <p><b>Contact with study authors:</b> we sent an email on 20 January 2021 but received no response.</p>   |

### Risk of bias

| Bias | Authors' judgement | Support for judgement |
|------|--------------------|-----------------------|
|------|--------------------|-----------------------|

### Remote care through telehealth for people with inflammatory bowel disease (Review)

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.



## Hughes 2017 (Continued)

|  |              |  |
|--|--------------|--|
| Random sequence generation (selection bias)                              | Unclear risk | Insufficient information to make a decision.   |
| Allocation concealment (selection bias)                                  | Unclear risk | Insufficient information to make a decision.   |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk    | Type of study that cannot be blinded.  |
| Blinding of outcome assessment (detection bias)<br>Study level           | Unclear risk | Single-blind design (outcomes assessor) according to trial registration, but this is inconsistent with the methods reported. We wrote to the study authors for clarification but received no response. |
| Incomplete outcome data (attrition bias)<br>Study level                  | Unclear risk | Insufficient information on withdrawals offered to judge and no response from study authors.   |
| Selective reporting (reporting bias)                                     | Unclear risk | Not all outcomes reported as per the trial registration.   |
| Other bias   | Low risk     | No differences in baseline characteristics and no other concerns.  |

## Ley 2020

### Study characteristics

|              |   |
|--------------|---|
| Methods      | <b>Study design:</b> prospective RCT<br><br><b>Study duration:</b> not reported<br><br><b>Setting:</b> not reported   |
| Participants | <b>State of disease at beginning of study:</b> all in remission<br><br><b>Disease type:</b> UC<br><br><b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Age 18–65 years</li> <li>• UC diagnosis</li> <li>• Clinical remission</li> <li>• Stable dose of 5-ASA monotherapy for ≥ 2 months before study entry</li> </ul> <b>Exclusion criteria:</b> not reported<br><br><b>Age at beginning of study:</b> <ul style="list-style-type: none"> <li>• IG: mean 38 years</li> <li>• CG: mean 34.3 years</li> </ul> <b>Sex: m/f IG: 14/7 CG: 11/7</b> <ul style="list-style-type: none"> <li>• IG: 14 men, 7 women</li> <li>• CG: 11 men, 7 women</li> </ul> <b>Number randomised:</b> |

### Remote care through telehealth for people with inflammatory bowel disease (Review)

## Ley 2020 (Continued)

- IG: 21
- CG: 18

**Number reaching end of study:** not reported

|               |  |
|---------------|--|
| Interventions | <p><b>IG:</b> iPhone adherence application that included medication reminders</p> <p><b>CG:</b> sham application that included educational materials and the capability of recording medication intake, without medication reminders</p>   |
| Outcomes      | <p><b>Duration of follow-up:</b> not reported</p> <p><b>Primary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Medication adherence</li> <li>• BMQ as a method of adherence prediction</li> </ul> <p><b>Secondary outcomes as defined by study authors:</b> not reported</p> |
| Notes         | <p><b>Funding source:</b> "research support from Takeda Pharmaceuticals"</p> <p><b>Conflicts of interest:</b> not reported</p> <p><b>Contact with study authors:</b> we sent an email on 17 October 2021 but received no response.</p>   |

### Risk of bias

| Bias   | Authors' judgement | Support for judgement                                       |
|--|--------------------|---|
| Random sequence generation (selection bias)                              | Unclear risk       | Insufficient detail to make a decision.                     |
| Allocation concealment (selection bias)                                  | Unclear risk       | Insufficient detail to make a decision.                     |
| Blinding of participants and personnel (performance bias)<br>Study level | Low risk           | Double-blind RCT.   |
| Blinding of outcome assessment (detection bias)<br>Study level           | Unclear risk       | Insufficient detail to make a decision.                     |
| Incomplete outcome data (attrition bias)<br>Study level                  | Unclear risk       | Insufficient detail to make a decision.                     |
| Selective reporting (reporting bias)                                     | Unclear risk       | Insufficient detail to make a decision.                     |
| Other bias   | Low risk           | No baseline imbalance apparent and no other concerns noted. |

## Malickova 2020

### Study characteristics

|         |                          |
|---------|--------------------------|
| Methods | <b>Study design:</b> RCT |
|---------|--------------------------|

### Remote care through telehealth for people with inflammatory bowel disease (Review)

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

**Malickova 2020** (Continued)

**Study duration:** June 2018–August 2019

**Setting:** Prague hospital, Czechia

|               |   |
|---------------|---|
| Participants  | <p><b>State of disease at beginning of study:</b> all in remission</p> <p><b>Disease type:</b></p> <ul style="list-style-type: none"> <li>IG: CD (n = 44), UC (n = 46)</li> <li>CG: CD (n = 19), UC (n = 18)</li> </ul> <p><b>Inclusion criteria:</b></p> <ul style="list-style-type: none"> <li>Age &gt; 18 years</li> <li>CD or UC diagnosis</li> <li>In remission (controlled by endoscopic examination implemented during the last 12 months before the start of the study)</li> <li>Computer literacy</li> <li>Regular access to PC, tablet, or smartphone</li> <li>Working email address</li> <li>Informed consent</li> </ul> <p><b>Exclusion criteria:</b> Not reported</p> <p><b>Age at beginning of study:</b></p> <ul style="list-style-type: none"> <li>IG: median 43 years (IQR 28–56)</li> <li>CG: median 42 years (IQR 23–60)</li> </ul> <p><b>Sex:</b></p> <ul style="list-style-type: none"> <li>IG: 44 men, 46 women</li> <li>CG: 15 men, 22 women</li> </ul> <p><b>Number randomised:</b></p> <ul style="list-style-type: none"> <li>IG: 94</li> <li>CG: 37</li> </ul> <p><b>Number reaching end of study:</b></p> <ul style="list-style-type: none"> <li>IG: 90</li> <li>CG: 37</li> </ul> |
| Interventions | <p><b>IG:</b> participants were telemonitored and connected with their doctors and IBD nurses through the IBD Assistant application, available online. They received email reminders at regular intervals to fill in standard electronic assessments. An emergency questionnaire, for use in case of deterioration, advised participants to contact a doctor. Participants contacted the doctor primarily through the IBD Assistant web application; in-person visits were scheduled only after a recommendation via the IBD Assistant application. FC was measured at least 4 times/12 months with at-home CalpoSmart system.</p> <p><b>CG:</b> participants attended usual checkups every 3 months in outpatient clinics with their gastroenterologists (clinical examination and laboratory testing). Participants could have an unscheduled acute consultation in case of any difficulties, or an at-home doctor's visit in the event of unfavourable examination results.</p>  |
| Outcomes      | <p><b>Duration of follow-up:</b> 12 months</p> <p><b>Primary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>Outpatient visits</li> <li>Disease activity</li> </ul>  |

**Remote care through telehealth for people with inflammatory bowel disease (Review)**

## Malickova 2020 (Continued)

- Inflammation markers
- Intercurrent infections
- Hospitalisations
- Costs

**Secondary outcomes as defined by study authors:** not reported

### Notes

**Funding source:** "The study was supported by the IBD-Comfort Foundation Fund and the Prevention Fund of the General Health Insurance Company of the Czech Republic."

**Conflicts of interest:** Study authors declared no conflict of interest.

**Contact with study authors:** we sent an email on 27 October 2021 for further clarification regarding risk of bias, and we received a response on 1 November 2021.

### Risk of bias

| Bias   | Authors' judgement | Support for judgement  |
|--|--------------------|--|
| Random sequence generation (selection bias)                              | Low risk           | Quote (personal correspondence): "Assignment to a telemedicine or control group was performed by a simple random allocation using a table of random numbers."  |
| Allocation concealment (selection bias)                                  | Unclear risk       | Insufficient detail to make a decision.  |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk          | Type of study that cannot be blinded.  |
| Blinding of outcome assessment (detection bias)<br>Study level           | Low risk           | Quote (personal correspondence): "the evaluation of the objectives pursued was carried out without knowing which of the groups the entity belongs to."   |
| Incomplete outcome data (attrition bias)<br>Study level                  | Low risk           | Low attrition, explained and balanced between groups.  |
| Selective reporting (reporting bias)                                     | Unclear risk       | Outcomes reported as per the last paragraph of the introduction, but no trial registration and variances are missing.  |
| Other bias   | Unclear risk       | Huge difference in numbers randomised (IG 90/CG 37) not explained in paper, but a study author provided clarification.<br><br>Quote (personal correspondence): "Initially, a 3:1 split was considered, ie 90 subjects in the telemedicine and 30 subjects in the control branch. The final 90/37 ratio was due to a change in the randomization design." |

## McCombie 2020

### Study characteristics

#### Methods

**Study design:** prospective RCT

**Study duration:** August 2015–December 2016

## Remote care through telehealth for people with inflammatory bowel disease (Review)

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

**McCombie 2020** (Continued)

**Setting:** Southern, Canterbury, Waitemata, and Hutt Valley District Health Boards across New Zealand

**Participants**
**State of disease at beginning of study:**

IG: SCCAI mean 1.6 (SD 2.5); HBI mean 2.7 (SD 3.00)\*

CG: SCCAI mean 1.1 (SD 1.5); HBI mean 2.7 (SD 3.0)\*

\*SCCAI  $\leq 2$ : remission, SCCAI  $\leq 3$ : relapse (for UC); HBI  $\leq 4$ : remission, HBI  $> 4$ : relapse (for CD)

**Disease type:**

- IG: CD (n = 37), UC (n = 13)
- CG: CD (n = 36), UC (n = 14)

**Inclusion criteria:**

- Age  $\geq 16$  years
- Confirmed UC or CD
- $\geq 2$  outpatient appointments in the last 12 months
- $< 3$  disease flares in the past 12 months

**Exclusion criteria:**

- Indeterminate colitis
- Severe disease with close monitoring
- Possible surgical intervention
- Previous surgery
- Pregnancy
- Ileostomy, colostomy, or ileal pouch–anal anastomosis
- Inability or unwillingness to provide written consent

**Age at beginning of study:**

- IG: mean 35.2 years (SD 12.4)
- CG: mean 34.3 years (SD 12.9)

**Sex:**

- IG: 26 men, 24 women
- CG: 23 men, 27 women

**Number randomised:**

- IG: 53
- CG: 54

**Number reaching end of study:**

- IG: 47
- CG: 49

**Interventions**

**IG:** IBDsmart and IBDoc apps. IBDsmart allowed participants to complete symptom scores and send them to their doctor. Participants could log in and fill out a questionnaire (CDAI or SCCAI), which produced a score indicating disease severity. In this way, the app tracked long-term trends of symptom scores, and the healthcare team were contacted immediately in case of high disease severity. IBDoc allowed participants to measure their FC levels by testing stool samples with a medical device, and sending the results to their doctor via an app built into IBDoc called CalApp.

**CG:** usual outpatient treatment

**Outcomes**

**Duration of follow-up:** 12 months

**Remote care through telehealth for people with inflammatory bowel disease (Review)**

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

## McCombie 2020 (Continued)

### Primary outcomes as defined by study authors:

- Noninferiority of IBDsmart and IBDoc to standard care

### Secondary outcomes as defined by study authors:

- Health-related QoL at 3, 6, and 9 months
- Participant-reported usability/acceptability
- Doctor-reported usability/acceptability
- Adherence
- FC

#### Notes

**Funding source:** "The Healthcare Otago Charitable Trust (no grant number) and The New Zealand Society of Gastroenterology Janssen Research Fellowship (no grant number) in 2015 and the gut health network, a research theme located at the Department of Medicine, University of Otago."

**Conflicts of interest:** none

**Contact with study authors:** we sent an email on 17 October 2021 and the study authors provided additional information.

### Risk of bias

| Bias   | Authors' judgement | Support for judgement   |
|--|--------------------|---|
| Random sequence generation (selection bias)                              | Low risk           | Quote: "Randomization occurred by a computer program randomly allocating participants to 1 of the 2 groups. Randomization was stratified by disease type (CD vs UC) and location of outpatient appointments (Waitemata, Hutt Valley, Canterbury, and Southern District Health Boards)." |
| Allocation concealment (selection bias)                                  | Low risk           | Quote: "The allocations were put in sequenced envelopes, which were to be opened by the recruiting nurse, gastroenterologist, or researcher."   |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk          | Quote: "Participants were not blinded to which group they were in."   |
| Blinding of outcome assessment (detection bias)<br>Study level           | High risk          | Masking not used.   |
| Incomplete outcome data (attrition bias)<br>Study level                  | Low risk           | Low and balanced attrition: only 4 dropouts and there was no reason recorded except that participants had asked to withdraw.  |
| Selective reporting (reporting bias)                                     | Low risk           | No major difference from the trial registration.  |
| Other bias   | Low risk           | Some baseline data missing for participants who dropped out without completing baseline assessment, but no important differences.   |

## Reich 2019

### Study characteristics

#### Methods

**Study design:** prospective RCT

### Remote care through telehealth for people with inflammatory bowel disease (Review)

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

**Reich 2019** (Continued)

**Study duration:** November 2017–March 2018

**Setting:** Boston Medical Center, Boston, MA, USA

## Participants

**State of disease at beginning of study:**

IG: HBI (for CD): mean 4.6 (SD 3.8); SCCAI (for UC): mean 4.3 (SD 3.0)

CG: HBI (for CD): mean 4.6 (SD 4.1); SCCAI (for UC): mean 4.3 (SD 2.8)

**Disease type:**

IG: CD (n = 36), UC (n = 28)

CG: CD (n = 36), UC (n = 27)

**Inclusion criteria:**

- Age ≥ 18 years
- Both sexes
- IBD diagnosis (CD, UC, or indeterminate colitis) by standard criteria
- Scheduled appointment at outpatient gastroenterology clinic or infusion unit

**Exclusion criteria:**

- Inability to communicate in English
- Cognitive impairment that would impair participation
- Lack of access to computer with internet
- Expected move from study area during the study

**Age at beginning of study:**

- IG: mean 41 years (SD 15.7)
- CG: mean 42 years (SD 16.4)

**Sex:**

- IG: 35 men, 28 women (1 person missing)
- CG: 42 men, 21 women

**Number randomised:**

- IG: 64
- CG: 63

**Number reaching end of study:**

- IG: 46
- CG: 29

## Interventions

**IG:** MyChart: a patient portal that allowed participants to see various parts of their medical record, and send and receive secure messages with their provider. Participants received educational information about IBD every 2 weeks along with reminders to take their medications and get vaccinated for influenza and pneumococcal pneumonia at 2 weeks and 3 months after enrolment.

**CG:** participants were sent generic messages through MyChart that were not related to IBD (e.g. "Did you know that you could send your provider a message through MyChart if you need to refill a medication? Please contact your provider if you need your medications refilled.")

## Outcomes

**Duration of follow-up:** 6 months

**Primary outcomes as defined by study authors:**



## Reich 2019 (Continued)

- QoL (SIBDQ)

### Secondary outcomes as defined by study authors:

- MyChart portal satisfaction
- Vaccine uptake for influenza and pneumonia

|       |   |
|-------|---|
| Notes | <p><b>Funding source:</b> "Supported by a generous gift from Aimee &amp; Kleanthis Dendrinis and Robin &amp; Andrew Davis."</p> <p><b>Conflicts of interest:</b> none</p> <p><b>Contact with study authors:</b> we sent an email on 21 January 2021 but received no response.</p> |
|-------|---|

### Risk of bias

| Bias   | Authors' judgement | Support for judgement   |
|--|--------------------|---|
| Random sequence generation (selection bias)                              | Unclear risk       | <p>Quote: "After baseline data were collected, subjects were randomized in a 1:1 ratio of experimental to control arm stratified by MyChart naïve/active status using a block size of two."</p> <p>Comments: randomisation method not provided; no response to our email sent on 21 January 2021.</p> |
| Allocation concealment (selection bias)                                  | Unclear risk       | Insufficient information to make a decision.  |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk          | Due to the nature of a study, it is not possible to blind.  |
| Blinding of outcome assessment (detection bias)<br>Study level           | Unclear risk       | Insufficient information to make a decision; no response to our email sent on 21 January 2021.  |
| Incomplete outcome data (attrition bias)<br>Study level                  | Unclear risk       | Higher attrition in the control group and imbalance was 28% attrition vs 56% – reason for all dropouts is "lost to follow up" with no further details. No response to our email sent on 21 January 2021.  |
| Selective reporting (reporting bias)                                     | Low risk           | Time to referral for behavioural health not reported, but no other missing outcomes as prespecified in trial registration.  |
| Other bias   | Low risk           | No concerns with baseline characteristics between groups.   |

## Siegel 2018

### Study characteristics

|              |   |
|--------------|---|
| Methods      | <p><b>Study design:</b> cluster-RCT</p> <p><b>Study duration:</b> 3 years</p> <p><b>Setting:</b> 16 gastroenterology practices across the USA (8 academic, 8 community-based)</p> |
| Participants | <b>State of disease at beginning of study:</b> not reported   |

### Remote care through telehealth for people with inflammatory bowel disease (Review)

**Siegel 2018** (Continued)

**Disease type:** CD

**Inclusion criteria:**

- Age > 18
- CD diagnosis within past 15 years of diagnosis
- No current or prior disease complications
- Not on immunomodulators or biologics but considered a candidate for these treatments

**Exclusion criteria:** not reported

**Age at beginning of study:**

- IG: median 32 years (range 18–69)
- CG: median 31 years (range 18–69)

**Sex:**

- IG: 64 men, 69 women
- CG: 24 men, 45 women

**Number randomised:**

- IG: 133
- CG: 69

**Number reaching end of study:** not reported

|               |  |
|---------------|--|
| Interventions | <b>IG:</b> a decision aid including an online programme reviewing benefits and risks of treatment options combined with a personalised risk prediction tool (PROSPECT) for Crohn's disease<br><br><b>CG:</b> standard of care  |
| Outcomes      | <b>Duration of follow-up:</b> 3 years<br><br><b>Primary outcomes as defined by study authors:</b> <ul style="list-style-type: none"> <li>• Choice of combination therapy</li> </ul> <b>Secondary outcomes as defined by study authors:</b> <ul style="list-style-type: none"> <li>• Decision conflict</li> <li>• Understanding of the disease</li> </ul> |
| Notes         | <b>Funding source:</b> not reported<br><br><b>Conflicts of interest:</b> not reported<br><br><b>Contact with study authors:</b> we sent an email on 21 January 2021 but received no response.  |

**Risk of bias**

| Bias  | Authors' judgement | Support for judgement                        |
|---|--------------------|--|
| Random sequence generation (selection bias) | Unclear risk       | Insufficient information to make a decision. |
| Allocation concealment (selection bias)     | Unclear risk       | Insufficient information to make a decision. |

## Siegel 2018 (Continued)

|  |              |   |
|--|--------------|---|
| Blinding of participants and personnel (performance bias)<br>Study level | Unclear risk | Insufficient information to make a decision.  |
| Blinding of outcome assessment (detection bias)<br>Study level           | Unclear risk | Insufficient information to make a decision.  |
| Incomplete outcome data (attrition bias)<br>Study level                  | Unclear risk | Insufficient information to make a decision.  |
| Selective reporting (reporting bias)                                     | Unclear risk | Insufficient information to make a decision.  |
| Other bias   | Low risk     | Demographics were similar between groups, with more women in the control group and slightly shorter disease duration in the intervention group. |

## Stunkel 2012

### Study characteristics

|               |  |
|---------------|--|
| Methods       | <b>Study design:</b> prospective RCT<br><b>Study duration:</b> 38 weeks<br><b>Setting:</b> remote, conducted in USA  |
| Participants  | <b>State of disease at beginning of study:</b> mild to moderate<br><b>Disease type:</b> not reported<br><b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• IBD diagnosis</li> <li>• Access to a smart device (iPhone/iPad/iPod touch or Android).</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• Blackberry smartphones (app not fully optimised for this device)</li> </ul> <b>Age at beginning of study:</b> 20–84 years<br><b>Sex:</b> 44 men, 46 women<br><b>Number randomised:</b> 90<br><b>Number reaching end of study:</b> not reported |
| Interventions | <b>IG:</b> daily use of app (WellApps, New York, NY) to record symptoms, track pain, stress levels, frequency, and quality of bowel movements<br><b>CG:</b> education about websites such as www.ccfa.org for information on IBD   |
| Outcomes      | <b>Duration of follow-up:</b> 38 weeks<br><b>Primary outcomes as defined by study authors:</b>   |

### Remote care through telehealth for people with inflammatory bowel disease (Review)

**Stunkel 2012** (Continued)

- Background information
- Change in QoL
- Time to follow-up
- Participant satisfaction

**Secondary outcomes as defined by study authors:** not reported

**Notes**

**Funding source:** not reported

**Conflicts of interest:** not reported

**Contact with study authors:** we sent an email on 17 October 2021 but received no response.

**Risk of bias**

| Bias   | Authors' judgement | Support for judgement                        |
|--|--------------------|--|
| Random sequence generation (selection bias)                              | Unclear risk       | Insufficient information to make a decision. |
| Allocation concealment (selection bias)                                  | Unclear risk       | Insufficient information to make a decision. |
| Blinding of participants and personnel (performance bias)<br>Study level | Unclear risk       | Insufficient information to make a decision. |
| Blinding of outcome assessment (detection bias)<br>Study level           | Unclear risk       | Insufficient information to make a decision. |
| Incomplete outcome data (attrition bias)<br>Study level                  | Unclear risk       | Insufficient information to make a decision. |
| Selective reporting (reporting bias)                                     | Unclear risk       | Insufficient information to make a decision. |
| Other bias   | Unclear risk       | Insufficient information to make a decision. |

**Wang 2020**
**Study characteristics**

|              |  |
|--------------|--|
| Methods      | <p><b>Study design:</b> not reported</p> <p><b>Study duration:</b> May 2016–April 2018</p> <p><b>Setting:</b> remote (through General Hospital of the Eastern Theater, China)</p>  |
| Participants | <p><b>State of disease at beginning of study:</b> postoperative CD</p> <ul style="list-style-type: none"> <li>• IG: 33 people with active disease</li> <li>• CG: 39 people with active disease</li> </ul> <p><b>Disease type:</b> CD</p> |

## Wang 2020 (Continued)

**Inclusion criteria:**

- Age 18–65 years
- CD diagnosis based on clinical, imaging, and endoscopy screening, > 6 months prior to study entry than 6 months
- CD-related surgical treatment
- No allergies or contraindications to azathioprine (given to participants for postoperative maintenance treatment)
- Ability to read and browse information
- Fluency in use of WeChat app
- Voluntary participation

**Exclusion criteria:**

- Current use of other drugs as maintenance treatment
- Cognitive impairment
- Illiteracy or other language or communication impairment
- Inability to use WeChat app
- Current participation in other research or psychological interventions

**Age at beginning of study:**

IG: mean 32.46 years (SD 10.11)

CG: mean 33.85 years (SD 11.2)

**Sex:**

- IG: 57 men, 63 women
- CG: 59 men, 60 women

**Number randomised:**

- IG: 120
- CG: 119

**Number reaching end of study:**

- IG: 101
- CG: 96

|               |   |
|---------------|---|
| Interventions | <p><b>IG:</b> WeChat platform: a drug self-management platform based on the 5 key points of self-management theory (self-cognition, goal-setting, self-monitoring, self-motivation, and self-evaluation), implemented using WeChat.</p> <p><b>CG:</b> regular health education and guidance on drugs by designated nurses during inpatient stay. Participants provided with a brochure with drug guidance upon discharge. The content of the brochure included basic knowledge of drugs, drug usage and effects, how to deal with common problems, and how to attend follow-ups in outpatient clinic. Doctors provided follow-up guidance every 2 months.</p> |
| Outcomes      | <p><b>Duration of follow-up:</b> 6 months</p> <p><b>Primary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Drug adherence (MMAS-8 score)</li> <li>• Proportion and duration of relapses</li> </ul> <p><b>Secondary outcomes as defined by study authors:</b></p> <ul style="list-style-type: none"> <li>• Azathioprine metabolites</li> <li>• FC levels</li> </ul>  |

## Wang 2020 (Continued)

Notes

**Funding source:** Nursing Project of Military Medical Science and Technology Youth Cultivation Plan, No. 19QNP077

**Conflicts of interest:** not reported

**Contact with study authors:** we did not send an email owing to the language barrier. We translated this study using an online translator.

### Risk of bias

| Bias   | Authors' judgement | Support for judgement   |
|--|--------------------|---|
| Random sequence generation (selection bias)                              | Low risk           | Computer-generated.   |
| Allocation concealment (selection bias)                                  | Low risk           | Sealed envelopes.   |
| Blinding of participants and personnel (performance bias)<br>Study level | High risk          | Open-label study.   |
| Blinding of outcome assessment (detection bias)<br>Study level           | Unclear risk       | Not mentioned.  |
| Incomplete outcome data (attrition bias)<br>Study level                  | Low risk           | Low and balanced attrition and reasons.   |
| Selective reporting (reporting bias)                                     | Unclear risk       | No trial registration. The outcomes specified in the method section are poorly reported, especially relapses. |
| Other bias   | Low risk           | No baseline imbalances between groups.  |

5-ASA: 5-aminosalicylic acid; AGA: American Gastroenterological Association; aPCDAI: abbreviated Paediatric Crohn's Disease Activity Index; BMI: body mass index; BMQ: Brief Medication Questionnaire; CCKNOW: Crohn's and Colitis Knowledge; CD: Crohn's disease; CDAI: Crohn's Disease Activity Index; CG: control group; CRP: C-reactive protein; EQ-5D: EuroQol five-dimension questionnaire; FC: faecal calprotectin; HADS: Hospital Anxiety and Depression Scale; HBI: Harvey Bradshaw Index; IBD: inflammatory bowel disease; IBDQ: Inflammatory Bowel Disease Questionnaire; IG: intervention group; IQR: interquartile range; MARS: Medication Adherence Report Scale; MMAS: Morisky Medication Adherence Scale; PCDAI: Pediatric Crohn's Disease Activity Index; PUCAI: Paediatric Ulcerative Colitis Activity Index; QoL: quality of life; RCT: randomised controlled trial; SCCAI: Simple Clinical Colitis Activity Index; SD: standard deviation; SF-12/36: Medical Outcomes Study 12/36-item Short-Form Health Survey; SIBDQ: Short Inflammatory Bowel Disease Questionnaire; TIBS: Total Inflammatory Burden Score; TNF: tumour necrosis factor; UC: ulcerative colitis; VAS: visual analogue scale.

### Characteristics of excluded studies [ordered by study ID]

| Study         | Reason for exclusion                                  |
|---------------|---|
| Ankersen 2017 | Wrong intervention.                                   |
| Camba 2013    | Wrong study design.                                   |
| Carlsen 2017b | Wrong intervention (scheduling infliximab infusions). |

### Remote care through telehealth for people with inflammatory bowel disease (Review)

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

| Study                            | Reason for exclusion  |
|----------------------------------|---|
| <a href="#">Creed 2019</a>       | Wrong study design.   |
| <a href="#">Del Hoyo 2021</a>    | Wrong study design.   |
| <a href="#">Elkjaer 2010b</a>    | Wrong intervention.   |
| <a href="#">Gray 2020</a>        | Wrong study design.   |
| <a href="#">Greenley 2015</a>    | Wrong study design (participating youth were recruited sequentially from 1 of 2 paediatric IBD centres in the Midwest region of the USA). |
| <a href="#">Jambaulikar 2015</a> | Wrong intervention.   |
| <a href="#">Krier 2011</a>       | Wrong study design (blinded administrative staff randomly scheduled clinic appointments to newly established patients).                   |
| <a href="#">Mastronardi 2020</a> | Wrong study design.   |
| <a href="#">Miloh 2017</a>       | Wrong study design (participants served as their own controls; information provided by study author).                                     |
| <a href="#">Moss 2010</a>        | Wrong study design.   |
| <a href="#">NCT00310362</a>      | Wrong population.   |
| <a href="#">NCT01852097</a>      | Wrong intervention.   |
| <a href="#">NCT02265588</a>      | Wrong intervention.   |
| <a href="#">NCT02707068</a>      | Wrong intervention.   |
| <a href="#">NCT03486158</a>      | Wrong intervention.   |
| <a href="#">NCT03695783</a>      | Wrong intervention.   |
| <a href="#">NCT04151420</a>      | Wrong study design.   |
| <a href="#">NCT04165265</a>      | Wrong study design.   |
| <a href="#">Oser 2018</a>        | Wrong intervention.   |
| <a href="#">RBR-79dn4k</a>       | Wrong intervention.   |
| <a href="#">Snoei 2009</a>       | Wrong study design.   |
| <a href="#">Sutton 2019</a>      | Wrong intervention.   |
| <a href="#">Tripp 2017</a>       | Wrong intervention.   |
| <a href="#">Zhang 2020</a>       | Wrong intervention.   |

IBD: inflammatory bowel disease.



## Characteristics of studies awaiting classification *[ordered by study ID]*

### Bonnaud 2021

|               |   |
|---------------|---|
| Methods       | RCT   |
| Participants  | 54  |
| Interventions | IG: EasyMICI–MaMICI telemedicine platform<br>CG: standard care  |
| Outcomes      | Primary outcomes: <ul style="list-style-type: none"> <li>Efficacy of the software platform, as measured by QoL and quality of care.</li> </ul> Secondary outcomes: <ul style="list-style-type: none"> <li>Changes in the use of healthcare resources</li> <li>Patient satisfaction in the MaMICI group</li> </ul> |
| Notes         | We identified this study during our update search, and we will include it in the next update of this review.  |

### Hommel 2015

|               |   |
|---------------|---|
| Methods       | RCT   |
| Participants  | 140   |
| Interventions | IG: Telehealth Behavioral Treatment<br>CG: education  |
| Outcomes      | Primary outcomes: <ul style="list-style-type: none"> <li>Medication adherence</li> </ul> Secondary outcomes: <ul style="list-style-type: none"> <li>Health-related QoL</li> <li>Disease severity</li> <li>Healthcare utilisation</li> </ul> |
| Notes         | We contacted the study authors on 21 January 2021 but received no response.   |

### NCT02085083

|               |  |
|---------------|--|
| Methods       | RCT  |
| Participants  | 150  |
| Interventions | IG: regular telephone and email access to an IBD nurse<br>CG: minimal Intervention |

## Remote care through telehealth for people with inflammatory bowel disease (Review)

### NCT02085083 (Continued)

|          |   |
|----------|---|
| Outcomes | <p>Primary outcomes:</p> <ul style="list-style-type: none"> <li>• Patient satisfaction</li> <li>• Medication adherence</li> <li>• Healthcare utilisation</li> <li>• Transition readiness</li> </ul> <p>Secondary outcomes:</p> <ul style="list-style-type: none"> <li>• QoL</li> <li>• Disease activity</li> <li>• Disease knowledge</li> </ul> |
| Notes    | We contacted the study authors on 21 January 2021 but received no response.   |

### NCT02694042

|               |  |
|---------------|--|
| Methods       | RCT  |
| Participants  | 39   |
| Interventions | <p>IG: Mission is Remission Group</p> <p>CG: no intervention</p>   |
| Outcomes      | <p>Primary outcomes:</p> <ul style="list-style-type: none"> <li>• Self-efficacy</li> <li>• Health-related QoL</li> </ul> <p>Secondary outcomes:</p> <ul style="list-style-type: none"> <li>• Medication taking behaviour</li> <li>• Disease activity</li> <li>• Disease knowledge</li> <li>• Physical and social activity participation</li> <li>• Transition readiness</li> </ul> |
| Notes         | We contacted the study authors on 21 January 2021 but received no response.  |

### NCT03059186

|               |   |
|---------------|---|
| Methods       | RCT   |
| Participants  | 129   |
| Interventions | <p>IG: online daily gratitude journal</p> <p>CG: no intervention</p>  |
| Outcomes      | <p>Primary outcomes:</p> <ul style="list-style-type: none"> <li>• Depression and anxiety</li> <li>• Disease activity</li> </ul> |

### Remote care through telehealth for people with inflammatory bowel disease (Review)

## NCT03059186 (Continued)

Secondary outcomes:

- Self-efficacy
- Gratitude
- Emotion regulation

|       |  |
|-------|--|
| Notes | We contacted the study authors on 21 January 2021; they told us the study was not yet published. |
|-------|--|

## NCT03186872

|               |  |
|---------------|--|
| Methods       | RCT  |
| Participants  | 90   |
| Interventions | IG: digital behavioural programme app<br>CG: no intervention   |
| Outcomes      | Primary outcomes:<br><ul style="list-style-type: none"> <li>• Anxiety</li> </ul> Secondary outcomes:<br><ul style="list-style-type: none"> <li>• Depression</li> </ul> |
| Notes         | We contacted the study authors on 21 January 2021 but received no response.  |

## NCT04754620

|               |  |
|---------------|--|
| Methods       | RCT  |
| Participants  | 139  |
| Interventions | IG: online visit by a smartphone application<br>CG: standard face-to-face visit  |
| Outcomes      | Primary outcomes:<br><ul style="list-style-type: none"> <li>• Satisfaction score with the video visits</li> </ul> Secondary outcomes: not reported |
| Notes         | We will include this study in an update of this review.  |

## NTR2892

|               |                              |
|---------------|------------------------------|
| Methods       | RCT                          |
| Participants  | 211                          |
| Interventions | IG: nurse-based intervention |

## Remote care through telehealth for people with inflammatory bowel disease (Review)

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

**NTR2892** (Continued)

CG: patient-centred (eHealth) intervention

|          |   |
|----------|---|
| Outcomes | Primary outcomes: <ul style="list-style-type: none"> <li>Information recall</li> <li>Medication adherence</li> </ul> Secondary outcomes: <ul style="list-style-type: none"> <li>Nurse-patient communication</li> <li>Current levels of generalised anxiety</li> <li>Psychological distress</li> </ul> |
| Notes    | We contacted the study authors on 21 January 2021 but received no response.   |

**NTR4648**

|               |   |
|---------------|---|
| Methods       | RCT   |
| Participants  | 220   |
| Interventions | 1: Once daily versus twice daily use of 5-ASA medication (Mezavant)<br>2: Interactive apps in UC patients on 5-ASA medication (Mezavant) on adherence   |
| Outcomes      | Primary outcome: <ul style="list-style-type: none"> <li>Compliance with 5-ASA medication (Mezavant) objectively measured by presence of 5-ASA metabolites in urine at 6 months</li> </ul> Secondary outcomes: <ul style="list-style-type: none"> <li>Adherence at 12 and 18 months</li> <li>Adherence by questionnaire</li> <li>Clinical as well as endoscopic and histological remission</li> <li>Safety</li> <li>QoL</li> <li>Costs and cost-effectiveness</li> </ul> |
| Notes         | We contacted the study authors on 21 January 2021 but received no response.   |

5-ASA: 5-aminosalicylic acid; CG: control group; IBD: inflammatory bowel disease; IG: intervention group; QoL: quality of life; RCT: randomised controlled trial.

**Characteristics of ongoing studies** [ordered by study ID]

**ACTRN12617000389303**

|               |  |
|---------------|--|
| Study name    | Establishing the role of teleconsulting in the care of chronic conditions in rural areas of the Southern District Health Board (SDHB): a randomised controlled trial (RCT) in patients with inflammatory bowel disease |
| Methods       | RCT  |
| Participants  | Target 75  |
| Interventions | IG: teleconsulting + IBDsmart  |

**Remote care through telehealth for people with inflammatory bowel disease (Review)**

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

**ACTRN12617000389303** (Continued)

CG: standard medical care

|                     |   |
|---------------------|---|
| Outcomes            | Primary outcomes: <ul style="list-style-type: none"> <li>Disease control measured by clinical disease activity indices</li> </ul> Secondary outcomes: <ul style="list-style-type: none"> <li>Cost effectiveness</li> <li>Acceptability</li> </ul> |
| Starting date       | 1 April 2017  |
| Contact information | Christine.Ho@otago.ac.nz<br><a href="mailto:Michael.Schultz@otago.ac.nz">Michael.Schultz@otago.ac.nz</a>  |
| Notes               | We contacted the study authors on 20 January 2020. They told us the trial was ongoing with last patient out in April 2021 and that analysis and results could be expected afterwards.   |

**IRCT2020061304775**

|                     |   |
|---------------------|---|
| Study name          | Evaluation of the effectiveness of mobile-based inflammatory bowel disease management system by using gamification techniques on disease activity index, mental health and quality of life  |
| Methods             | RCT   |
| Participants        | 210   |
| Interventions       | IG: education and disease management via mobile phone<br>CG: standard care and routine outpatient clinics based on guidelines   |
| Outcomes            | Primary outcomes: <ul style="list-style-type: none"> <li>QoL index</li> <li>Disease activity index</li> <li>Hospital Anxiety and Depression</li> </ul> Secondary <ul style="list-style-type: none"> <li>Self-efficacy scale</li> <li>Non-adherence</li> </ul> |
| Starting date       | 22 November 2022  |
| Contact information | <a href="mailto:narges.norouzkhani@yahoo.com">narges.norouzkhani@yahoo.com</a>  |
| Notes               | We identified this study during the update search   |

**NCT03985800**

|            |  |
|------------|--|
| Study name | Specialty medical homes to improve outcomes for patients with IBD and behavioral health conditions |
|------------|--|

**Remote care through telehealth for people with inflammatory bowel disease (Review)**

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration.

**NCT03985800** (Continued)

|                     |  |
|---------------------|--|
| Methods             | RCT  |
| Participants        | Estimated 990  |
| Interventions       | IG: TEAM-care as usual approach<br>CG: TECH-telehealth approach  |
| Outcomes            | Primary outcomes: <ul style="list-style-type: none"> <li>• Disease severity</li> <li>• Symptom severity</li> </ul> Secondary outcomes: <ul style="list-style-type: none"> <li>• Functional impairment</li> <li>• Healthcare utilization</li> <li>• Self-efficacy</li> <li>• QoL</li> </ul> |
| Starting date       | 1 July 2019  |
| Contact information | <a href="mailto:meyersj5@upmc.edu">meyersj5@upmc.edu</a>   |
| Notes               |  |

**NCT04207008**

|                     |  |
|---------------------|--|
| Study name          | Trial of a decision support intervention for adolescents and young adults with ulcerative colitis (iB-Decide)  |
| Methods             | RCT  |
| Participants        | 42   |
| Interventions       | IG: iBDecide Decision Support Application<br>CG: no intervention   |
| Outcomes            | Primary outcomes: <ul style="list-style-type: none"> <li>• Feasibility</li> <li>• Acceptability</li> </ul> Secondary outcomes: <ul style="list-style-type: none"> <li>• Decisional conflict</li> <li>• Perceived shared decision making</li> <li>• Decision preference congruence</li> </ul> |
| Starting date       | 7 February 2020  |
| Contact information | Ellen Lipstein, MD, MPH  |
| Notes               |  |

**Remote care through telehealth for people with inflammatory bowel disease (Review)**

## NCT04388865

|                     |   |
|---------------------|---|
| Study name          | Patient Automated Text Hovering for IBD (PATH-IBD)  |
| Methods             | RCT   |
| Participants        | Estimated 150   |
| Interventions       | IG: clinical hovering<br>CG: no intervention  |
| Outcomes            | Primary outcomes: <ul style="list-style-type: none"> <li>• SIBDQ response</li> </ul> Secondary outcomes: <ul style="list-style-type: none"> <li>• Patient satisfaction</li> <li>• Medication adherence</li> </ul> |
| Starting date       | 23 February 2021  |
| Contact information | Caitlin McDonald, <a href="mailto:MPH215-615-1571cmcdona@pennmedicine.upenn.edu">MPH215-615-1571cmcdona@pennmedicine.upenn.edu</a><br>Cathy Reitz, MPH215-614-0282catherine.reitz@pennmedicine.upenn.edu          |
| Notes               |   |

## NCT04653259

|               |   |
|---------------|---|
| Study name    | Digital nutrition therapy for patients with IBD (LYFEMD)  |
| Methods       | RCT   |
| Participants  | 44  |
| Interventions | IG: LYFE MD app<br>CG: conventional management  |
| Outcomes      | Primary outcomes: <ul style="list-style-type: none"> <li>• QoL</li> <li>• Stress level</li> <li>• Sleep quality</li> <li>• Weekly physical activity minutes from both moderate and vigorous leisure-time activity</li> <li>• Well-being and positive aspect</li> <li>• Anxiety severity</li> <li>• Depression</li> <li>• Behaviour compliance</li> </ul> Secondary outcomes: <ul style="list-style-type: none"> <li>• Diet quality</li> <li>• FC</li> </ul> |



**NCT04653259** (Continued)

- Disease activity (HBI and partial Mayo score)

|                     |   |
|---------------------|---|
| Starting date       | 15 May 2021   |
| Contact information | <a href="mailto:mkothand@ucalgary.ca">mkothand@ucalgary.ca</a> ; <a href="mailto:lorian.taylor@ucalgary.ca">lorian.taylor@ucalgary.ca</a> |
| Notes               | We identified this study during the update search.  |

**NCT04861597**

|                     |  |
|---------------------|--|
| Study name          | Digital behavioral interventions in inflammatory bowel disease   |
| Methods             | RCT  |
| Participants        | 50   |
| Interventions       | IG: internet-based cognitive behavioral therapy (iCBT)<br>CG: digital mood tracking  |
| Outcomes            | Primary outcomes: <ul style="list-style-type: none"> <li>• Psychological distress</li> <li>• Health-related QoL</li> </ul> Secondary outcomes: <ul style="list-style-type: none"> <li>• individual process level barriers and facilitators to iCBT implementation (measured via surveys and semi-structured interviews)</li> </ul> |
| Starting date       | 27 April 2021  |
| Contact information | <a href="mailto:rgreywoode@montefiore.org">rgreywoode@montefiore.org</a> ; <a href="mailto:rebecca.almonte@einsteinmed.org">rebecca.almonte@einsteinmed.org</a>  |
| Notes               | We identified this study during the update search.   |

**Norton 2021**

|               |   |
|---------------|---|
| Study name    | A supported online self-management for symptoms of fatigue, pain and urgency/incontinence in people with inflammatory bowel disease: the IBD-BOOST trial  |
| Methods       | RCT   |
| Participants  | 680   |
| Interventions | IG: facilitator supported online intervention for people who have expressed a desire for intervention for fatigue, pain and/or urgency/incontinence<br>CG: standard care                        |
| Outcomes      | Primary outcomes: <ul style="list-style-type: none"> <li>• UK Inflammatory Bowel Disease Questionnaire (UK-IBDQ) and global rating of symptom relief at 6 months after randomisation</li> </ul> |

**Remote care through telehealth for people with inflammatory bowel disease (Review)**

## Norton 2021 (Continued)

### Secondary outcomes:

- UK-IBDQ at 12 months
- Rating of satisfaction with results of BOOST programme at 6 and 12 months
- Global rating of symptom relief at 12 months
- Numerical pain rating scale at baseline, 6 and 12 months after randomisation
- Vaizey (faecal) incontinence score, reflecting participants' perceptions of severity at baseline, 6 and 12 months after randomisation
- IBD-Fatigue score at baseline, 6 and 12 months after randomisation
- IBD-Control score at baseline, 6 and 12 months after randomisation
- EQ-5D-5L general health-related quality of life at baseline and 6 and 12 months after randomisation

|                     |  |
|---------------------|--|
| Starting date       | 1 November 2017  |
| Contact information | <a href="mailto:l.miller@qmul.ac.uk">l.miller@qmul.ac.uk</a> |
| Notes               | We identified this study during the update search.           |

## RBR-7t8fv7

|                     |   |
|---------------------|---|
| Study name          | Clinical trial of the effectiveness of telephone nursing care to individuals with inflammatory bowel disease  |
| Methods             | RCT   |
| Participants        | 113   |
| Interventions       | IG: telenursing and nursing care<br>CG: nursing care  |
| Outcomes            | Primary outcomes: <ul style="list-style-type: none"> <li>• Relapse</li> </ul> Secondary outcomes: <ul style="list-style-type: none"> <li>• Hospitalisation</li> </ul> |
| Starting date       |   |
| Contact information | Rachel Santos <a href="mailto:enfarachael@hotmail.com">enfarachael@hotmail.com</a>  |
| Notes               |   |

EQ-5D-5L: EuroQol five-dimension, five-level questionnaire; FC: faecal calprotectin; HBI: Harvey-Bradshaw Index; QoL: quality of life; RCT: randomised controlled trial; SIBDQ: Short Inflammatory Bowel Disease Questionnaire.

## DATA AND ANALYSES

### Remote care through telehealth for people with inflammatory bowel disease (Review)


Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

**Comparison 1. Web-based disease monitoring versus usual care**

| Outcome or subgroup title   | No. of studies | No. of participants | Statistical method                        | Effect size        |
|---|----------------|---------------------|---|--------------------|
| <b>1.1 Disease activity (adults)</b>  | 3              | 428                 | Std. Mean Difference (IV, Random, 95% CI) | 0.09 [-0.11, 0.29] |
| 1.1.1 Crohn's disease   | 2              | 273                 | Std. Mean Difference (IV, Random, 95% CI) | 0.03 [-0.21, 0.28] |
| 1.1.2 Ulcerative colitis  | 3              | 155                 | Std. Mean Difference (IV, Random, 95% CI) | 0.19 [-0.13, 0.52] |
| <b>1.2 Disease activity (adults; fixed-effect sensitivity analysis)</b>               | 3              | 428                 | Std. Mean Difference (IV, Fixed, 95% CI)  | 0.09 [-0.11, 0.29] |
| 1.2.1 Crohn's disease   | 2              | 273                 | Std. Mean Difference (IV, Fixed, 95% CI)  | 0.03 [-0.21, 0.28] |
| 1.2.2 Ulcerative colitis  | 3              | 155                 | Std. Mean Difference (IV, Fixed, 95% CI)  | 0.19 [-0.13, 0.52] |
| <b>1.3 Flare-ups/relapse (dichotomous; adults)</b>                                    | 5              | 868                 | Risk Ratio (M-H, Random, 95% CI)          | 1.09 [0.93, 1.27]  |
| 1.3.1 Mixed inflammatory bowel disease  | 1              | 42                  | Risk Ratio (M-H, Random, 95% CI)          | 1.17 [0.47, 2.89]  |
| 1.3.2 Crohn's disease   | 2              | 309                 | Risk Ratio (M-H, Random, 95% CI)          | 1.12 [0.73, 1.71]  |
| 1.3.3 Ulcerative colitis  | 4              | 517                 | Risk Ratio (M-H, Random, 95% CI)          | 1.08 [0.90, 1.30]  |
| <b>1.4 Flare-ups/relapse (dichotomous; adults; fixed-effect sensitivity analysis)</b> | 5              | 868                 | Risk Ratio (M-H, Fixed, 95% CI)           | 1.10 [0.94, 1.29]  |
| 1.4.1 Mixed inflammatory bowel disease  | 1              | 42                  | Risk Ratio (M-H, Fixed, 95% CI)           | 1.17 [0.47, 2.89]  |
| 1.4.2 Crohn's disease   | 2              | 309                 | Risk Ratio (M-H, Fixed, 95% CI)           | 1.11 [0.81, 1.52]  |
| 1.4.3 Ulcerative colitis  | 4              | 517                 | Risk Ratio (M-H, Fixed, 95% CI)           | 1.09 [0.91, 1.32]  |
| <b>1.5 Flare-ups (continuous; adults)</b>   | 1              | 909                 | Mean Difference (IV, Random, 95% CI)      | 0.00 [-0.06, 0.06] |
| <b>1.6 Flare-ups/relapse (dichotomous; children)</b>                                  | 1              | 170                 | Risk Ratio (M-H, Random, 95% CI)          | 0.99 [0.65, 1.51]  |
| 1.6.1 Mixed inflammatory bowel disease  | 1              | 170                 | Risk Ratio (M-H, Random, 95% CI)          | 0.99 [0.65, 1.51]  |
| <b>1.7 Quality of life (adults)</b>   | 4              | 1099                | Std. Mean Difference (IV, Random, 95% CI) | 0.08 [-0.04, 0.20] |

| Outcome or subgroup title                                       | No. of studies | No. of participants | Statistical method                        | Effect size        |
|---|----------------|---------------------|---|--------------------|
| 1.7.1 Mixed inflammatory bowel disease                          | 2              | 971                 | Std. Mean Difference (IV, Random, 95% CI) | 0.07 [-0.06, 0.19] |
| 1.7.2 Crohn's disease   | 1              | 70                  | Std. Mean Difference (IV, Random, 95% CI) | 0.39 [-0.09, 0.86] |
| 1.7.3 Ulcerative colitis  | 2              | 58                  | Std. Mean Difference (IV, Random, 95% CI) | 0.03 [-0.62, 0.69] |
| 1.8 Quality of life (adults; fixed-effect sensitivity analysis) | 4              | 1099                | Std. Mean Difference (IV, Fixed, 95% CI)  | 0.08 [-0.04, 0.20] |
| 1.8.1 Mixed inflammatory bowel disease                          | 2              | 971                 | Std. Mean Difference (IV, Fixed, 95% CI)  | 0.07 [-0.06, 0.19] |
| 1.8.2 Crohn's disease   | 1              | 70                  | Std. Mean Difference (IV, Fixed, 95% CI)  | 0.39 [-0.09, 0.86] |
| 1.8.3 Ulcerative colitis  | 2              | 58                  | Std. Mean Difference (IV, Fixed, 95% CI)  | 0.02 [-0.50, 0.54] |
| 1.9 Medication adherence (continuous; adults)                   | 1              | 671                 | Mean Difference (IV, Random, 95% CI)      | 0.24 [0.01, 0.47]  |
| 1.10 Medication adherence (continuous; children)                | 1              | 33                  | Mean Difference (IV, Random, 95% CI)      | 0.00 [-0.63, 0.63] |
| 1.11 Medication adherence (dichotomous; adults)                 | 2              | 89                  | Risk Ratio (M-H, Random, 95% CI)          | 0.87 [0.62, 1.21]  |
| 1.11.1 Mixed inflammatory bowel syndrome                        | 1              | 42                  | Risk Ratio (M-H, Random, 95% CI)          | 0.86 [0.53, 1.38]  |
| 1.11.2 Ulcerative colitis                                       | 1              | 47                  | Risk Ratio (M-H, Random, 95% CI)          | 0.88 [0.55, 1.41]  |

## Analysis 1.1. Comparison 1: Web-based disease monitoring versus usual care, Outcome 1: Disease activity (adults)




### Footnotes

- (1) TELE-IBD every other week vs usual care  
(2) TELE-IBD every week vs usual care

### Risk of bias legend

- (A) Random sequence generation (selection bias)  
(B) Allocation concealment (selection bias)  
(C) Blinding of participants and personnel (performance bias)  
(D) Blinding of outcome assessment (detection bias)  
(E) Incomplete outcome data (attrition bias)  
(F) Selective reporting (reporting bias)  
(G) Other bias

## Analysis 1.2. Comparison 1: Web-based disease monitoring versus usual care, Outcome 2: Disease activity (adults; fixed-effect sensitivity analysis)




### Footnotes

- (1) TELE-IBD every week vs usual care  
(2) TELE-IBD every other week vs usual care

### Risk of bias legend

- (A) Random sequence generation (selection bias)  
(B) Allocation concealment (selection bias)  
(C) Blinding of participants and personnel (performance bias)  
(D) Blinding of outcome assessment (detection bias)  
(E) Incomplete outcome data (attrition bias)  
(F) Selective reporting (reporting bias)  
(G) Other bias

**Analysis 1.3. Comparison 1: Web-based disease monitoring versus usual care, Outcome 3: Flare-ups/relapse (dichotomous; adults)****Footnotes**


- (1) TELE-IBD every week vs usual care  
(2) TELE-IBD every other week vs usual care

**Risk of bias legend**

- (A) Random sequence generation (selection bias)  
(B) Allocation concealment (selection bias)  
(C) Blinding of participants and personnel (performance bias)  
(D) Blinding of outcome assessment (detection bias)  
(E) Incomplete outcome data (attrition bias)  
(F) Selective reporting (reporting bias)  
(G) Other bias



### Analysis 1.4. Comparison 1: Web-based disease monitoring versus usual care, Outcome 4: Flare-ups/relapse (dichotomous; adults; fixed-effect sensitivity analysis)




#### Footnotes


- (1) TELE-IBD every week vs usual care  
(2) TELE-IBD every other week vs usual care

#### Risk of bias legend

- (A) Random sequence generation (selection bias)  
(B) Allocation concealment (selection bias)  
(C) Blinding of participants and personnel (performance bias)  
(D) Blinding of outcome assessment (detection bias)  
(E) Incomplete outcome data (attrition bias)  
(F) Selective reporting (reporting bias)  
(G) Other bias


**Analysis 1.5. Comparison 1: Web-based disease monitoring  
versus usual care, Outcome 5: Flare-ups (continuous; adults)****Risk of bias legend**

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

**Analysis 1.6. Comparison 1: Web-based disease monitoring versus  
usual care, Outcome 6: Flare-ups/relapse (dichotomous; children)****Risk of bias legend**

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

## Analysis 1.7. Comparison 1: Web-based disease monitoring versus usual care, Outcome 7: Quality of life (adults)




### Footnotes

- (1) TELE-IBD every week vs usual care  
(2) TELE-IBD every other week vs usual care

### Risk of bias legend


- (A) Random sequence generation (selection bias)  
(B) Allocation concealment (selection bias)  
(C) Blinding of participants and personnel (performance bias)  
(D) Blinding of outcome assessment (detection bias)  
(E) Incomplete outcome data (attrition bias)  
(F) Selective reporting (reporting bias)  
(G) Other bias

**Analysis 1.8. Comparison 1: Web-based disease monitoring versus usual care, Outcome 8: Quality of life (adults; fixed-effect sensitivity analysis)****Footnotes**


- (1) TELE-IBD every other week vs usual care  
(2) TELE-IBD every week vs usual care

**Risk of bias legend**


- (A) Random sequence generation (selection bias)  
(B) Allocation concealment (selection bias)  
(C) Blinding of participants and personnel (performance bias)  
(D) Blinding of outcome assessment (detection bias)  
(E) Incomplete outcome data (attrition bias)  
(F) Selective reporting (reporting bias)  
(G) Other bias

**Analysis 1.9. Comparison 1: Web-based disease monitoring versus usual care, Outcome 9: Medication adherence (continuous; adults)****Risk of bias legend**

- (A) Random sequence generation (selection bias)  
(B) Allocation concealment (selection bias)  
(C) Blinding of participants and personnel (performance bias)  
(D) Blinding of outcome assessment (detection bias)  
(E) Incomplete outcome data (attrition bias)  
(F) Selective reporting (reporting bias)  
(G) Other bias

**Analysis 1.10. Comparison 1: Web-based disease monitoring versus usual care, Outcome 10: Medication adherence (continuous; children)****Risk of bias legend**

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

**Analysis 1.11. Comparison 1: Web-based disease monitoring versus usual care, Outcome 11: Medication adherence (dichotomous; adults)****Risk of bias legend**


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

**Comparison 2. Telephone-based disease monitoring versus face-to-face monitoring**

| Outcome or subgroup title                   | No. of studies | No. of participants | Statistical method               | Effect size       |
|---|----------------|---------------------|----------------------------------|-------------------|
| 2.1 Flare-ups/relapse (dichotomous; adults) | 1              | 42                  | Risk Ratio (M-H, Random, 95% CI) | 1.17 [0.47, 2.89] |


| Outcome or subgroup title   | No. of studies | No. of participants | Statistical method                   | Effect size         |
|---|----------------|---------------------|--------------------------------------|---------------------|
| 2.2 Flare-ups/relapse (dichotomous; children)   | 1              | 86                  | Risk Ratio (M-H, Random, 95% CI)     | 0.24 [0.03, 2.05]   |
| 2.3 Quality of life (children)  | 1              | 67                  | Mean Difference (IV, Random, 95% CI) | 7.00 [-0.29, 14.29] |
| 2.4 Number of episodes accessing health-care (one or more hospital admissions; children)                  | 1              | 86                  | Risk Ratio (M-H, Random, 95% CI)     | 0.95 [0.06, 14.77]  |
| 2.5 Medication adherence (adults)   | 1              | 42                  | Risk Ratio (M-H, Random, 95% CI)     | 0.50 [0.25, 0.98]   |
| 2.6 Participant engagement (adults)   | 1              | 42                  | Risk Ratio (M-H, Random, 95% CI)     | 1.05 [0.89, 1.25]   |
| 2.7 Rate of attendance/engagement with the intervention (scheduled consultations not cancelled; children) | 1              | 76                  | Mean Difference (IV, Random, 95% CI) | -0.50 [-1.38, 0.38] |
| 2.8 Rate of attendance/engagement with the intervention (missed consultations; children)                  | 1              | 76                  | Mean Difference (IV, Random, 95% CI) | 1.00 [0.48, 1.52]   |
| 2.9 Rate of attendance of interactions with health professionals (children)                               | 1              | 86                  | Risk Ratio (M-H, Random, 95% CI)     | 0.86 [0.74, 1.00]   |

### Analysis 2.1. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 1: Flare-ups/relapse (dichotomous; adults)




#### Risk of bias legend


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

**Analysis 2.2. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 2: Flare-ups/relapse (dichotomous; children)****Risk of bias legend**


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

**Analysis 2.3. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 3: Quality of life (children)****Risk of bias legend**


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

**Analysis 2.4. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 4: Number of episodes accessing healthcare (one or more hospital admissions; children)****Risk of bias legend**


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

**Analysis 2.5. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 5: Medication adherence (adults)****Risk of bias legend**

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


**Analysis 2.6. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 6: Participant engagement (adults)****Risk of bias legend**

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


**Analysis 2.7. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 7: Rate of attendance/engagement with the intervention (scheduled consultations not cancelled; children)****Risk of bias legend**

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias



**Analysis 2.8. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 8: Rate of attendance/engagement with the intervention (missed consultations; children)****Risk of bias legend**

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

**Analysis 2.9. Comparison 2: Telephone-based disease monitoring versus face-to-face monitoring, Outcome 9: Rate of attendance of interactions with health professionals (children)****Risk of bias legend**

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

## ADDITIONAL TABLES

**Table 1. Study and participant details**

| Study ID             | Trial registration | Disease type <sup>a</sup>   | Disease state (relapse/remission)           | Numbers randomised | Concurrent therapies <sup>a</sup>  | Ethnicity <sup>a</sup> | Socio-economic status <sup>a</sup>   | Conflicts of interest   | Funding  |
|----------------------|--------------------|---|---|--------------------|--|------------------------|--|---|--|
| <b>Akobeng 2015</b>  | NCT02319798        | Mixed IBD<br><br>CD:<br>IG: 36; CG: 35<br><br>UC/IC:<br>IG: 8; CG: 7                          | Remission                                   | IG: 44<br>CG: 42   | NR   | NR                     | NR   | "The authors report grants from Research for Patient Benefit Programme, UK National Institute for Health Research, during the conduct of the study"   | "The project was funded by Research for Patient Benefit Programme, UK National Institute for Health Research (grant number PB-PG-0408-16218)." |
| <b>Ankersen 2019</b> | NCT02492555        | Mixed IBD<br><br>CD:<br>IG: 13 (26%); CG: 10 (19.2%)<br><br>UC:<br>IG: 35 (70%); CG: 39 (75%) | Remission or mild-moderate disease activity | IG: 50<br>CG: 52   | None:<br>IG: 9 (18.0%); CG: 10 (19.2%)<br><br>5-ASA:<br>IG: 27 (54.0%); CG: 24 (46.2%)<br><br>Corticosteroids:<br>IG: 4 (8.0%); CG: 4 (7.7%)<br><br>Immunomodulators:<br>IG: 3 (6.0%); CG: 9 (17.3%)<br><br>Biological therapy:<br>IG: 7 (14.0%); CG: 5 (9.6%) | NR                     | Length of education after high school:<br><br>Short:<br>IG: 2; CG: 4<br>Medium:<br>IG: 40; CG: 31<br>Higher/academic:<br>IG: 6; CG: 13<br><br>Occupation:<br>Yes:<br>IG: 38; CG: 42<br>No:<br>IG: 12; CG: 10 | "Ankersen DV has received grants from Ferring Pharmaceuticals, Crohn Colitis patient society Denmark, North Zealand University Hospital and nonfinancial support from Calpro AS; Weimers P has received grants from Ferring lægemidler and Tillotts Pharma AG as well as nonfinancial support from Janssen-Cilag A/S, Calpro AS, and Vifor Pharma Nordiska AB; Marker D has received non-financial support from Calpro AS and Pharmacosmos; Bennedsen M has received other financial support from AbbVie, Tillotts, Takeda, MSD and Pfizer; Saboori S has received non-financial support from Janssen-Cilag and Salofalk; Paridaens K is an employee of Ferring Pharma- | "Calpro AS; Crohn-Colitis patient society Denmark; and North Zealand University Hospital and Ferring Pharmaceuticals."                         |

**Table 1. Study and participant details** (Continued)

|              |             |  |   |                    |    |  |                   |  |   |
|--------------|-------------|--|---|--------------------|----|--|-------------------|--|---|
|              |             |  |   |                    |    |  |                   | ceuticals; Burisch J has received grants from AbbVie, Takeda, Tillotts Pharma and personal fees from AbbVie, Janssen-Cilag, Celgene, Samsung Bioepis, MSD, Pfizer and Takeda; Munkholm P has none to declare." |   |
| Atreja 2018  | NCT02322307 | Mixed IBD  | Unclear   | IG: 162<br>CG: 158 | NR | White: 82.2%<br>Black: 5.3%<br>Hispanic: 9.1%                          | College education | NR   | "The study is supported by the Crohn's & Colitis Foundation of America (grant #253624) and the National Institutes of Health (5K23 DK97451-02)."  |
| Carlsen 2017 | NCT01860651 | Mixed IBD<br><br>CD:<br>IG: 8; CG: 13<br><br>UC:<br>IG: 19; CG: 13 | CD (remission):<br>IG: 2; CG: 5<br><br>CD (mild):<br>IG: 5; CG: 6<br><br>CD (moderate):<br>IG: 0; CG: 2<br><br>CD (severe):<br>IG: 1; CG: 0<br><br>UC (remission):<br><br>IG: 14; CG: 9<br><br>UC (mild):<br>IG: 5; CG: 4 | IG: 27<br>CG: 26   | NR | Ethnicity is reported in the trial registration, but not in the paper. | NR                | None   | "European Crohn's and Colitis Organization, Queen Louise's Hospital Foundation, TrygFoundation, CALPRO A/S, Tillotts Pharma, Capital Region Denmark, Alice and Frimodts Foundation, Ulcerative colitis and Crohn's Danish Patient Society, and Merck Sharp and Dome." |
| Chauhan 2016 | NA          | Mixed IBD  | NR  | IG+CG: 60          | NR | NR   | NR                | NR   | NR  |

**Table 1. Study and participant details** (Continued)

|                     |   |   |                                 |  |  |  |  |   |
|---------------------|---|---|---------------------------------|--|--|--|--|---|
| <b>Cross 2012</b>   | NCT00620126 UC  | Mixed: remission and active disease             | IG: 25<br>CG: 22                | Steroids:<br>Total: 5; IG: 3;<br>CG: 2<br><br>Immune suppressants:<br>Total: 20; IG: 14; CG: 6<br><br>Infliximab:<br>Total: 14; IG: 7; CG: 7   | White:<br>Total: 31;<br>IG: 16; CG: 15<br><br>Other:<br>Total: 16;<br>IG: 9; CG: 7   | Disease knowledge:<br>Limited:<br>Total: 7; IG: 4; CG: 3<br><br>Good:<br>Total: 30; IG: 15; CG: 15<br><br>Excellent:<br>Total: 10; IG: 4; CG: 6  | NR   | "Broad Medical Research Program (BRMP-0190), University of Maryland General Clinical Research Center Grant (M01 RR 16500), General Clinical Research Centers Program, National Center for Research Resources (NCRR), NIH, and the Baltimore Education and Research Foundation." |
| <b>Cross 2019</b>   | NCT01692743 CD:<br>IG1: 79;<br>IG2: 78;<br>CG: 79<br><br>UC/IC:<br>IG1: 36;<br>IG2: 38;<br>CG: 38 | Mixed, remission (148) and active disease (200) | IG1: 115<br>IG2: 116<br>CG: 117 | Aminosalicylates:<br>Total: 108;<br>IG1: 29; IG2: 39; CG: 40<br><br>Corticosteroids:<br>Total: 64; IG1: 17; IG2: 27; CG: 20<br><br>Mercaptopurine/azathioprine:<br>Total: 111;<br>IG1: 33; IG2: 42; CG: 36<br><br>Anti-TNF:<br>Total: 206;<br>IG1: 66; IG2: 68; CG: 72 | White:<br>Total: 319;<br>IG1: 108;<br>IG2: 111; CG: 100<br><br>African American:<br>Total: 24;<br>IG1: 5; IG2: 5; CG: 14<br><br>Asian:<br>Total: 1;<br>IG1: 1; IG2: 0; CG: 0<br><br>Other:<br>Total: 3;<br>IG1: 1; IG2: 0; CG: 0 | Insurance status:<br>None:<br>Total: 14; IG1: 0; IG2: 1; CG: 13<br>Medical assistance:<br>Total: 6; IG1: 1; IG2: 2; CG: 3<br>Medicare:<br>Total: 15; IG1: 6; IG2: 1; CG: 8<br>Commercial:<br>Total: 198; IG1: 67; IG2: 70; CG: 61<br>Other:<br>Total: 64; IG1: 24; IG2: 27; CG: 13 | "None"   | "Agency for Healthcare Research and Quality (1R01HS018975-01A1) and the University of Maryland general clinical research centers program."  |
| <b>De Jong 2017</b> | NCT02173002 Mixed IBD   | Mixed Remission:                                | IG: 465<br>CG: 444              | No medication/mesalazine:<br>IG: 147; CG: 173  | NR   | Education:<br>University:<br>IG: 54; CG: 49<br>Higher vocational education:  | "MJDJ reports non-financial support from Merck Sharpe & Dohme, outside the submitted | "Academic incentive fund of the Maastricht University Medical Centre (31962340B)."  |

**Table 1. Study and participant details** *(Continued)*

IG: 394;  
CG: 380

Active:  
IG: 71; CG:  
64

Immunosup-  
presants:  
IG: 131; CG:  
122

Biologics:  
IG: 166; CG:  
170

IG: 103; CG: 98  
Intermediate vo-  
cational educa-  
tion:  
IG: 160; CG: 157  
Secondary edica-  
tion:  
IG: 56; CG: 55  
Primary educa-  
tion:  
IG: 6; CG: 8  
Missing data:  
IG: 86; CG: 77

work. AEvdM-dJ reports grants and non-financial support from Takeda, personal fees from AbbVie, and non-financial support from Tramedico, all outside the submitted work. AAvB reports personal fees from AbbVie, MSD, Ferring, Tramedico, Takeda, Pfizer, and Janssen, all outside the submitted work. GD reports speaker's fees from Shire, AbbVie, and Takeda, and a grant for investigator-initiated research from Takeda, all outside the submitted work. AAM reports grants from Grünenthal, Zon MW GGG (government), Will Pharma, BioActor, Pentax Europe, Falk Pharma, and Almiral Pharma, all outside the submitted work. AB received research grants to her department from AbbVie, Amgen, and Merck, and advisory board honoraria from Janssen and Sandoz, all unrelated to the current work. MJP reports personal fees from AbbVie, Ferring, Janssen, and Takeda, and grants from Falk, all outside the submitted work. All other authors declare no competing interests."

**Table 1. Study and participant details** (Continued)

|                      |             |   |   |                              |   |    |  |   |   |
|----------------------|-------------|---|---|------------------------------|---|----|--|---|---|
| <b>Del Hoyo 2018</b> | NCT02943538 | CD: IG1: 13/21; IG2: 13/21; CG: 14/21<br>UC: IG1: 8/21; IG2: 8/21; CG: 7/21 | Remission and active Remission: CD: IG1: 6; IG2: 9; CG: 10<br>UC: IG1: 2; IG2: 1; CG: 2 | IG1: 21<br>IG2: 21<br>CG: 21 | Immunomodulators: IG1: 10; IG2: 9; CG: 10<br>Biologics: IG1: 4; IG2: 4; CG: 4<br>Combination therapy: IG1: 5; IG2: 6; CG: 6<br>Corticosteroids: IG1: 2; IG2: 2; CG: 1 | NR | Education: Primary education: 9/30; secondary education: 21/30; university: 29/30<br>Work Productivity and Activity Impairment: Not working: IG1: 7/21; IG2: 5/21; CG: 8/21<br>Percentage of work hours missed: IG1: median 40% (IQR 15%–62.5%); IG2: median 32.5% (IQR 7.5%–57.5%); CG: median 27.5% (IQR 0%–52%)<br>Work impairment score: IG1: median 7 (IQR 3–10); IG2: median 10 (IQR: 2.25–10); CG: median 7 (IQR 2.75–10)<br>Social impairment score: IG1: median 3.5 (IQR 2–7); IG2: median 6 (IQR 2.75–8); CG: median 3.5 (IQR 1–5.75)<br>Satisfaction score: CG: median 49.5 (IQR 42.5–53.75); IG1: median 53 (IQR 50– | "DD is the general manager of Connected Health Services." | "Grants from the Instituto de Salud Carlos III-Fondo de Investigaciones Sanitarias (FIS PI12/00277) and co-funded by FEDER (Fondo Europeo de Desarrollo Regional)." |
|----------------------|-------------|---|---|------------------------------|---|----|--|---|---|

59); IG2: median  
52 (IQR 47.5–55)

|                     |    |    |                       |                    |   |    |   |   |   |
|---------------------|----|----|-----------------------|--------------------|---|----|---|---|---|
| <b>Elkjaer 2010</b> | NR | UC | Mild/moderate disease | IG: 117<br>CG: 116 | 5-ASA systemic:<br>Asacol:<br>IG: 78; CG: 68<br>Pentasa:<br>IG: 8; CG: 7<br>Dipentum:<br>IG: 2; CG: 4<br>Premid:<br>IG: 2; CG: 2<br>Salazopyrin:<br>IG: 3; CG: 6<br>Mezavant:<br>IG: 0; CG: 0<br>None:<br>IG: 12; CG: 19<br><br>Suppositories:<br>Asacol:<br>IG: 3; CG: 2<br>Pentasa:<br>IG: 12; CG: 9<br>Mesasal:<br>IG: 3; CG: 1<br>Prednisolon:<br>IG: 1; CG: 0<br>None:<br>IG: 88; CG: 94<br><br>Enema /<br>Foam:<br>Asacol:<br>IG: 4; CG: 4<br>Pentasa:<br>IG: 7; CG: 6<br>Colifoam:<br>IG: 4; CG: 4<br>Pred-clysmas:<br>IG: 0; CG: 0<br>None:<br>IG: 90; CG: 92 | MR | Marital status:<br>Married:<br>IG: 69/105; CG: 82/106<br>Single:<br>IG: 36/105; CG: 24/106<br><br>Education:<br>Academic:<br>IG: 33/105; CG: 29/106 in CG<br>Other education:<br>IG: 55/105; CG: 64/106<br>During education:<br>IG: 16/105; CG: 5/106<br>No education:<br>IG: 1/105; CG: 8/106<br><br>Occupation:<br>Paid:<br>IG: 82/105; CG: 86/106<br>Unpaid:<br>IG: 1/105; CG: 4/106<br>Support:<br>IG: 15/105; CG: 6/106<br>Pensioner:<br>IG: 7/105; CG: 10/106 | "PM is member of the advisory boards in Fer-<br>ring, Tillots, MSD and<br>Swedish Orphan. ME is<br>member of the advisory<br>board in Swedish Or-<br>phan. HS is member of<br>the advisory board in<br>Swedish Orphan. CO'M<br>is on the International<br>Advisory Board of<br>Abbott, MSD, and Shire<br>Pharmaceutical Company.<br>He has unrestricted<br>educational grants from<br>Abbott and MSD" | "Colitis Crohn Patient<br>Organisation, Moran's<br>Foundation, Vibeke<br>Binder & Povl Riis' Foundation,<br>Bayer Health Care<br>Funding, Augustinus<br>Foundation, Munkholms<br>Foundation, Tillotts<br>Funding, Scientific<br>Council at Herlev<br>Hospital, Prof. Fagerhol<br>Research Foundation,<br>Aase & Einar<br>Danielsen Foundation,<br>Ole Trock-Jansen &<br>Hustrus Foundation,<br>and European Crohn<br>Colitis Organisation." |
|---------------------|----|----|-----------------------|--------------------|---|----|---|---|---|

**Table 1. Study and participant details** (Continued)

|                    |             |   |           |                  |   |    |  |  |  |
|--------------------|-------------|---|-----------|------------------|---|----|--|--|--|
| <b>Heida 2018</b>  | NTR3759     | Mixed IBD<br>CD:<br>IG: 39; CG: 42<br>UC:<br>IG: 45; CG: 44 | Remission | IG: 84<br>CG: 86 | Immunomodulators:<br>IG: 69; CG: 65<br><br>Aminosalicylates:<br>IG: 57; CG: 52                                    | NR | Emotional quotient:<br>Low ( $\leq 89$ ):<br>IG: 5; CG: 5<br>Average (90–109):<br>IG: 37; CG: 30<br>High ( $\geq 110$ ):<br>IG: 46; CG: 51<br>Missing:<br>IG: 21; CG: 14 | "PFvR, AH and AMK received funding for joint research projects from BÜHLMANN Laboratories and CisBio Bioassays. All other authors had no support from any organization for the submitted work, no financial relationships with any organizations that might have an interest in the submitted work in the previous 2 years, and no other relationships or activities that could appear to have influenced the submitted work." | "This work was supported by ZonMw Health Care Efficiency Research [grant number 837001001], Innovation Fund Dutch Insurance Companies [grant number B12-204–2509], and NutsOhra Fund [grant number 1301-002]. RKW is supported by the Netherlands Organization for Scientific Research [NWO] [grant number 016.136.308]. Reagents for the Quantum Blue® calprotectin point-of-care tests were an unrestricted donation by Bühlmann Laboratories AG. An unrestricted start-up grant for the development of the web-based programme IBD-live was awarded by Ferring Pharmaceuticals BV." |
| <b>Hughes 2017</b> | NCT02707068 | IBD   | NR        | IG: 32<br>CG: 31 | NR  | NR | NR   | "None"   | NR   |
| <b>Ley 2020</b>    | NR          | UC  | Remission | IG: 21<br>CG: 18 | Lialda:<br>IG: 7; CG: 11<br><br>Apriso:<br>IG: 1; CG: 0<br><br>Balsalazide:<br>IG: 5; CG: 4<br><br>Sulfasalazine: | NR | Employment:<br>Student:<br>IG: 3; CG: 5<br>Part-time:<br>IG: 1; CG: 1;<br>Full-time:<br>IG: 16; CG: 11<br>Unemployed:<br>IG: 1; CG: 1                                    | "Freddy Caldera has received research support from Takeda Pharmaceuticals and Sanofi. He has been a consultant for Takeda and Celgene. All remaining authors report no proprietary in-   | "This study was supported by research support from Takeda Pharmaceuticals."  |



**Table 1. Study and participant details** (Continued)

|                  |                   |             |           |        |                  |    |                     |        |                         |
|------------------|-------------------|-------------|-----------|--------|------------------|----|---------------------|--------|-------------------------|
|                  |                   |             |           |        | IG: 1; CG: 0     |    | Education:          |        | terest in the products  |
|                  |                   |             |           |        | Asacol/delzi-    |    | High school:        |        | named in this article." |
|                  |                   |             |           |        | col:             |    | IG: 4; CG: 0        |        |                         |
|                  |                   |             |           |        | IG: 0; CG: 2     |    | College:            |        |                         |
|                  |                   |             |           |        | Asacol HD:       |    | IG: 3; CG: 5        |        |                         |
|                  |                   |             |           |        | IG: 7; CG: 1     |    | Bachelors and       |        |                         |
|                  |                   |             |           |        |                  |    | above:              |        |                         |
|                  |                   |             |           |        |                  |    | IG: 14; CG: 13      |        |                         |
|                  |                   |             |           |        |                  |    | Marital status:     |        |                         |
|                  |                   |             |           |        |                  |    | Single:             |        |                         |
|                  |                   |             |           |        |                  |    | IG: 9; CG: 7        |        |                         |
|                  |                   |             |           |        |                  |    | Significant oth-    |        |                         |
|                  |                   |             |           |        |                  |    | er/married:         |        |                         |
|                  |                   |             |           |        |                  |    | IG: 10; CG: 11      |        |                         |
|                  |                   |             |           |        |                  |    | Divorced/wid-       |        |                         |
|                  |                   |             |           |        |                  |    | owed:               |        |                         |
|                  |                   |             |           |        |                  |    | IG: 2; CG: 0        |        |                         |
| <hr/>            |                   |             |           |        |                  |    |                     |        |                         |
| <b>Malickova</b> | NR                | CD:         | Remission | IG: 94 | Corticos-        | NR | Marital status:     | NR     | NR                      |
| <b>2020</b>      |                   | IG: 44/94;  |           | CG: 37 | teroids:         |    | Single:             |        |                         |
|                  |                   | CG: 19/37   |           |        | IG: 6; CG: 3     |    | IG: 29; CG: 14      |        |                         |
|                  |                   | UC:         |           |        | Azathio-         |    | Married/partner:    |        |                         |
|                  |                   | IG: 46/94;  |           |        | prine/6 - mer-   |    | IG: 55; CG: 20      |        |                         |
|                  |                   | CG: 18/37   |           |        | captopurine:     |    | Divorced/sepa-      |        |                         |
|                  |                   |             |           |        | IG: 30; CG: 17   |    | rated: IG: 6; CG: 3 |        |                         |
|                  |                   |             |           |        | Methotrexate:    |    |                     |        |                         |
|                  |                   |             |           |        | IG: 0; CG: 1     |    |                     |        |                         |
|                  |                   |             |           |        | Mesalazine:      |    |                     |        |                         |
|                  |                   |             |           |        | IG: 49; CG: 20   |    |                     |        |                         |
|                  |                   |             |           |        | Antibiotics:     |    |                     |        |                         |
|                  |                   |             |           |        | IG: 0; CG: 1     |    |                     |        |                         |
| <hr/>            |                   |             |           |        |                  |    |                     |        |                         |
| <b>McCom-</b>    | AC-               | Mixed IBD   | Mean: re- | IG: 53 | 5-ASA:           | NR | NR                  | "None" | "This work was          |
| <b>bie 2020</b>  | TRN12615000342516 | CD:         | mission   | CG: 54 | IG: 20; CG: 20   |    |                     |        | supported by the        |
|                  |                   | IG: 37; CG: |           |        | Biologics:       |    |                     |        | Healthcare Otago        |
|                  |                   | 36          |           |        | IG: 15; CG: 18   |    |                     |        | Charitable Trust (no    |
|                  |                   | UC:         |           |        | Thiop-           |    |                     |        | grant number) and       |
|                  |                   | IG: 13; CG: |           |        | urine/methotrex- |    |                     |        | The New Zealand So-     |
|                  |                   | 14          |           |        | ate:             |    |                     |        | ciety of Gastroen-      |
|                  |                   |             |           |        | IG: 37; CG: 27   |    |                     |        | terology Janssen Re-    |
|                  |                   |             |           |        |                  |    |                     |        | search Fellowship       |

**Table 1. Study and participant details** (Continued)

|                     |             |   |  |                    |  |  |    |        |   |
|---------------------|-------------|---|--|--------------------|--|--|----|--------|---|
|                     |             |   |  |                    | None:<br>IG: 2; CG: 3  |  |    |        | (no grant number) in 2015 and the gut health network, a research theme located at the Department of Medicine, University of Otago." |
| <b>Reich 2019</b>   | NCT03241992 | Mixed IBD<br><br>CD:<br>IG: 36; CG: 36<br><br>UC:<br>IG: 28; CG: 27 | Mean: re-mission   | IG: 64<br>CG: 63   | Mesalamine:<br>IG:19; CG: 18<br><br>Immunomodulators:<br>IG: 17; CG: 25<br><br>Biologics:<br>IG 39; CG 40<br><br>Steroids:<br>IG: 6; CG: 9 | White:<br>IG: 48; CG: 49<br><br>Black:<br>IG: 8; CG: 7<br><br>Other:<br>IG: 6; CG: 7 | NR | "None" | "This project was funded by a generous gift from Aimee & Kleanthis Dendrinis and Robin & Andrew Davis."                             |
| <b>Siegel 2018</b>  | NR          | CD  | NR   | IG: 133<br>CG: 69  | NR   | NR   | NR | NR     | NR  |
| <b>Stunkel 2012</b> | NR          | IBD   | Mild to moderate disease   | Total: 90          | NR   | NR   | NR | NR     | NR  |
| <b>Wang 2020</b>    | NR          | CD  | Post-operative CD<br><br>Relapse:<br>IG: 33; CG: 39<br><br>Remission:<br>IG: 87; CG: 80<br><br>CG: Relapse 39, Remission 80. | IG: 120<br>CG: 119 | NR   | NR   | NR | NR     | "The project was funded by Nursing Project of Military Medical Science and Technology Youth Cultivation Plan, No. 19QNP077."        |

<sup>a</sup> Numbers refer to number of participants unless otherwise specified.

5-ASA: 5-aminosalicylic acid; CD: Crohn's disease; CG: control group; IBD: inflammatory bowel disease; IC: indeterminate colitis IG: intervention group; IQR: interquartile range; n: number of participants; NR: not reported; UC: ulcerative colitis.

**Table 2. Intervention details**

| Study ID             | Intervention description  | Type of telehealth                          | Control intervention description   | Type of control intervention  | Intervention length | Is the education part of a package of measures (e.g. diagnostic tools, etc.)? | Outcome measurement points | Follow-up measurement points |
|----------------------|---|---|--|-------------------------------|---------------------|---|----------------------------|------------------------------|
| <b>Akobeng 2015</b>  | "A call from the gastroenterology doctor at the time of their appointment. The consulting doctor contacted the patient and parents via a telephone number (home or mobile) that the parents and patient had previously supplied as the number they would like to be contacted on."  | Telephone consultations                     | Routine appointments in hospital as usual  | Usual care                    | 24 weeks            | No  | 6, 12, 18, 24 months       | None after end of study      |
| <b>Ankersen 2019</b> | "If patients experienced a recurrence of disease visualized on constant care web application (web-app), they were instructed to contact the electronic care (eCare) personnel by phone or via the patient's personal web-wall, for an early consultation to assess the need of individualized treatment adjustment or diagnostic investigation. Daily web ward rounds were performed by the eCare nurses in close collaboration with a medical doctor." | Mobile phone application disease monitoring | Patients allocated to the CG were instructed in how to screen themselves every 3 months. | Self-screening                | 12 months           | No  | 12 months                  | None after end of study      |
| <b>Atreja 2018</b>   | "HealthPROMISE app: Patients track their Quality Of Life and symptoms every 2 weeks, providers can use the visual data to provide better care."   | Mobile phone application disease monitoring | Patient education application, no further details provided                               | Patient education application | 104 weeks           | NR  | Day 495, day 575           | None after end of study      |

**Table 2. Intervention details** (Continued)

|                     |  |                                  |   |            |           |  |                     |                         |
|---------------------|--|----------------------------------|---|------------|-----------|--|---------------------|-------------------------|
| <b>Carlsen 2017</b> | "Electronic traffic light system, which guides the scheduling of infliximab treatment at intervals of 4 to 12 weeks. The traffic light system is based on patient-registered symptom scores and measures of fecal calprotectin (FC), combined into a total inflammation burden score (TIBS). The repeatedly measured TIBS form a curve on a traffic light graph system consisting of the colors green, yellow, and red. Depending on the color, patients are advised regarding the timing of their next IFX treatment."    | Web-based disease monitoring     | Hospital's IBD care guidelines (national pediatric IBD standard care in Denmark), with outpatient visits every 3rd month, including blood samples and FC.   | Usual care | 2 years   | NR   | End of study        | None after end of study |
| <b>Chauhan 2016</b> | Telephone follow-up visits by an IBD nurse practitioner  | Telephone follow-ups             | Clinic follow-up visit by an IBD nurse practitioner   | Usual care | 6 months  | NR   | 6 months            | None after end of study |
| <b>Cross 2012</b>   | "Mobile phone for participants and a decision support server and website for staff and providers. The web system send texts to participants grading their IBD symptoms and collected data from each testing session. Educational tips were also sent via text. The provider could individualise alerts and action plans for each participant. If pre-determined criteria were met the nurse reviewed and if necessary management changes were made. Medication changes were also updated and communicated to the patient." | Web-based care management portal | "Comprehensive assessment, a guideline-concordant therapy plan, scheduled and as-needed clinic visits, scheduled and as-needed telephone calls, administration of educational fact sheets about disease-specific topics. Administration of educational materials was not standardised and was at the discretion of the provider." | Usual care | 12 months | Disease-specific education provided by C&C Foundation of America | 6 months, 12 months | None after end of study |
| <b>Cross 2019</b>   | "Mobile phone for participants and website for providers. The web system sends texts to participants to  | Web-based care man-              | "The standard of care for participants in this study  | Usual care | 12 months | "Education-<br>al curriculum: educa-                             | 6 and 12 months     | None after end of study |

**Table 2. Intervention details** (Continued)

|                     |  |                                  |  |            |           |    |  |                         |
|---------------------|--|----------------------------------|--|------------|-----------|----|--|-------------------------|
|                     | grade their IBD symptoms. The website provides an interface for staff and providers for participants profiles and collected data from each testing session. The provider can individualize alerts and action plans for each participant. If pre-determined criteria were met after testing, simultaneous action plans and email alerts were sent to the participant and nurse respectively. The nurse reviewed the information and if necessary consulted the provider for management changes. Medication changes were updated in the participant profile and communicated to the participant."  | agement portal                   | is modeled after the standard of care at all three study sites. Comprehensive assessment, a guideline concordant therapy plan scheduled and as needed clinic visits, scheduled and as needed telephone calls, and administration of educational fact sheets about disease-specific topics when appropriate." |            |           |    | tion tips either twice weekly (IG1) or every week (IG2). Educational materials for CG administration was not standardized and was at the discretion of the treating provider." |                         |
| <b>De Jong 2017</b> | "MyIBDcoach is a secured webpage with an HTML application for tablet or smartphone. The system includes monthly monitoring modules, as well as intensified monitoring modules, outpatient visit modules, e-learning modules, a personal care plan, and an administrator page used by the health-care provider. When parameters recorded by the monitoring modules exceeded predefined thresholds, the safety and continuity of care were ensured by the creation of alerts (red flags) on the administrator page of each local hospital. If an alert was received, a health-care provider on the local team contacted the patient for further assessment within two working days. Visits to the outpatient clinic were based on the nature and severity of the clinical complaints. At any time, patients were able to communicate easily with their health-care provider by sending a message to the health-care providers' administration office." | Web-based care management portal | "Patients in the standard care group continued their routine follow-up visits following the local protocol, with an opportunity to schedule an extra visit if symptoms relapsed."  | Usual care | 12 months | NR | 12 months  | None after end of study |

**Table 2. Intervention details** (Continued)

|                  |  |                                    |   |            |           |                        |                 |                         |
|------------------|--|------------------------------------|---|------------|-----------|------------------------|-----------------|-------------------------|
| Del Hoyo<br>2018 | IG1: "Follow-up and monitoring were performed telematically using the integrated platform for management of chronically ill patients (NOMHAD-CHRONIC app). Patients connected to the platform via the Internet using a computer or an app on a mobile phone or tablet had to self-complete questionnaires. In addition, they received advice, reminders, educational material about their disease, and information on prevention. This information was received by the case managers and filtered using an intelligent prioritization system with generation of alerts and push notifications according to an integrated intervention protocol"          | IG1: remote web-based monitoring   | "The CG patients received the normal care provided in the IBD Unit (Outpatient Clinic) for patients with moderately to highly complex IBD, based on national and European clinical guidelines. Treatment was adjusted according to the evolution of disease activity and medication adherence, which was measured using specific indexes and biological markers used to report the study outcomes during office visits or telephone calls.<br><br>This care was complemented by ad hoc hospital care in case of flareups or if the patient's health deteriorated for any reason. Ad hoc intensive care was maintained until the patient's condition stabilized, at which point he or she returned to follow-up based on standard care in the Unit." | Usual care | 24 weeks  | NR                     | 12 and 24 weeks | None after end of study |
|                  | IG2: "The G_NT patients were asked about their health through telephone calls by the nursing staff in the IBD Unit. Authors performed telephone assessment periodically by using structured interviews to evaluate health status, and clinical activity was self-recorded at home. The interventions depended on the results of the interview and changes in the medication or follow-up schedule established by nurses with the support of medical staff, according to the alerts and action plans designed in the intervention protocol. Furthermore, they provided these patients with all educational elements made available to the other 2 groups" | IG2: nurse-assisted telephone care |   |            |           |                        |                 |                         |
| Elkjaer<br>2010  | "Patients received a remote education session on IBD and training on   | Web-based education                | "Patients in the control group con-   | Usual care | 12 months | IG: web platform, edu- | End of study    | None after end of study |

**Table 2. Intervention details** *(Continued)*

|                    |   |   |  |                       |          |                                      |              |                         |
|--------------------|---|---|--|-----------------------|----------|--------------------------------------|--------------|-------------------------|
|                    | <p>the web-based programme on how to recognise relapses and start treatment guided by the programme.</p> <p>In case of relapse, patients were requested to log on daily and complete the disease activity score (SCCAI) until they entered the green zone. Patients should then log on once a week for a total of 4 weeks after the initiation of relapse. Once remission was achieved patients had to use the program once a month until the next relapse occurred."</p>   | and self-treatment                                    | tinued the conventional treatment and follow-up in the IBD out-patient clinic."  |                       |          | cation from staff members            |              |                         |
| <b>Heida 2018</b>  | <p>"Participants received automated email alerts to fill in a symptom score and to send in a stool sample. The results of both the symptom score and the calprotectin stool test were uploaded on the IBD-live website and cumulated in a colour-coded disease flare risk stratification that was visible to the individual participant and the local IBD team. This resulted in an individual prediction for flare with associated treatment advice and test interval."</p>  | Automated email alerts, and web-based tele-monitoring | Regular checks in the consultation room as before the trial  | Usual care            | 52 weeks | Yes, FC samples – diagnostic measure | End of study | None after end of study |
| <b>Hughes 2017</b> | <p>"Quality Of Life Tool for IBD (QOLITI). The cognitive-behavioural therapy (CBT)-inspired manual contains several chapters each of which addresses a different topic with information, guidance in setting goals for behaviour change and accompanying tasks to aid implementation which is completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals among others. 3 x 30 minutes of telephone support by a trained healthcare professional along with the manual were included. Tele-</p> | CBT self-complete manual and telephone consultations  | Waitlist control group waits until after the study finishes to receive the same manual, but without telephone support sessions | Usual care (waitlist) | 8 weeks  | Yes, educational manual              | End of study | None after end of study |

**Table 2. Intervention details** *(Continued)*

phone calls occurred at two, four and six weeks post-randomisation."

|                       |  |  |  |                  |           |                                      |                    |                         |
|-----------------------|--|--|--|------------------|-----------|--------------------------------------|--------------------|-------------------------|
| <b>Ley 2020</b>       | Adherence iPhone application that included medication reminders  | Web-based phone application for medication adherence | Sham application installed that included educational materials and the capability of recording medication intake, without medication reminders   | Sham application | NR        | No                                   | End of study       | NR                      |
| <b>Malickova 2020</b> | "Patients were telemonitored and connected with their doctors and IBD nurses through an IBD Assistant application. They received email reminders at regular intervals to fill in standard electronic assessments. In case of deterioration, they had an emergency questionnaire that advised on contacting a doctor. All communication with the doctor was made primarily through the IBD Assistant web application, personal visits were carried out only after a previous recommendation via the IBD Assistant application. FC was measured at least 4 times/12months with at home CalpoSmart system." | Web-based application telemonitoring                 | "There were usual check-ups every 3 months in outpatient clinics with their gastroenterologists, during which the patients were examined clinically and laboratory. In case of any difficulties, patients had an unscheduled acute consultation, or were visited by a doctor on the basis of unfavorable examination results." | Usual care       | 12 months | Yes, FC samples – diagnostic measure | End of study       | None after end of study |
| <b>McCombie 2020</b>  | "IBDsmart is an app that allows inflammatory bowel disease (IBD) patients to regularly fill in symptom scores and get them sent to their doctor. It is used by the patients by logging in and filling out a questionnaire. When they fill out the questionnaire, a score is produced which indicates the severity of the disease. This way long term trends of symptom scores are kept on the smartphone and the healthcare team can be contacted immediately via the app in cases where   | Web-based telemonitoring                             | "Usual outpatient treatment. The usual treatment group will not have access to the smartphone apps. Usual outpatient treatment, for the purposes of this study, entails the patient seeing their treating gastroen-  | Usual care       | 12 months | Yes, FC samples – diagnostic measure | 3, 6, 9, 12 months | None                    |



**Table 2. Intervention details** (Continued)

|                     |   |   |   |  |                 |   |  |                                     |
|---------------------|---|---|---|--|-----------------|---|--|-------------------------------------|
|                     | <p>disease severity is high. IBDoc is an app that allows IBD patients to measure their faecal calprotectin levels and get their results sent to their doctor. The way the app works is the participant provides a stool sample which is analysed using a medical device which produces an output that can be read via the camera by an app. The calprotectin app communicates with the IBD app which produces a faecal calprotectin score which is high, medium, or low; the level indicates how much physical disease activity is occurring in the patient. These results can also be sent to the healthcare professional team."</p> |   | <p>terologist as they usually would."</p>   |  |                 |   |  |                                     |
| <b>Reich 2019</b>   | <p>"Patients received information via an application about IBD every 2 weeks along with reminders to take their medications. They also received a reminder about getting vaccinated for influenza and pneumococcal pneumonia at 2 weeks, and 3 months after enrollment."</p>  | <p>Web-based IBD-specific information and electronic reminders for medication adherence</p> | <p>Participants were sent generic messages unrelated to IBD.</p>                            | <p>Sham web-based information unrelated to IBD</p> | <p>6 months</p> | <p>Yes, educational information about IBD sent via messages</p>   | <p>End of study</p>                            | <p>None</p>                         |
| <b>Siegel 2018</b>  | <p>"A decision aid including an online program reviewing benefits and risks of treatment options combined with a personalised risk prediction tool for Crohn's disease."</p>  | <p>Decision-aid online programme for choice of combination therapy</p>                      | <p>Standard of care</p>   | <p>Usual care</p>                                  | <p>3 years</p>  | <p>Yes, benefits and risks of treatment review</p>                | <p>End of study</p>                            | <p>NR</p>                           |
| <b>Stunkel 2012</b> | <p>"Subjects downloaded and used an application daily to record symptoms, track pain, stress levels, frequency and quality of bowel movements."</p>   | <p>Web-based application disease monitoring</p>   | <p>The control group was educated about websites providing information on IBD.</p>          | <p>Usual care</p>                                  | <p>38 weeks</p> | <p>No</p>   | <p>End of intervention (varied 8–38 weeks)</p> | <p>IG: 104 days<br/>CG: 87 days</p> |
| <b>Wang 2020</b>    | <p>"Nurse-led web-based follow-up program for disease monitoring, patient medication reminders, medication education and nurse-caregiver-patient communication"</p>   | <p>Web-based disease monitoring and medication</p>  | <p>"The patients in the control group received regular health education and guidance on</p> | <p>Usual care</p>                                  | <p>6 months</p> | <p>Yes. Disease monitoring, patient reminders, patient educa-</p> | <p>End of months 1, 2, 4, 6</p>                | <p>NR</p>                           |

**Table 2. Intervention details** *(Continued)*

|                     |   |   |
|---------------------|---|---|
| tion adher-<br>ence | drugs by designated nurses during their in-patient stay. They were handed a brochure with drug guidance upon discharge. The content of the brochure included basic knowledge of drugs, drug usage and effects, how to deal with common problems, and how to attend follow-ups in outpatient clinic. Every two months, doctors followed-up guidance by telephone." | tion, nursing-patient group chat for questions. |
|---------------------|---|---|

CG: control group; FC: faecal calprotectin; IBD: inflammatory bowel disease; IG: intervention group; NR: not reported.

**Table 3. Telehealth details**

| Study ID             | Time to response  | Staff and programmes delivering the intervention                     | Resources required for the intervention and who provided them  | Access issues as reported in studies (e.g. disabilities, financial issues) | Data security   |
|----------------------|---|--|--|--|---|
| <b>Akobeng 2015</b>  | NR  | IG: gastroenterologist<br>CG: gastroenterologist                     | Gastroenterologist provided by the hospital; telephone access  | None apart from lack of access to a telephone                              | NR  |
| <b>Ankersen 2019</b> | NR  | IG: eCare Nurse<br>CG: eCare Nurse                                   | Smartphone (participants' own); eCare nurses + doctors for the web rounds  | NR   | NR  |
| <b>Atreja 2018</b>   | NR  | NR   | Smartphone, access to the Internet (participants' own)   | NR   | NR  |
| <b>Carlsen 2017</b>  | NR  | IG: programme<br>CG: hospital staff                                  | Smartphone, access to internet (participants' own). Training by principal investigator   | NR   | NR  |
| <b>Chauhan 2016</b>  | NR  | IBD nurse practitioner   | Telephone (participants' own)  | NR   | NR  |
| <b>Cross 2012</b>    | NR  | Home telemanagement/ standard care staff                             | "[...] for participants without an active telephone line, a cell phone is provided to transmit self-testing results over a secure wireless network." | NR   | Data transmitted from the participant's home were deidentified and encrypted. |
| <b>Cross 2019</b>    | IG: "Results are available immediately after self-test completion. Clinical care issues that require immediate attention are directed to the provider's office or on call service at each site. Providers are available to study nurse coordinators daily to provide guidance for | IG: web portal, nursing staff, doctors<br>CG: doctors, nursing staff | IG: mobile phone (participants' own), electronic weight scale  | NR   | NR  |

**Table 3. Telehealth details** *(Continued)*

|                      |  |   |   |    |  |
|----------------------|--|---|---|----|--|
|                      | management changes.  |   |   |    |  |
|                      | CG: face-to-face appointments"   |   |   |    |  |
| <b>De Jong 2017</b>  | IG: "If an alert was received, a health-care provider on the local team contacted the patient for further assessment within two working days." | IG: website<br><br>CG: standard hospital care   | IG: computer/tablet/smartphone and internet access (participants' own), administration office | NR | NR   |
| <b>Del Hoyo 2018</b> | NR   | IG: the platform, specialised medical staff and nurses<br><br>Telephone IG: nursing staff<br><br>CG: hospital staff | Telephone, mobile phone, internet access (participants' own)                                  | NR | "TECCU Web platform protects the confidentiality of health data. The access to patient station and to work station requires a personal password only known by the patient and healthcare providers, respectively. Moreover, healthcare providers register patients in the platform with a generic name and a code only identifiable by investigators. Finally, to avoid data correlation by a nonauthorized person, data included in the Web platform are not connected to other hospital information systems. Thus, only case managers and health professionals can see all the clinical history separately." |

**Table 3. Telehealth details** (Continued)

|                       |    |  |  |  |    |
|-----------------------|----|--|--|--|----|
| <b>Elkjaer 2010</b>   | NR | IG: web platform, education from staff members<br><br>CG: staff members (regular care) | Computer (participants' own)   | NR   | NR |
| <b>Heida 2018</b>     | NR | IG: programme<br><br>CG: specialists not defined                                       | Access to telephone, internet, and email (participants' own)                     | Participants required to have access to telephone, internet, and email, and good knowledge of Dutch  | NR |
| <b>Hughes 2017</b>    | NR | IG: telephone calls + self-management<br><br>CG: self-management                       | Manuals, task books, telephones and personnel, provider not mentioned            | "Suicidal patients will be directly referred to liaison psychiatry or their GP and will not be able to access the study as the intensity of the manual intervention is within the low-moderate range." | NR |
| <b>Ley 2020</b>       | NR | IG/CG: iPhone app  | iPhone, provider not mentioned   | NR   | NR |
| <b>Malickova 2020</b> | NR | IG: Web IBD Assistant App<br><br>CG: gastroenterologist                                | PC, tablet, or smartphone, and working email address (participants' own)         | Excluded: no smartphone/PC, language barrier, no email, no wifi  | NR |
| <b>McCombie 2020</b>  | NR | IG: smartphone app + gastroenterologist<br><br>CG: gastroenterologist                  | IG: smartphone (can be borrowed). 17/50 participants used a borrowed smartphone. | Excluded: people unable to provide written consent   | NR |
| <b>Reich 2019</b>     | NR | IG/CG: Electronic Health Record (EHR) patient portal (EPIC's Mychart)                  | Computer with internet (participants' own)                                       | Excluded: non-English speaking, cognitive impairment that would impair participation, no computer with internet.   | NR |
| <b>Siegel 2018</b>    | NR | IG: online programme<br><br>CG: NR   | NR   | NR   | NR |
| <b>Stunkel 2012</b>   | NR | IG: smartphone app<br><br>CG: self-education using websites                            | Smartphones (participants' own)  | "Patients with Blackberry® smartphones were excluded as the app was not fully opti-  | NR |

**Table 3. Telehealth details** (Continued)

|           |    |                              |                                       |  |    |
|-----------|----|------------------------------|---------------------------------------|--|----|
| Wang 2020 | NR | IG: mobile app<br>CG: nurses | Mobile phones, provider not mentioned | mized for this device."<br>People "not able to use the app" were excluded from the study | NR |
|-----------|----|------------------------------|---------------------------------------|--|----|

CG: control group; IBD: inflammatory bowel disease; IG: intervention group; NR: not reported.

**Table 4. Primary outcome data**

| Study ID      | 1a. Disease activity at study end  | 1b. Flare-ups/relapses measured clinically/endoscopically/histologically (n, unless otherwise specified)  | 1c. Quality of life   |
|---------------|--|---|---|
| Akobeng 2015  | NR   | Disease relapses over 24 months<br>IG: 1/44<br>CG: 4/42   | Median IMPACT QoL at 12 months:<br>IG (n = 36): median 113 points (IQR 105–125); calculated SD 14.8<br>CG (n = 31): median 106 points (IQR 95–116); calculated SD 15.5<br><br>Mean IMPACT QoL:<br>IG: mean 108.2 points (95% CI 101.6–114.7)<br>CG: mean 102.5 points (95% CI 96.5–108.4) |
| Ankersen 2019 | <p>"Two assessors classified disease activity as (1) Chronic continuous course, red throughout 1 year; (2) Chronic continuous course, yellow throughout 1 year; (3) Chronic continuous course, red and yellow throughout 1 year; (4) Continuous remission course, green throughout 1 year; (5) Intermittent course; green, yellow and red throughout 1 year; and (6) Intermittent course; green with a single relapse (yellow or red) throughout 1 year."</p> <p>Mean % over 1 year:</p> <p>SCCAI scores:<br/>IG (n = 37) green/yellow/red: 82%/15%/3%<br/>CG (n = 35) green/yellow/red: 87%/10%/3%</p> <p>HBI scores:<br/>IG (n = 6) green/yellow/red: 72%/28%/0%</p> | <p>Study authors stated they "analysed the number of relapses (FC and SCCAI) in each intervention group based on 83 (99%) and 70 (97%) patients respectively"; however, the numbers randomised were 50 and 52.</p> <p>"Moderate" and "Severe" relapses combined:<br/>IG (FC): 22<br/>CG (FC): 17<br/>IG (SCCAI): 14<br/>CG (SCCAI): 9</p> | <p>Short IBDQ change in QoL:<br/>IG: mean 0.56 points (SD 6.78)<br/>CG: mean 4.04 points (SD 9.24)</p>  |

**Table 4. Primary outcome data** (Continued)

CG (n = 9) green/yellow/red:  
66%/34%/0%

TIBS scores:  
IG (n = 43) green/yellow/red:  
60%/26%/14%  
CG (n = 39)  
green/yellow/red:  
61%/22%/16%

|                     |  |  |   |
|---------------------|--|--|---|
| <b>Atreja 2018</b>  | NR   | NR   | IG: SIBDQ QoL at 575 days mean 25.2 points (SD 11.3)<br>CG: not reported  |
| <b>Carlsen 2017</b> | Stated as an outcome but no data   | NR   | Stated as an outcome but no data  |
| <b>Chauhan 2016</b> | Study authors did not provide data, but commented there was no significant change.   | NR   | Study authors did not provide data, but commented there was no significant change.  |
| <b>Cross 2012</b>   | Seo index scores:<br>IG: mean 122 points (SD 39.3)<br>CG: mean 113.6 points (SD 28)<br><br>Remission rates at 12 months:<br>IG: n = 19/25 (77%)<br>CG: n = 16/22 (76%)   | Relapses at 12 months:<br>IG: 6<br>CG: 6   | IBDQ:<br>IG: mean 178.1 points (unspecified variance measure 32.1)<br>CG: mean 187.3 points (unspecified variance measure 32.2)   |
| <b>Cross 2019</b>   | HBI:<br>CG: mean 3.7 points (SD 3.6)<br>IG1: mean 4.2 points (SD 3.9)<br>IG2: mean 3.2 points (SD 3.4)<br><br>SCCAI:<br>CG: mean 1.4 points (SD 1.4)<br>IG1: mean 1.7 points (SD 1.9)<br>IG2: mean 2.0 points (SD 1.8) | CD:<br>CG: 29/79 (36.5%)<br>IG1: 31/79 (39.1%)<br>IG2: 23/78 (29.6%)<br><br>UC/IC:<br>CG: 7/36 (18.5%)<br>IG1: 8/36 (21.7%)<br>IG2: 13/38 (33.3%)  | IBDQ at study end:<br>CG: mean 179.3 points (unspecified variance measure 28.2)<br>IG1: mean 181.5 points (unspecified variance measure 28.2)<br>IG2: mean 179.2 points (unspecified variance measure 32.8) |
| <b>De Jong 2017</b> | NR   | Number of flares during the 12 months of follow-up:<br>"Flares were defined as clinical symptoms indicative of disease activity with, as a rule, concomitant calprotectin of more than 250 µg/g in the stool or active disease determined by endoscopy, MRI, or CT. In daily practice, in case of clinically severe symptoms suggestive for disease activity, the treating physician occasionally judged these symptoms to be evident enough to adjust therapy. Therefore, to capture all clinical flares, clinical episodes were defined as flares if symptoms suggestive of disease activity resulted in a dose escalation or initiation of a new drug to induce remission." | SIBDQ at study end:<br>IG mean 54.44 points (unspecified variance measure 9.05)<br>CG: mean 53.71 points (unspecified variance measure 9.87)  |

**Table 4. Primary outcome data** (Continued)

|                      |   |  |  |
|----------------------|---|--|--|
|                      |   | IG: mean 0.19 events (unspecified variance measure 0.42)<br>CG: mean 0.19 events (unspecified variance measure 0.44)   |  |
| <b>Del Hoyo 2018</b> | <p>Measured only by proxy (FC levels) and no variance given:</p> <p>"At 24 weeks, the median FC level for clinical activity improved progressively from a baseline value of 490 µg/g to 137 µg/g in IG2(teccu) and from 526 µg/g to 115.5 µg/g in IG1(tele); however, this reduction was smaller in CG, from 330 µg/g to 230 µg/g."</p> | <p>Inactive disease after 24 weeks<br/>IG1: 14/21 (66.7%) → 7 relapses<br/>IG2: 17/21 (81%) → 4 relapses<br/>CG: 15/21 (71.4%) → 6 relapses</p> <p>"Remission was evaluated using the modified HBI for patients with CD. For patients with UC, we used the SCCAI (also known as the Walmsley index) for remote check-ups together with the partial Mayo score for face-to-face visits. For remote check-ups in patients with UC, clinical remission was defined as a Walmsley score ≤ 2, whereas mild-to-moderate and severe activities were defined as scores of 3-5 and &gt;5, respectively. Patients with CD and an HBI &lt; 5 were considered to be in clinical remission, whereas patients with scores of 5-7, 8-16, or &gt;16 were considered to have mild, moderate, or severe activity, respectively. In the face-to-face visits, clinical remission was defined as a partial Mayo score ≤ 2 and no individual Mayo sub-score &gt; 1; scores of 2-5, 6-8, and were defined as mild, moderate, and severe disease activity, respectively"</p> | <p>Measured with the IBDQ-9 and the EQ-5D. VAS were also used.</p> <p>Median IBDQ-9 at end:<br/>IG1: 53 points<br/>IG2: 52.5 points<br/>CG: 53 points</p> <p>Median EQ-5D at end:<br/>IG1: 1 point<br/>IG2: 1 point<br/>CG: 1 point</p> <p>Median VAS values at study end:<br/>NR</p> <p>Figure 6 possibly presents variance but unclear if SDs or something else.</p> |
| <b>Elkjaer 2010</b>  | NR  | <p>SCCAI score &gt; 5 used to define a relapse.</p> <p>Total relapses:<br/>IG: 93/169<br/>CG: 87/164</p> <p>Denmark:<br/>IG: 60/105 (51%) + 12 (randomised but did not participate) = 72/117<br/>CG: 60/106 (52%) + 10 (randomised but did not participate) = 70/116<br/>Mean relapses:<br/>IG: mean 1.1 events (range 0–6)<br/>CG: mean 0.8 events (range 0–4)</p> <p>Ireland:<br/>IG: 20/51 (39%) + 1 (randomised but did not participate) = 21/52<br/>CG: 10/41 (24%) + 7 (randomised but did not participate) = 17/48<br/>Mean relapses:<br/>IG: mean 0.6 events (range 0–4)<br/>CG: 0.2 events (range 0–1)</p>  | "Disease specific QoL was improved in the web-group, as well as general health, vitality, role emotional, and social functioning, compared to control group"   |
| <b>Heida 2018</b>    | NR  | "Disease flares – disease activity requiring therapy intensification (steroid therapy, exclusive enteral nutrition, aminosalicylate dose escalation, or introduction of anti-TNF antibodies)"  | <p>IBD-specific IMPACT-III scores</p> <p>Mean change in QoL:<br/>IG: 1.32 points<br/>CG: –0.32 points</p>  |



**Table 4. Primary outcome data** (Continued)

|                       |   |   |  |
|-----------------------|---|---|--|
|                       |   | Flare-ups during 52 weeks:<br>IG: 28/84<br>CG: 29/86  | No variance provided.<br><br>IG: 54% reported a positive change.<br><br>CG: 44% reported a positive change.  |
| <b>Hughes 2017</b>    | NR  | NR  | NR   |
| <b>Ley 2020</b>       | NR  | NR  | NR   |
| <b>Malickova 2020</b> | HBI mean score at end of study (no variance provided):<br>IG: 3.48 points<br>CG: 2.71 points<br><br>Partial Mayo mean scores at end of study (no variance provided):<br>IG: 2.71 points<br>CG: 2.57 points  | NR, study only reported the relapses that required hospitalisation.   | NR   |
| <b>McCombie 2020</b>  | SCCAI:<br>3 months<br>IG: mean 1.6 points (SD 1.7)<br>CG: mean 0.5 points (SD 0.7)<br>6 months<br>IG: mean 2.5 points (SD 2.2)<br>CG: mean 1.9 points (SD 2.0)<br>9 months<br>IG: mean 3.4 points (SD 2.7)<br>CG: mean 2.6 points (SD 4.8)<br>12 months<br>IG: mean 1.5 points (SD 1.1)<br>CG: mean 1.7 points (SD 1.9)<br><br>HBI:<br>3 months<br>IG: mean 4.3 points (SD 3.5)<br>CG: mean 3.6 points (SD 2.3)<br>6 months:<br>IG: mean 4.2 points (SD 3.8)<br>CG: mean 2.5 points (SD 3.1)<br>9 months:<br>IG: mean 3.9 points (SD 4.0)<br>CG: mean 1.8 points (SD 1.9)<br>12 months:<br>IG: mean 2.4 points (SD 3.4)<br>CG: mean 2.0 points (SD 2.5) | UC flare-ups (months 3–12)<br>IG: 9/13 (70%)<br>CG: 6/14 (42.7%)<br><br>CD flare-ups (months 3–12)<br>IG: 17/37 (47.2%)<br>CG: 9/36 (25.7%) | IBDQ (CD)<br>3 months<br>IG: mean 173.9 points (SD 30.0)<br>CG: mean 160.1 points (SD 35.1)<br>6 months<br>IG: mean 177.5 points (SD 27.9)<br>CG: mean 163.1 points (SD 36.7)<br>9 months<br>IG: mean 178.9 points (SD 27.8)<br>CG: mean 159.0 points (SD 31.4)<br>12 months<br>IG: mean 178.0 points (SD 20.6)<br>CG: mean 167.3 points (SD 32.6)<br><br>IBDQ (UC)<br>3 months<br>IG: mean 184.6 points (SD 21.7)<br>CG: mean 186.6 points (SD 21.0)<br>6 months<br>IG: mean 188.0 points (SD 28.6)<br>CG: mean 175.5 points (SD 31.8)<br>9 months<br>IG: mean 181.6 points (SD 30.4)<br>CG: mean 181.9 points (SD 27.7)<br>12 months<br>IG: mean 189.5 points (SD 24.5)<br>CG: mean 179.6 points (SD 24.3) |
| <b>Reich 2019</b>     | NR  | NR  | Median SIBDQ at 6 months (no variance provided):<br>IG: 58 points<br>CG: 57.5 points   |
| <b>Siegel 2018</b>    | NR  | NR  | NR   |
| <b>Stunkel 2012</b>   | NR  | NR  | IBDQ at study end:<br>IG: mean 172.9 points (unspecified variance measure 26.8)  |

**Table 4. Primary outcome data** (Continued)

CG: mean 169.3 points (unspecified variance measure 29.3)

| Wang 2020 | NR | NR | NR |
|-----------|----|----|----|
|-----------|----|----|----|

CD: Crohn's disease; CG: control group; CT: computerised tomography; EQ-5D: EuroQol five-dimension questionnaire; FC: faecal calprotectin; HBI: Harvey-Bradshaw Index; IBD: inflammatory bowel disease; IBDQ: Inflammatory Bowel Disease Questionnaire; IG: intervention group; IQR: interquartile range; MRI: magnetic resonance imaging; n: number of participants; NR: not reported; QoL: quality of life; SCCAI: Simple Colitis Clinical Activity Index; SD: standard deviation; SIBDQ: Short Inflammatory Bowel Disease Questionnaire TIBS: total inflammation burden scoring; TNF: tumour necrosis factor; UC: ulcerative colitis; VAS: visual analogue scale.

**Table 5. Secondary outcome data**

| Study ID            | 2a. Number of episodes of accessing healthcare (out-patient/remote/inpatient)           | 2b. Medication adherence | 2c. Participant engagement | 2d. Rate of attendance/engagement (number of planned appointments/interactions attended)  | 2e. Rate of attendance of interactions with professionals   | 2f. Costs or cost/time-effectiveness (as judged by study authors)  |
|---------------------|---|--------------------------|----------------------------|---|---|--|
| <b>Akobeng 2015</b> | Number of participants with ≥ 1 hospital admissions due to IBD:<br>IG: 1/44<br>CG: 1/42 | NR                       | NR                         | Number of consultations scheduled by the hospital for each participant that were not then cancelled by the hospital:<br>IG: median 4.5 (IQR 3–5.3); imputed SD 1.7<br>CG: median 5 (IQR 3–6); imputed SD 2.2<br><br>Number of consultations attended per participant:<br>IG: median 4 (IQR 3–4); imputed SD 0.74<br>CG: median 3 (IQR 2–4); | Number of participants with ≥ 1 consultation, as allocated before the 12-month follow-up:<br>IG: 36 (82%)<br>CG: 40 (95%) | Costs to the NHS:<br><br>"Estimates of NHS costs for the intervention (including staff costs and telephone costs) showed that telephone consultation had a mean cost of UK £35.41 per patient consultation compared with £51.12 for face-face consultation, difference £15.71" |

**Table 5. Secondary outcome data** (Continued)

|                          |  |   |  | imputed SD<br>1.48  |    |  |
|--------------------------|--|---|--|---|----|--|
| <b>Ankersen<br/>2019</b> | NR   | Adherence to medication was measured by a self-assessment questionnaire (MARS)<br><br>MARS score:<br>IG: median 23.57 points (IQR 21.50–24.25); calculated SD 2.03<br>CG: median 24.17 points (IQR 23.50–24.80); calculated SD 0.96 | "The 88 patients that completed the study were asked seven questions at follow-up. There was no statistical difference between the two intervention groups on any of the seven yes/no questions assessing patient satisfaction." | NR  | NR | NR   |
| <b>Atreja<br/>2018</b>   | NR   | NR  | NR   | NR  | NR | NR   |
| <b>Carlsen<br/>2017</b>  | <p>Outpatient visits:<br/>IG: total 85; median 2 (IQR 2–3)<br/><br/>CG: total 185; median 8 (IQR 4–9)</p> <p>On-demand outpatient visits:<br/>IG: total 47; median (IQR 0–3);<br/><br/>CG: total 39; median 1 (IQR 0–2)</p> <p>Acute/hospitalisations:<br/>IG: total 3; median 0 (IQR 0–0);<br/><br/>CG: total 10; median 0 (IQR 0–1)</p> <p>Planned outpatient visits:<br/>IG: total 38; median 2 (IQR 1–2);<br/><br/>CG: total 146; median 7 (IQR 3–7)</p> <p>Contacts in total:<br/>IG: total 88; median 2 (IQR 2–4);<br/><br/>CG: total 195; median 8.5 (IQR 4–10)</p> | <p>Mean MARS scores (from trial registration):<br/>IG: mean 23.3 points (95% CI 22.9–23.6); calculated SD 0.88<br/>CG: mean 23.3 points (95% CI 22.9–23.7); calculated SD 0.97</p>  | "The adherence to the web program was 81% (384/475 expected entries)."   | Planned outpatient visits:<br>IG: total 38; median 2 (IQR 1–2)<br>CG: total 146; median 7 (IQR 3–7) | NR | "From a socioeconomic perspective, the reduced school absence and fewer outpatient visits in the web group represent an economic gain, as parents do not require leave from work, and it saves the time and expense of travel to/from our hospital." |

**Table 5. Secondary outcome data** (Continued)

|                     |  |   |  |    |    |   |
|---------------------|--|---|--|----|----|---|
| <b>Chauhan 2016</b> | NR   | NR  | NR   | NR | NR | "The average parking and travel costs for patients randomised to intervention were CAN \$25.83, and their average loss of income was CAN \$17.00. The median duration of health-care contact was longer in the intervention group (52 minutes [IQR 38–81] vs 17 minutes [IQR 15.0–21.2]), with wait time was longer in intervention (median 31.6 minutes [IQR 8–56] vs 0 minutes" |
| <b>Cross 2012</b>   | NR   | Based on the MMAS.<br><br>For the purpose of evaluating percent of participants adherent to therapy, the variable was dichotomised to "adherent" or "non-adherent." Any response of yes to one of the 4 items was scored as "non-adherent."<br><br>IG: 14/25 (57%)<br>CG: 14/22 (67%) | NR   | NR | NR | NR  |
| <b>Cross 2019</b>   | Extracted from the electronic medical records during 1 year before and after randomization. Post-randomisation numbers reported as rates adjusted for 100 participants per year (hospitalisations, surgery, emergency department and of- | NR  | "Adherence was defined as the completion of 80% (278/348) or more of the weekly or every other week self-assessments." | NR | NR | NR  |

**Table 5. Secondary outcome data** (Continued)

|                      |  |  |  |    |    |   |
|----------------------|--|--|--|----|----|---|
|                      | <p>face visits, procedures, intravenous therapeutics, and telephone and electronic encounters). Unclear if these are only for the randomised participants.</p> <p>CG: 2099<br/>IG1: 2235<br/>IG2: 1935</p>   |  | No data presented.   |    |    |   |
| <b>De Jong 2017</b>  | <p>Number of hospital admissions, unique participants:<br/>IG: 16<br/>CG: 29</p> <p>Mean outpatient visits:<br/>IG: gastroenterologist: mean 1.26 (SD 1.18); nurse: mean 0.29 (0.68); total: mean 1.55 (SD 1.50)<br/>CG: gastroenterologist: mean 1.98 (SD 1.19); nurse: mean 0.36 (0.84); total: mean 2.34 (SD 1.64)</p> <p>Mean telephone consultations:<br/>IG: gastroenterologist: mean 0.58 (SD 0.98); nurse: mean 0.7 (SD 1.59); total: mean 1.28 (SD 2.06)<br/>CG: gastroenterologist: mean 0.84 (SD 1.11); nurse: mean 0.74 (SD 1.9); total: mean 1.57 (SD 2.44)</p> <p>The number of outpatient visits and telephone consultations with gastroenterologists and nurses during the 12-month period were retrieved from participants' electronic medical records.</p> | <p>Mean MMAS score:<br/>IG: mean 7.01 points (SD 1.40)<br/>CG: mean 6.77 points (SD 1.61)</p>                                    | NR   | NR | NR | <p>Calculated mean annual direct costs, per participant:<br/>IG: EUR 7048<br/>CG EUR 7423</p> <p>Calculated mean indirect costs, per participant:<br/>IG: EUR 1886<br/>CG: EUR 2058</p> |
| <b>Del Hoyo 2018</b> | <p>Outpatient visits:<br/>IG1 85 (29.5%)<br/>IG2 72 (25%)<br/>CG 131 (45.5%)</p> <p>Telephone calls:<br/>IG1 118 (66.7%)<br/>IG2 12 (6.8%)<br/>CG 47 (26.5%)</p> <p>Study authors recorded the number of outpatient visits and telephone consultations for all 3 groups during the study. As these numbers were per participant,</p>   | <p>Medication adherence according to Morisky-Green index:<br/>IG1 33.3% (7/21)<br/>IG2 57.1% (12/21)<br/>CG 66.7% (14/21) CG</p> | <p>Participants who adhered to &gt; 80% of check-ups (considered compliant):<br/>IG1 20 (95.2%)<br/>IG2 18 (85.7%)<br/>CG 19 (90.5%)</p> | NR | NR | <p>"There is a high probability that the use of the TECCU Web-platform produces a greater improvement in disease activity at a lower societal cost."</p>                                |

**Table 5. Secondary outcome data** (Continued)

we could not use them for meta-analysis.

|                       |   |  |   |    |    |   |
|-----------------------|---|--|---|----|----|---|
| <b>Elkjaer 2010</b>   | Acute visits:<br>IG: 21<br>CG: 107<br><br>Routine visits:<br>IG: 35<br>CG: 92<br><br>Emails/phone calls:<br>IG: 86/21<br>CG 7/17  | NR   | Compliance:<br>IG: 73%<br>CG: 42%   | NR | NR | The study authors converted the numbers of medications and professional visits into financial savings for department and found it cost-effective.   |
| <b>Heida 2018</b>     | Mean face-to-face encounters with health providers:<br>IG: 3.6<br>CG: 4.3   | NR   | Compliance with study protocol (> 80% response to alerts):<br>IG: 48<br>CG: 72<br><br>Did not respond to any emails:<br>IG: 10<br>CG: NR<br><br>Insufficient compliance (< 80% response to alerts):<br>IG: 26<br>CG: 14 | NR | NR | "Home tele-monitoring led to a mean annual cost-saving of €89 per participant in the intention-to-treat analysis. The intervention was most cost-saving in participants who were compliant (mean annual saving 360 euros)." |
| <b>Hughes 2017</b>    | NR  | NR   | Completed at least 1 telephone session:<br>IG: 80%<br>CG: NR  | NR | NR | NR  |
| <b>Ley 2020</b>       | NR  | Mean adherence at study end (measured by MPR):<br>IG: 0.539<br>CG: 0.462 | NR  | NR | NR | NR  |
| <b>Malickova 2020</b> | Median number of visits to doctor per participant<br>IG: 0<br>CG: 4<br><br>Median number of visits to IBD nurse per participant<br>IG: 0.3<br>CG: 0.9<br><br>Median number of hospitalisations<br>IG: 1 | NR   | IG: 4 non-compliant<br>CG: NR   | NR | NR | "Annual average costs remotely / tele-medically monitored patient (CZK 2,060 / patient / year) were 25% lower than the cost of the same standardly outpatient patient (CZK 2,580 / patient / year)"                         |

**Table 5. Secondary outcome data** (Continued)

CG: 0

|                      |   |    |  |   |    |    |
|----------------------|---|----|--|---|----|----|
| <b>McCombie 2020</b> | <p>Gastroenterologist appointments:<br/>IG: mean 0.6 (SD 0.9)<br/>CG: mean 1.7 (SD 0.8)</p> <p>Surgical appointments:<br/>IG: mean 0.1: (SD 0.4)<br/>CG: mean 0.1: (SD 0.4)</p> <p>IBD hospitalisations:<br/>IG: mean 0.1 (SD 0.3)<br/>CG: mean 0.1 (SD 0.4)</p> <p>Nights in hospital:<br/>IG: mean 0.1 (SD 0.4)<br/>CG: mean 0.8 (SD 3.9)</p> | NR | <p>"At the end of 12 months, patients in the smart-phone app group completed 2 system usability scales. The questionnaires asked about the instructions provided for the apps, what issues with the apps they experienced during the study, and whether they would keep using the apps in the future and recommend them to other people with IBD."</p> <p>No data presented.</p> | <p>For IBDoc, 15 (30%) completed all readings. 14 (28%) completed 4. 6 (12%) completed 3. 2 (4%) completed 2. 6 (12%) completed 1. 7 (14%) completed 0.</p> <p>For IBDs-mart, 25 (50%) completed all readings. 9 (18%) completed 4. 7 (14%) completed 3. 1 (2%) completed 2. 7 (14%) completed 1. 1 (2%) completed 0.</p> | NR | NR |
| <b>Reich 2019</b>    | NR  | NR | <p>33% reported logging onto My-Chart monthly, whereas 32% logged on weekly, and 13% logged on every other week.</p>   | NR  | NR | NR |
| <b>Siegel 2018</b>   | NR  | NR | NR   | NR  | NR | NR |
| <b>Stunkel 2012</b>  | NR  | NR | <p>"The experimental group did feel that the mobile app was easy to use and subjectively improved their ability to</p>   | NR  | NR | NR |

**Table 5. Secondary outcome data** (Continued)

|                  |    | track and correlate symptoms"  |    |    |    |    |
|------------------|----|--|----|----|----|----|
| <b>Wang 2020</b> | NR | Month 1<br>MMAS < 6:<br>IG: 27<br>CG: 34<br>MMAS ≥ 6:<br>IG: 93<br>CG: 85<br><br>Month 2<br>MMAS < 6:<br>IG: 30<br>CG: 35<br>MMAS ≥ 6:<br>IG: 90<br>CG: 84<br><br>Month 4<br>MMAS < 6:<br>IG: 23<br>CG: 37<br>MMAS ≥ 6:<br>IG: 97<br>CG: 82<br><br>Month 6<br>MMAS < 6:<br>IG: 22<br>CG: 42<br>MMAS ≥ 6:<br>IG: 98<br>CG: 77 | NR | NR | NR | NR |

IBD: inflammatory bowel disease; IQR: interquartile range; MARS: Medication Adherence Rating Scale; MMAS: Morisky Medication Adherence Scale; MPR: Medication Possession Ratio; NHS: UK National Health Service; SD: standard deviation.

## APPENDICES

### Appendix 1. CENTRAL Search strategy (via Ovid Evidence-Based Medicine Reviews Database)

- exp Inflammatory bowel diseases/
- (inflammatory bowel disease\* or IBD or UC or CD).tw,kw.
- crohn\*.tw,kw.
- (colitis or regional enteritis or proctocolitis or coloproctitis).tw,kw.
- or/1-4
- (phone\* or phoning or telephone\* or telecom or telecommunicat\* or tele-communicat\* or teleconferenc\* or tele-conferenc\* or telegraph\* or tele-graph\*).tw,kw.
- exp Telecommunications/
- (Electronic Mail\* or email\* or e-mail\* or Telefacsimile or fax or telehealth or tele-health or telemed\* or tele-med\* or ehealth or e-health or mhealth or m-health).tw,kw.
- (instant messag\* or SMS or text or texting).tw,kw.
- (webcast\* or webina\* or virtual conferenc\*).tw,kw.
- ((web or internet or online or video or virtual or mobile or digital\*) adj5 (care or communicat\* or health\* or medicine\* or medical or clinic\* or physician\* or treat\* or therap\* or intervention\* or conferenc\* or connect\*)).tw,kw.
- (mobile or hotline or videoconferenc\* or wireless).tw,kw.



- 13.mobile applications/ or web browser/
- 14.(remote\* adj5 (care or communicat\* or health\* or medicine\* or medical or clinic\* or physician\* or treat\* or therap\* or intervention\* or conferenc\* or connect\*)).tw,kw.
- 15.(GoToMeeting or GoToWebinar or zoom meeting or spotMe or TurboMeeting or Livestorm).tw,kw.
- 16.(Google Meet\* or Cisco Webex or Microsoft Teams or join\*me).tw,kw.
- 17.or/6-16
- 18.5 and 17

## Appendix 2. MEDLINE Search strategy (via Ovid)

1. exp Inflammatory bowel diseases/
2. (inflammatory bowel disease\* or IBD or UC or CD).tw,kw.
3. crohn\*.tw,kw.
4. (colitis or regional enteritis or proctocolitis or coloproctitis).tw,kw.
5. or/1-4
6. (phone\* or phoning or telephone\* or telecom or telecommunicat\* or tele-communicat\* or teleconferenc\* or tele-conferenc\* or telegraph\* or tele-graph\*).tw,kw.
7. exp Telecommunications/
8. (Electronic Mail\* or email\* or e-mail\* or Telefacsimile or fax or telehealth or tele-health or telemed\* or tele-med\* or ehealth or e-health or mhealth or m-health).tw,kw.
9. (instant messag\* or SMS or text or texting).tw,kw.
- 10.(webcast\* or webina\* or virtual conferenc\*).tw,kw.
- 11.((web or internet or online or video or virtual or mobile or digital\*) adj5 (care or communicat\* or health\* or medicine\* or medical or clinic\* or physician\* or treat\* or therap\* or intervention\* or conferenc\* or connect\*)).tw,kw.
- 12.(mobile or hotline or videoconferenc\* or wireless).tw,kw.
- 13.mobile applications/ or web browser/
- 14.(remote\* adj5 (care or communicat\* or health\* or medicine\* or medical or clinic\* or physician\* or treat\* or therap\* or intervention\* or conferenc\* or connect\*)).tw,kw.
- 15.(GoToMeeting or GoToWebinar or zoom meeting or spotMe or TurboMeeting or Livestorm).tw,kw.
- 16.(Google Meet\* or Cisco Webex or Microsoft Teams or join\*me).tw,kw.
- 17.or/6-16
- 18.5 and 17
- 19.randomized controlled trial.pt.
- 20.controlled clinical trial.pt.
- 21.random\*.ab.
- 22.placebo.ab.
- 23.trial.ab.
- 24.groups.ab.
- 25.or/19-24
- 26.exp animals/ not humans.sh.
- 27.25 not 26
- 28.18 and 27

Note: Lines 19-27. RCT filter: Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); Ovid format. (Lefebvre 2022). We made the following minor revisions: we used “random\*” instead of “randomized.ab” or “randomly.ab.” to capture word variations such as “randomised, randomization, random”; we removed “drug therapy.fs.” from the above filter as this review is not related to drug therapy.

## Appendix 3. Embase Search strategy (via Ovid)

1. exp inflammatory bowel disease/
2. (inflammatory bowel disease\* or IBD or UC or CD).tw,kw.
3. crohn\*.tw,kw.
4. (colitis or regional enteritis or proctocolitis or coloproctitis).tw,kw.
5. or/1-4

6. (phone\* or phoning or telephone\* or telecom or telecommunicat\* or tele-communicat\* or teleconferenc\* or tele-conferenc\* or telegraph\* or tele-graph\*).tw,kw.
7. telecommunication/ or telephone/ or text messaging/ or fax/
8. (Electronic Mail\* or email\* or e-mail\* or Telefacsimile or fax or telehealth or tele-health or telemed\* or tele-med\* or ehealth or e-health or mhealth or m-health).tw,kw.
9. (instant messag\* or SMS or text or texting).tw,kw.
- 10.(webcast\* or webina\* or virtual conferenc\*).tw,kw.
- 11.((web or internet or online or video or virtual or mobile or digital\*) adj5 (care or communicat\* or health\* or medicine\* or medical or clinic\* or physician\* or treat\* or therap\* or intervention\* or conferenc\* or connect\*)).tw,kw.
- 12.(mobile or hotline or videoconferenc\* or wireless).tw,kw.
- 13.e-mail/ or hotline/ or mobile phone/ or videoconferencing/ or webcast/ or wireless communication/ or exp web browser/
- 14.(remote\* adj5 (care or communicat\* or health\* or medicine\* or medical or clinic\* or physician\* or treat\* or therap\* or intervention\* or conferenc\* or connect\*)).tw,kw.
- 15.(GoToMeeting or GoToWebinar or zoom meeting or spotMe or TurboMeeting or Livestorm).tw,kw.
- 16.(Google Meet\* or Cisco Webex or Microsoft Teams or join\*me).tw,kw.
- 17.or/6-16
- 18.5 and 17
- 19.random:.tw.
- 20.placebo:.mp.
- 21.double-blind:.tw.
- 22.or/19-21
- 23.exp animal/ not human/
- 24.22 not 23
- 25.18 and 24

Note: Line 19-22. [Hedges](#) Best balance of sensitivity and specificity filter for identifying "therapy studies" in Embase.

#### Appendix 4. PsycInfo Search strategy (via Ovid)

1. ulcerative colitis/
2. (inflammatory bowel disease\* or IBD or UC or CD).tw.
3. crohn\*.tw.
4. (colitis or regional enteritis or proctocolitis or coloproctitis).tw.
5. or/1-4
6. (phone\* or phoning or telephone\* or telecom or telecommunicat\* or tele-communicat\* or teleconferenc\* or tele-conferenc\* or telegraph\* or tele-graph\*).tw.
7. exp communications media/
8. (Electronic Mail\* or email\* or e-mail\* or Telefacsimile or fax or telehealth or tele-health or telemed\* or tele-med\* or ehealth or e-health or mhealth or m-health).tw.
9. (instant messag\* or SMS or text or texting).tw.
- 10.(webcast\* or webina\* or virtual conferenc\*).tw.
- 11.((web or internet or online or video or virtual or mobile or digital\*) adj5 (care or communicat\* or health\* or medicine\* or medical or clinic\* or physician\* or treat\* or therap\* or intervention\* or conferenc\* or connect\*)).tw.
- 12.(mobile or hotline or videoconferenc\* or wireless).tw.
- 13.exp mobile applications/
- 14.(remote\* adj5 (care or communicat\* or health\* or medicine\* or medical or clinic\* or physician\* or treat\* or therap\* or intervention\* or conferenc\* or connect\*)).tw.
- 15.(GoToMeeting or GoToWebinar or zoom meeting or spotMe or TurboMeeting or Livestorm).tw.
- 16.(Google Meet\* or Cisco Webex or Microsoft Teams or join\*me).tw.
- 17.or/6-16
- 18.5 and 17
- 19.random:.tw.
- 20.18 and 19

Note: line 19. PsycINFO RCT filter: [Eady 2008](#); [Ovid]- Single term Best sensitivity & Best specificity.

## Appendix 5. CINAHL (via EBSCO)

S18 S17 (Limiters - Exclude MEDLINE records)

S17 S15 AND S16

S16 MH "treatment outcomes+" OR MH "experimental studies+" or random\*

S15 S3 AND S14

S14 S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13

S13 TX Google Meet\* or Cisco Webex or Microsoft Teams or join\*me

S12 TX GoToMeeting or GoToWebinar or zoom meeting or spotMe or TurboMeeting or Livestorm

S11 TX remote\* AND TX ( care or communicat\* or health\* or medicine\* or medical or clinic\* or physician\* or treat\* or therap\* or intervention\* or conferenc\* or connect\* )

S10 TX mobile or hotline or videoconferenc\* or wireless

S9 TX ( web or internet or online or video or virtual or mobile or digital\* ) AND TX ( care or communicat\* or health\* or medicine\* or medical or clinic\* or physician\* or treat\* or therap\* or intervention\* or conferenc\* or connect\* )

S8 TX webcast\* or webina\* or virtual conferenc\*

S7 TX instant messag\* or SMS or text or texting

S6 TX Electronic Mail\* or email\* or e-mail\* or Telefacsimile or fax or telehealth or tele-health or telemed\* or tele-med\* or ehealth or e-health or mhealth or m-health

S5 (MH "Telecommunications")

S4 TX phone\* or phoning or telephone\* or telecom or telecommunicat\* or tele-communicat\* or teleconferenc\* or tele-conferenc\* or telegraph\* or tele-graph\*

S3 S1 OR S2

S2 TX inflammatory bowel disease\* or IBD or crohn\* or colitis or regional enteritis or proctocolitis or colorectitis

S1 (MH "Inflammatory Bowel Diseases+")

Note: line S16: CINAHL filter for treatment studies [Wong 2006](#), [Table 3] Best sensitivity, Ovid format.

## Appendix 6. AMED Search strategy (via Ovid)

1. exp inflammatory bowel disease/
2. (inflammatory bowel disease\* or IBD or UC or CD).tw.
3. crohn\*.tw.
4. (colitis or regional enteritis or proctocolitis or colorectitis).tw.
5. or/1-4
6. (phone\* or phoning or telephone\* or telecom or telecommunicat\* or tele-communicat\* or teleconferenc\* or tele-conferenc\* or telegraph\* or tele-graph\*).tw.
7. exp Telecommunications/
8. (Electronic Mail\* or email\* or e-mail\* or Telefacsimile or fax or telehealth or tele-health or telemed\* or tele-med\* or ehealth or e-health or mhealth or m-health).tw.
9. (instant messag\* or SMS or text or texting).tw.
10. (webcast\* or webina\* or virtual conferenc\*).tw.
11. ((web or internet or online or video or virtual or mobile or digital\*) adj5 (care or communicat\* or health\* or medicine\* or medical or clinic\* or physician\* or treat\* or therap\* or intervention\* or conferenc\* or connect\*)).tw.
12. (mobile or hotline or videoconferenc\* or wireless).tw.
13. (remote\* adj5 (care or communicat\* or health\* or medicine\* or medical or clinic\* or physician\* or treat\* or therap\* or intervention\* or conferenc\* or connect\*)).tw.
14. (GoToMeeting or GoToWebinar or zoom meeting or spotMe or TurboMeeting or Livestorm).tw.

### Remote care through telehealth for people with inflammatory bowel disease (Review)

Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

15.(Google Meet\* or Cisco Webex or Microsoft Teams or join\*me).tw.

16.or/6-15

17.5 and 16

## Appendix 7. Clinicaltrials.gov Search strategy

Advanced search:

Condition or disease: inflammatory bowel disease OR IBD OR ulcerative colitis OR Crohn OR Crohn's or Crohns

Intervention/treatment: remote care OR telemed OR tele-med OR tele-medicine OR tele-medical OR telehealth OR tele-health OR telecom OR telecommunication OR tele-communication OR ehealth OR e-health

Study type: Interventional studies (Clinical trials)

## Appendix 8. WHO ICTRP Search strategy

Advanced search:

(inflammatory bowel disease\* or IBD or ulcerative colitis or crohn\*) AND (remote\* or tele\* or phone\* or ehealth\* or e-health\*)

Recruitment status: All

## HISTORY

Protocol first published: Issue 4, 2021

## CONTRIBUTIONS OF AUTHORS

MG: conceived the review question, secured funding, designed and developed, screened, extracted, resolved conflicts, assessed certainty, contributed to writing and editing, advised on, approved the final version prior to submission, and is a guarantor of the review.

VS: developed, produced the first draft, screened, extracted, assessed certainty, contributed to writing and editing, made an intellectual contribution to, approved the final version prior to submission.

AA: resolved conflicts, advised on, and approved the final version of prior to submission.

TGH: screened, extracted, approved the final version prior to submission.

SL: screened, extracted, approved the final version prior to submission.

KB: screened, contributed to writing the plain language summary, approved the final version prior to submission.

## DECLARATIONS OF INTEREST

MG: has declared that they have no conflicts of interest.

VS: has declared that they have no conflicts of interest.

AA: was the principal investigator of a previously published randomised controlled trial that investigated the role of telephone consultation in paediatric inflammatory bowel disease. AA was not involved in screening for eligibility, data extraction, or risk of bias assessment for the trial he was involved in ([Akobeng 2015](#)).

TGH: has declared that they have no conflicts of interest.

SL: has declared that they have no conflicts of interest.

KB: has declared that they have no conflicts of interest.

The authors MG, AA, and VS are members of Cochrane Gut but were not involved in the editorial process or decision-making for this review.

## SOURCES OF SUPPORT

### Internal sources

- University of Central Lancashire, UK

Internal funding for MG and VS comes from their salary for their employment by the University of Central Lancashire.

### External sources

- NIHR grant, UK

Project: NIHR132748 - A programme of high priority Cochrane systematic reviews to investigate the management of Inflammatory Bowel Disease during and after the COVID-19 pandemic: Optimal biologic and immunomodulator therapies, diet therapies, telehealth, and education interventions (provided grant funding for the review)

## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

See [Gordon 2021b](#) (review protocol).

We updated our inclusion/exclusion criteria to clarify that we excluded studies where remote monitoring of blood or faecal tests was the only form of monitoring.

We added three outcomes: 'participant engagement', 'rate of attendance of interventions with healthcare professionals' and 'costs or cost/time-effectiveness'. 'Participant engagement' focused on adherence to or compliance with the intervention specifically, and with 'attendance of interventions' we aimed to differentiate between planned and attended sessions. We added the costs outcome to collect any available quantitative data on costs or cost/time-effectiveness.

We removed the outcomes 'change in disease activity' and 'change in quality of life' prespecified in the protocol, because we considered 'disease activity' and 'quality of life' to be sufficient.

We planned to remove cluster-RCTs in a sensitivity analysis to assess their impact on the results. However, the only included cluster-RCT provided no outcome data and was not included in any analysis ([Siegel 2018](#)).

In the protocol, we planned to conduct subgroup analysis by sex, but this was not possible due to a lack of data. Similarly, we were unable to conduct our planned sensitivity analyses for risk of bias and estimated standard deviations.

We had also planned to perform subgroup analyses based on age (adult/paediatric). However, we decided to present separate main analyses for adults and for children because of the significant differences of remote telehealth approaches for the two populations.

Based on peer review comments, we made some clarifications regarding how we intended to present our findings in the summary of findings tables.